

539,451

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 July 2004 (08.07.2004)

PCT

(10) International Publication Number
WO 2004/056361 A1

(51) International Patent Classification⁷: **A61K 31/404**,
C07D 209/12

Pharmacy, 29/39 Brunswick Square, London, Greater London WC1N 1AX (GB). **BERRY, Jane, Marie** [GB/GB]; School of Pharmaceutical Sciences, The University of Nottingham, University Park, Nottingham, Nottinghamshire NG7 2RD (GB).

(21) International Application Number:
PCT/GB2002/005842

(22) International Filing Date:
20 December 2002 (20.12.2002)

(74) Agents: **BRASNETT, Adrian, H.** et al.; Mewburn Ellis, York House, 23 Kingsway, London, Greater London WC2B 6HP (GB).

(25) Filing Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(26) Publication Language: English

(71) Applicant (*for all designated States except US*): **CANCER RESEARCH TECHNOLOGY LIMITED** [GB/GB]; Sardinia House, Sardinia Street, London WC2A 3NL (GB).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **STEVENS, Malcolm, Francis, Graham** [GB/GB]; School of Pharmaceutical Sciences, The University of Nottingham, University Park, Nottingham, Nottinghamshire NG7 2RD (GB). **WESTWELL, Andrew, David** [GB/GB]; School of Pharmaceutical Sciences, The University of Nottingham, University Park, Nottingham, Nottinghamshire NG7 2RD (GB). **POOLE, Tracey, Dawn** [GB/GB]; School of Pharmaceutical Sciences, The University of Nottingham, University Park, Nottingham, Nottinghamshire NG7 2RD (GB). **WELLS, Geoffrey** [GB/GB]; Department of Pharmaceutical and Biological Chemistry, The School of

Declaration under Rule 4.17:


— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report
— with amended claims and statement

[Continued on next page]

(54) Title: 4-(1-(SULFONYL)-1H-INDOL-2-YL)-4-(HYDROXY)-CYCLOHEXA-2,5-DIENONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS



(I)

(57) Abstract: This invention pertains to certain 4-(1-(sulfonyl)-1H-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds, and analogs thereof, including compounds of the following formula, which are, inter alia, antiproliferative agents, anticancer agents, and/or thioredoxin/thioredoxin reductase inhibitors: formula (I) wherein: Ar is a 1-(sulfonyl)-1H-indol-2-yl group; the bond marked α is independently: (a) a single bond; or: (b) a double bond; the bond marked β is independently: (a) a single bond; or: (b) a double bond; the group $-OR^O$ is independently: (a) $-OH$; (b) an ether group (e.g., $-OMe$); or: (c) an acyloxy (i.e., reverse ester) group (e.g., $-OC(=O)Me$); each of R^2 , R^3 , R^5 , and R^6 , is independently a ring substituent and is: (a) H; (b) a monovalent monodentate substituent; or: (c) a ring substituent which, together with an adjacent ring substituent, and together with the ring atoms to which these ring substituents are attached, form a fused ring; and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, for example, in the treatment of proliferative conditions, (e.g., cancer), and/or conditions mediated by thioredoxin/thioredoxin reductase.

WO 2004/056361 A1

WO 2005/056361 A1



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

**4-(1-(SULFONYL)-1H-INDOL-2-YL)-4-(HYDROXY)-CYCLOHEXA-2,5-DIENONE
COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS**

TECHNICAL FIELD

5

This invention pertains generally to the field of therapeutic agents, and more specifically to certain 4-(1-(sulfonyl)-1H-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds, and analogs thereof, which are, inter alia, antiproliferative agents, anticancer agents, and/or thioredoxin/thioredoxin reductase inhibitors.

10 The present invention also pertains to compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, for example, in the treatment of proliferative conditions, cancer, and/or conditions mediated by thioredoxin/thioredoxin reductase.

15

BACKGROUND



Throughout this specification, including the claims which follow, unless the context requires otherwise, the word "comprise," and variations such as "comprises" and "comprising," will be understood to imply the inclusion of a stated integer or step or
20 group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

It must be noted that, as used in the specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context
25 clearly dictates otherwise. Thus, for example, reference to "a pharmaceutical carrier" includes mixtures of two or more such carriers, and the like.


Ranges are often expressed herein as from "about" one particular value, and/or to "about" another particular value. When such a range is expressed, another
30 embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by the use of the antecedent "about," it will be understood that the particular value forms another embodiments.

- 2 -

Phenolic xenobiotics can be modified by cellular systems in a number of ways, e.g., oxidation, glucuronidation, sulphation, methylation, acetylation, etc., and the instability of certain phenolic protein tyrosine kinase (PTK) inhibitors has been documented. For example, the antitumor PTK inhibitor erbstatin, shown below, is known to have a short half-life (<30 min) in fetal calf serum (see, e.g., Umezawa et al., 1991), and the lack of correlation between the activity of tyrphostins, shown below, against isolated enzymes and their effects in vitro and in vivo, is noteworthy (see, e.g., Rambas et al., 1994). Di- and tri-phenolic tyrphostins decompose in solution to more active PTK inhibitors (see, e.g., Faaland et al., 1991), whereas tyrphostins devoid of hydroxy groups have a rapid onset of cellular activity (see, e.g., Reddy et al., 1992), implicating metabolic oxidation to a quinone (or other) moiety as a possible bioactivating step.




Wells et al., 2000, describe several benzothiazole substituted quinol derivatives, shown below, where R^1 is -Ac, -Me, -Et, -nPr, or $-\text{CH}_2\text{C}\equiv\text{CH}$, and R^2 is -Me or -Et. These compounds were reported to have activity against certain colon (HCT-116 and HT29) and breast (MCF-7 and MDA468) cancer cell lines in vitro. Note that there is no mention of possible application as thioredoxin/thioredoxin reductase inhibitors.





- 3 -



Stevens et al., 2003, describe various 4-aryl quinols and analogs thereof, including 4-(1H-indol-2-yl) quinols (see page 20 therein), wherein the 1H-indol-2-yl group bears an optional N-substituent (i.e., 1-substituent), denoted R^N , which is -H, C_{1-7} alkyl, C_{3-20} heterocyclyl, or C_{5-20} aryl (see page 22 therein). Nowhere in this document is there any teaching or suggestion of a 1-sulfonyl substituent on the 1H-indol-2-yl group (e.g., as R^N).



Two compounds that contain a hydroxycyclohexadienone structure and which apparently have antitumor activity have been reported: a hydroxylated flavone-substituted quinol (i.e., a chromone substituted quinol) (see, e.g., Wada et al., 1987) and an oxidized estrone (see, e.g., Milic et al., 1999).



Several related antitumor epoxyquinols, such as Manumycin A (see, e.g., Alcaraz et al., 1998) and LL-C 10037 α (see, e.g., Wipf et al., 1994) are known.



SUMMARY OF THE INVENTION

One aspect of the invention pertains to novel active compounds as described herein.

5

Another aspect of the invention pertains to a composition comprising an active compound as described herein and a pharmaceutically acceptable carrier or diluent.

10 Another aspect of the invention pertains to an active compound as described herein for use in a method of treatment of the human or animal body.

Another aspect of the invention pertains to use of an active compound as described herein for the manufacture of a medicament for use in the treatment of, 15 for example, a proliferative condition (e.g., cancer), a condition mediated by thioredoxin/thioredoxin reductase, etc.

Another aspect of the invention pertains to a method of inhibiting thioredoxin/thioredoxin reductase, *in vitro* or *in vivo*, comprising contacting a cell 20 with an effective amount of an active compound as described herein.

Another aspect of the invention pertains to a method of regulating cell proliferation, *in vitro* or *in vivo*, comprising contacting a cell with an effective amount of an active compound as described herein.

25

Another aspect of the invention pertains to a method of (a) inhibiting cell proliferation; (b) inhibiting cell cycle progression; (c) promoting apoptosis; or (d) a combination of one or more of these, *in vitro* or *in vivo*, comprising contacting a cell with an effective amount of a compound as described herein.

30

Another aspect of the invention pertains to a method for the treatment of, for example, a proliferative condition (e.g., cancer), a condition mediated by thioredoxin/thioredoxin reductase, etc., comprising administering to a subject

- 5 -

suffering from said condition a therapeutically-effective amount of an active compound, as described herein.

5 Another aspect of the present invention pertains to a kit comprising (a) the active compound, preferably provided as a pharmaceutical composition and in a suitable container and/or with suitable packaging; and (b) instructions for use, for example, written instructions on how to administer the active compound.

10 Another aspect of the present invention pertains to compounds *obtainable* by a method of synthesis as described herein, or a method comprising a method of synthesis as described herein.

15 Another aspect of the present invention pertains to compounds *obtained* by a method of synthesis as described herein, or a method comprising a method of synthesis as described herein.

20 Another aspect of the present invention pertains to novel intermediates, as described herein, which are suitable for use in the methods of synthesis described herein.

Another aspect of the present invention pertains to the use of such novel intermediates, as described herein, in the methods of synthesis described herein.

25 As will be appreciated by one of skill in the art, features and preferred embodiments of one aspect of the invention will also pertain to other aspect of the invention.

DETAILED DESCRIPTION OF THE INVENTIONCompounds

- 5 One aspect of the present invention pertains compounds having the following formula:



wherein:

Ar is a 1-(sulfonyl)-1H-indol-2-yl group;

the bond marked α is independently:

- 10 (a) a single bond; or:
(b) a double bond;

the bond marked β is independently:

- (a) a single bond; or:
(b) a double bond;

- 15 the group $-OR^0$ is independently:


- (a) $-OH$;
(b) an ether group (e.g., $-OMe$); or:
(c) an acyloxy (i.e., reverse ester) group (e.g., $-OC(=O)Me$);

each of R^2 , R^3 , R^5 , and R^6 , is independently a ring substituent and is:

- 20 (a) H;
(b) a monovalent monodentate substituent; or:
(c) a ring substituent which, together with an adjacent ring substituent, and together with the ring atoms to which these ring substituents are attached, form a fused ring;
- 25 and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof.

Optical Isomers

Note that, in these compounds, one, two, or three of the ring atoms (marked with an asterisk (*) in the following formula) may be chiral (for example, depending on the bonds α and β , and the substituents, R^2 , R^3 , R^5 and R^6) and if so, may be in R or S configuration. Unless otherwise specified, the resulting optical isomers (discussed below) are encompassed by the corresponding structure, which is silent as to configuration.

The Bonds, α and β

The bond marked α is independently a single bond or a double bond.


The bond marked β is independently a single bond or a double bond.

In one embodiment:

(a) α is independently a double bond and β is independently a double bond; or:

(b) α is independently a single bond and β is independently a single bond.

In one embodiment, α is independently a double bond and β is independently a double bond (and the compound is substituted cyclohexa-2,5-dienone):



(2)

- 8 -

In one embodiment, α is independently a single bond and β is independently a single bond (and the compound is substituted cyclohexan-2-one):



In one embodiment, α is independently a single bond and β is independently a double bond (and the compound is substituted cyclohex-2-enone):



Note that, in the context of α and β , a "double" bond includes both a simple double bond, such as the double bond in cyclohexene, and an aromatic "double" bond, such as, for example, the carbon-carbon bonds in benzene.

Quinol Ring Substituents, R^2 , R^3 , R^5 , and R^6

The ring substituents, R^2 , R^3 , R^5 , and R^6 , may be selected to improve the physical or biological properties of the compound, for example, to improve water solubility and/or bioavailability.

In one embodiment, each of R^2 , R^3 , R^5 , and R^6 , is independently a ring substituent and is:

(a) H;

or:

(b) a monovalent monodentate substituent (for example, as described below under the heading "Quinol Ring Substituents: Monovalent Monodentate Substituents");

or:

(c) a ring substituent which, together with an adjacent ring substituent, and

together with the ring atoms to which these ring substituents are attached, form a

fused ring (for example, as described below under the heading "Quinol Ring Substituents: Fused Rings").

Quinol Ring Substituents: Monovalent Monodentate Substituents

5

In one embodiment, said monovalent monodentate substituent (e.g., mentioned above in reference to R^2 , R^3 , R^5 , and R^6) is independently as defined below for R^P , or a thiol or thioether group (for example, as described below under the heading "Quinol Ring Substituents: Thiols and Thioethers").

10

In one embodiment, said monovalent monodentate substituent is independently selected from:

hydroxy (-OH);

halo;

15

azido;

C_{1-7} alkyl, including, e.g.,

halo- C_{1-7} alkyl;

amino- C_{1-7} alkyl (e.g., $-(CH_2)_w$ -amino);

carboxy- C_{1-7} alkyl (e.g., $-(CH_2)_w$ -COOH);

20

hydroxy- C_{1-7} alkyl (e.g., $-(CH_2)_w$ -OH);

C_{5-20} aryl- C_{1-7} alkyl;

ether, including, e.g.,

C_{1-7} alkoxy;

halo- C_{1-7} alkoxy;

25

amino- C_{1-7} alkoxy (e.g., $-O(CH_2)_w$ -amino);

carboxy- C_{1-7} alkoxy (e.g., $-O(CH_2)_w$ -COOH);

hydroxy- C_{1-7} alkoxy (e.g., $-O(CH_2)_w$ -OH);

C_{5-20} aryl- C_{1-7} alkoxy;

acyl, including, e.g.,

30

C_{1-7} alkyl-acyl;

halo- C_{1-7} alkyl-acyl;

amino- C_{1-7} alkyl-acyl (e.g., $-C(=O)(CH_2)_w$ -amino);

carboxy- C_{1-7} alkyl-acyl (e.g., $-C(=O)(CH_2)_w$ -COOH);

- 10 -

hydroxy-C₁₋₇alkyl-acyl (e.g., -C(=O)(CH₂)_w-OH);

C₅₋₂₀aryl-C₁₋₇alkyl-acyl;

C₅₋₂₀aryl-acyl; and

thiol (-SH);

5 thioether;

wherein w is an integer from 1 to 7, preferably 1 to 4, preferably 1, 2, or 3.

In one embodiment, said monovalent monodentate substituent is independently selected from:

- 10 -OH;
-F, -Cl, -Br, -I;
-N₃;
-Me, -Et, -nPr, -iPr, -tBu;
-OMe, -OEt, -O-nPr, -O-iPr, -O-tBu;
15 -C(=O)Me, -C(=O)Et, -C(=O)nPr, -C(=O)iPr, -C(=O)tBu, -C(=O)Ph, -
C(=O)Bn;
-SH;
-SMe, -SEt, -SnPr, -S-iPr, -S-nBu, -S-iBu, -S-sBu, -S-tBu, -S-CH₂-Ph,
-S-Ph;
20 a thioether group derived from cysteine, homocysteine, glutathione, or a
peptide of the type -Cys-(X)_y-Cys-, where X is an amino acid, and y is an
integer from 1 to 6.

25 In one embodiment, said monovalent monodentate substituent is independently
selected from: hydroxy, halo, C₁₋₇alkoxy, thiol, and thioether.

In one embodiment, said monovalent monodentate substituent is independently selected from:

- 30 -OH;
-F, -Cl, -Br, -I;
-OMe, -OEt, -O-nPr, -O-iPr, -O-tBu;
-SH;

- 11 -

-SMe, -SEt, -SnPr, -S-iPr, -S-nBu, -S-iBu, -S-sBu, -S-tBu, -S-CH₂-Ph,
-S-Ph;

a thioether group derived from cysteine, homocysteine, glutathione, or a
peptide of the type -Cys-(X)_y-Cys-, where X is an amino acid, and y is an
integer from 1 to 6.

In one embodiment, said monovalent monodentate substituent is independently
selected from: halo, thiol, and thioether.

In one embodiment, said monovalent monodentate substituent is independently
selected from:



-F, -Cl, -Br, -I;

-SH;

-SMe, -SEt, -SnPr, -S-iPr, -S-nBu, -S-iBu, -S-sBu, -S-tBu, -S-CH₂-Ph,

-S-Ph;

a thioether group derived from cysteine, homocysteine, glutathione, or a
peptide of the type -Cys-(X)_y-Cys-, where X is an amino acid, and y is an
integer from 1 to 6.

Quinol Ring Substituents: Thiols and Thioethers

In one embodiment, one or more of said monovalent monodentate substituent(s),
R², R³, R⁵, and R⁶, is a thiol (-SH) or a thioether group.

In one embodiment, if: α is a double bond and β is a double bond, then: thiols and
thioethers are excluded from the alternatives for said monovalent monodentate
substituents, R², R³, R⁵, and R⁶.

In one embodiment, one or both of R³ and R⁵, is a thiol or thioether group.

In one embodiment, exactly one of R³ and R⁵, is a thiol or thioether group.

In one embodiment, each of R³ and R⁵ is a thiol or thioether group.

In one embodiment, if: one or both of R^3 and R^5 is a thiol or thioether group; then: α is a single bond; and β is a single bond.

- 5 In one embodiment, if: R^3 is a thiol or thioether group; then: β is a single bond.
In one embodiment, if: R^5 is a thiol or thioether group; then: α is a single bond.
In one embodiment, if: each of R^3 and R^5 is a thiol or thioether group; then: α is a single bond; and β is a single bond.
- 10 In one embodiment, α is a single bond, β is a single bond, and: one or more of said monovalent monodentate substituent, R^2 , R^3 , R^5 , and R^6 , is a thiol or a thioether group.
- 15 In one embodiment, α is a single bond, β is a single bond, and: one or both of R^3 and R^5 is a thiol or thioether group.
- In one embodiment, α is a single bond, β is a single bond, and: exactly one of R^3 and R^5 is a thiol or thioether group.
- 20 In one embodiment, α is a single bond, β is a single bond, and: each of R^3 and R^5 is a thiol or thioether group.
- 25 In one embodiment, α is a single bond, β is a single bond, and: each of R^3 and R^5 is a thioether group, and: R^3 and R^5 are linked. For example, R^3 and R^5 may, together, form a part of a peptide comprising the sequence -Cys-(X)_y-Cys-, where X is an amino acid (e.g., α -amino acid), and y is an integer from 1 to 6 (e.g., 1, 2, 3, 4, 5, or 6), and the -SH groups of the two cysteine residues are attached to the cyclohexa-2,5-dienone ring.
- 30 Such compounds may be considered to be mono- and di-thiol adducts of the corresponding cyclohex-2,5-dienone (see below).

In such cases, the thiol and thioether group may collectively be denoted $-SR^S$.

In one embodiment, R^S is -H or an organic group (typically from 1 to 30 atoms other than hydrogen) which optionally bears one or more substituents, such as hydroxy, carboxy, carboxylate, acyloxy, amino, amido, and acyl amido groups.

5

In one embodiment:

- (a) R^S is -H, C_{1-7} alkyl (including, e.g., C_{5-20} aryl- C_{1-7} alkyl), C_{3-20} heterocyclyl, or C_{5-20} aryl; and is optionally substituted; or
- (b) $-SR^S$ is a thioether group derived from a thiol-containing amino acid or peptide.

10

In one embodiment:

- (a) R^S is -H, C_{1-7} alkyl (including, e.g., C_{5-20} aryl- C_{1-7} alkyl) or C_{5-20} aryl; and is optionally substituted; or
- (b) $-SR^S$ is a thioether group derived from a thiol-containing amino acid or peptide.

15

In one embodiment:

- (a) R^S is -H, C_{1-7} alkyl (including, e.g., C_{5-20} aryl- C_{1-7} alkyl) or C_{5-20} aryl; and is optionally substituted.

20

In one embodiment:

- (b) $-SR^S$ is a thioether group derived from a thiol-containing amino acid or peptide.


25

In one embodiment, $-SR^S$ is a thioether group derived from a thiol-containing compound, such as, for example, a thiol-containing amino acid, e.g., cysteine, homocysteine, etc., or a thiol-containing peptide, e.g., a peptide comprising a thiol-containing amino acid, for example, glutathione and peptides (e.g., comprising from 4 to 100, preferably from 4 to 20, more preferably 4 to 10, amino acids) comprising the sequence $-Cys-(X)_y-Cys-$, where X is an amino acid (e.g., α -amino acid), and y is an integer from 1 to 6 (e.g., 1, 2, 3, 4, 5, or 6); as well as and esters (e.g., methyl esters) and amides (e.g., acetic acid amides) thereof.

30

Some examples of such groups are shown below (where n is e.g., 1, 2, or 3):

- 14 -




In one embodiment:

- 5 (a) R^S is selected from: -H, -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu, -CH₂-Ph, -Ph; or:
- (b) -SR^S is a thioether group derived from cysteine, homocysteine, glutathione, or a peptide comprising the sequence -Cys-(X)_y-Cys-, where X is an amino acid, and y is an integer from 1 to 6.

10

15

The cyclohexa-2,5-dienone compounds described herein undergo addition reactions with thiols, to yield thiol mono- and/or di-adducts (see "Synthesis" below). Without wishing to be bound by any particular theory, it is believed that the addition reaction is reversible, and that such adducts may undergo elimination reaction, e.g., in vivo, to yield the original cyclohexa-2,5-dienone compound. In this way, the thiol mono- and/or di-adducts may act as prodrugs for the corresponding cyclohexa-2,5-dienone compounds; the thiol mono- and/or di-adducts may also have improved properties, e.g., water solubility, as compared to the corresponding cyclohexa-2,5-dienone compounds.



20

Quinol Ring Substituents: No Fused Rings

In one embodiment, each of R^2 , R^3 , R^5 , and R^6 , is independently a ring substituent and is:

- 5 (a) H;
or:
(b) a monovalent monodentate substituent (for example, as described below under the heading "Quinol Ring Substituents: Monovalent Monodentate Substituents").

- 10 In one embodiment, R^5 and R^6 are -H; and α , β , R^2 , R^3 , Ar, and R^O are as defined herein, but R^2 and R^3 do not also form a fused ring:



In one embodiment, R^2 and R^3 are -H; and α , β , R^5 , R^6 , Ar, and R^O are as defined herein, but R^5 and R^6 do not also form a fused ring:



15

In one embodiment, R^2 and R^6 are -H; and α , β , R^3 , R^5 , Ar, and R^O are as defined herein:



- 16 -

In one embodiment, R^3 and R^5 are -H; and α , β , R^2 , R^6 , Ar, and R^O are as defined herein:



5

In one embodiment, R^2 , R^3 , R^5 and R^6 are -H; and α , β , Ar, and R^O are as defined herein:



In one embodiment, R^2 , R^3 , R^5 and R^6 are -H; α is a double bond; β is a double bond; and Ar and R^O are as defined herein:



10

In one embodiment, R^2 , R^3 , R^5 and R^6 are -H; α is a single bond; β is a single bond; and Ar and R^O are as defined herein:



In one embodiment, R^2 , R^3 , R^5 and R^6 are -H; α is a single bond; β is a double bond; and Ar and R^O are as defined herein:



15

Ring Substituents: Fused Rings

In one embodiment, one or more ring substituents (e.g., R^3 , R^4 , R^5 , or R^6), together with an adjacent ring substituent (i.e., selected from the remainder of R^3 ,

- 17 -

R^4 , R^5 , and R^6), and together with the ring atoms to which these ring substituents are attached, form a fused ring (fused to the main ring).

In one embodiment,

- 5 (a) R^2 and R^3 , together with the ring atoms to which they are attached, form a fused ring;
(b) R^5 and R^6 , together with the ring atoms to which they are attached, form a fused ring; or:
(c) or both (a) and (b).

10

In one embodiment, the fused ring (or, if there are two fused rings, one of them, or each of them) is a fused aromatic ring.

15

In one embodiment, the fused ring (or, if there are two fused rings, one of them, or each of them) is a fused aromatic ring with 5 or 6 ring atoms.

20

In one embodiment, the fused ring (or, if there are two fused rings, one of them, or each of them) is a fused aromatic ring with 6 ring atoms.

In one embodiment, the fused ring (or, if there are two fused rings, one of them, or each of them) is a fused aromatic ring with 6 ring carbon atoms.

25

Where ring substituents, together with the ring atoms to which they are attached, form an aromatic ring (fused to the main ring), that ring may itself be substituted with one or more aryl substituents, for example, as defined for R^P .

30

In one embodiment, R^2 and R^3 , together with the ring atoms to which they are attached, form a fused ring, as described above (e.g., a fused aromatic ring; a fused aromatic ring with 5 or 6 ring atoms; a fused aromatic ring with 6 ring atoms; a fused aromatic ring with 6 ring carbon atoms).

- 18 -

In one embodiment, R^2 and R^3 form a fused benzene ring; β is a double bond; and α , Ar, R^O , R^5 , and R^6 are as defined herein:



In a further embodiment, R^5 and R^6 do not also form a fused ring.

5

In one embodiment, R^2 and R^3 form a fused benzene ring; β is a double bond; R^5 is -H; and α , R^6 , Ar, and R^O are as defined herein:



In one embodiment, R^2 and R^3 form a fused benzene ring; β is a double bond; R^6 is -H; and α , R^5 , Ar, and R^O are as defined herein:

10



In one embodiment, R^2 and R^3 form a fused benzene ring; β is a double bond; R^5 and R^6 are -H; and α , Ar, and R^O are as defined herein:



- 19 -

In one embodiment, R^2 and R^3 form a fused benzene ring; β is a double bond; R^5 and R^6 are -H; α is a double bond; and Ar and R^O are as defined herein:




5 In one embodiment, R^5 and R^6 , together with the ring atoms to which they are attached, form a fused ring, as described above (e.g., a fused aromatic ring; a fused aromatic ring with 5 or 6 ring atoms; a fused aromatic ring with 6 ring atoms; a fused aromatic ring with 6 ring carbon atoms).

10 In one embodiment, R^5 and R^6 form a fused benzene ring; α is a double bond; and β , R^2 , R^3 , Ar, and R^O are as defined herein:




In a further embodiment, R^2 and R^3 do not also form a fused ring.

15 In one embodiment, R^5 and R^6 form a fused benzene ring; α is a double bond; R^3 is -H; and β , R^2 , Ar, and R^O are as defined herein:



- 20 -

In one embodiment, R^5 and R^6 form a fused benzene ring; α is a double bond; R^2 is -H; and β , R^3 , Ar, and R^O are as defined herein:



(21)

Oxy Substituent, R^O

5

The oxy substituent, R^O , is independently: (a) -H; or: (b) other than -H.

In one embodiment, the group - OR^O is independently:

(a) -OH;

10

(b) an ether group (e.g., -OMe); or

(c) an acyloxy (i.e., reverse ester) group (e.g., -OC(=O)Me);

In one embodiment, R^O is independently:

(a) -H;

15

(b) C_{1-7} alkyl, C_{3-20} heterocyclyl, or C_{5-20} aryl; and is optionally substituted; or

(c) C_{1-7} alkyl-acyl, C_{3-20} heterocyclyl-acyl, or C_{5-20} aryl-acyl; and is optionally substituted.

In one embodiment, R^O is unsubstituted.

20

In one embodiment, R^O is substituted.

Oxy Substituent, R^O , is -H

In one embodiment, R^O is independently -H.

25

- 21 -

In one embodiment, R^O is -H; and R^2 , R^3 , R^5 , R^6 , α , β , and Ar are as defined herein:



5 In one embodiment, R^O is -H; α is a double bond; β is a double bond; and R^2 , R^3 , R^5 , R^6 , and Ar are as defined herein:



In one embodiment, R^O is -H; α is a single bond; β is a single bond; and R^2 , R^3 , R^5 , R^6 , and Ar are as defined herein:



10 In one embodiment, R^O is -H; α is a single bond; β is a double bond; and R^2 , R^3 , R^5 , R^6 , and Ar are as defined herein:



In one embodiment, R^O is -H; R^2 , R^3 , R^5 and R^6 are -H; α is a double bond; β is a double bond; and Ar is as defined herein:



- 22 -

In one embodiment, R^0 is -H; R^2 , R^3 , R^5 and R^6 are -H; α is a single bond; β is a single bond; and Ar is as defined herein:



In one embodiment, R^0 is -H; R^2 , R^3 , R^5 and R^6 are -H; α is a single bond; β is a double bond; and Ar is as defined herein:



In one embodiment, R^0 is -H; R^2 and R^3 form a fused benzene ring; R^5 and R^6 are -H; α is a double bond; β is a double bond; and Ar is as defined herein:



10 Oxy Substituent, R^0 , is Other Than -H

In one embodiment, R^0 is independently other than -H.

Without wishing to be bound by any particular theory, it is believed that the group
 15 -OR⁰ is converted (e.g., hydrolyzed, metabolized, etc.) to give the group -OH, in vivo. Consequently, in one embodiment, the group -OR⁰ is selected to be readily hydrolyzed in vivo.

In one embodiment, the group -OR⁰ is independently:

- 20 (b) an ether group; or
 (c) an acyloxy (i.e., reverse ester) group.

In one embodiment, the group -OR⁰ is independently (b).

In one embodiment, the group -OR⁰ is independently (c).

- 23 -

In one embodiment, R^O is independently:

(b) C_{1-7} alkyl, C_{3-20} heterocyclyl, or C_{5-20} aryl; and is optionally substituted;

(c) C_{1-7} alkyl-acyl, C_{3-20} heterocyclyl-acyl, or C_{5-20} aryl-acyl; and is optionally substituted.

5

In one embodiment, the group $-OR^O$ is independently (b).

In one embodiment, the group $-OR^O$ is independently (c).

In one embodiment, R^O is unsubstituted.

10 In one embodiment, R^O is substituted.

In one embodiment, R^O is optionally substituted with one more of the following groups:

hydroxy (-OH);

15 halo;

carboxy (-COOH);

amino; and,

C_{5-20} aryl.

20 In one embodiment, R^O is an amino- C_{1-7} alkyl-acyl group, of the formula $-C(=O)-J-K$, wherein J is a C_{1-7} alkylene group, and K is an amino group. In one embodiment, R^O is $-C(=O)(CH_2)_n-K$, where n is an integer from 1 to 7, preferably 1 to 3, and K is an amino group. For example, in one embodiment, R^O is $-C(=O)CH_2CH_2CH_2NH_2$.


25

The Aryl Group, Ar

The aryl group, Ar, is a 1-(sulfonyl)-1H-indol-2-yl group.

- 24 -

In one embodiment, Ar is a group of the following formula:



wherein:

R^{SO} is independently a sulfonyl substituent; and

5 each of R^{3N} , R^{4N} , R^{5N} , R^{6N} , and R^{7N} is independently an indolyl substituent.

The Sulfonyl Substituent, R^{SO}

10 In one embodiment, the sulfonyl substituent, R^{SO} , is C_{1-7} alkyl, C_{3-20} heterocyclyl, or C_{5-20} aryl; and is optionally substituted.

In one embodiment, R^{SO} is C_{1-7} alkyl or C_{5-20} aryl; and is optionally substituted.

In one embodiment, R^{SO} is C_{1-7} alkyl; and is optionally substituted.

15 In one embodiment, R^{SO} is C_{3-20} heterocyclyl; and is optionally substituted.

In one embodiment, R^{SO} is C_{5-20} aryl; and is optionally substituted.

In one embodiment, R^{SO} is unsubstituted.

In one embodiment, R^{SO} is substituted.

20

Examples of substituents are described below, for example, as defined for R^P .

The Sulfonyl Substituent, R^{SO} : Alkyl Sulfonyl

25 In one embodiment, R^{SO} is C_{1-7} alkyl; and is optionally substituted.

In one embodiment, R^{SO} is C_{1-6} alkyl; and is optionally substituted.

In one embodiment, R^{SO} is C_{1-5} alkyl; and is optionally substituted.

In one embodiment, R^{SO} is C_{1-4} alkyl; and is optionally substituted.

- 25 -

In one embodiment, R^{SO} is C_{1-3} alkyl; and is optionally substituted.

In one embodiment, R^{SO} is methyl or ethyl; and is optionally substituted.

In one embodiment, R^{SO} is methyl; and is optionally substituted.

5 In one embodiment, R^{SO} is substituted.

In one embodiment, R^{SO} is unsubstituted.

Examples of substituents are described below, for example, as defined for R^P .

10 When R^{SO} is -Me, the sulfonyl group, $-SO_2R^{SO}$, is "mesyl."

When R^{SO} is $-CF_3$, the sulfonyl group, $-SO_2R^{SO}$, is "triflyl."

When R^{SO} is -Et, the sulfonyl group, $-SO_2R^{SO}$, is "esyl."

When R^{SO} is $-C_4F_9$, the sulfonyl group, $-SO_2R^{SO}$, is "nonafllyl."

When R^{SO} is $-CH_2CF_3$, the sulfonyl group, $-SO_2R^{SO}$, is "tresyl."

15

The Sulfonyl Substituent, R^{SO} : Alkyl Sulfonyl: Substituents

In one embodiment, R^{SO} is C_{1-7} alkyl (or as defined above), optionally substituted with one more substituents as defined for R^P .

20

In one embodiment, R^{SO} is C_{1-7} alkyl (or as defined above), optionally substituted with one more of the following groups:

hydroxy (-OH);

halo;

25

carboxy (-COOH);

amino; and,

C_{5-20} aryl.

In one embodiment, R^{SO} is selected from:

30

hydroxy- C_{1-7} alkyl (e.g., $-(CH_2)_w-OH$);

halo- C_{1-7} alkyl;

carboxy- C_{1-7} alkyl (e.g., $-(CH_2)_w-COOH$);

amino- C_{1-7} alkyl (e.g., $-(CH_2)_w-amino$); and,

C₅₋₂₀aryl-C₁₋₇alkyl;

wherein w is an integer from 1 to 7, preferably 1 to 4, preferably 1, 2, or 3.

The Sulfonyl Substituent, R^{SO}: Heterocyclyl Sulfonyl

5

In one embodiment, R^{SO} is C₃₋₂₀heterocyclyl; and is optionally substituted.

In one embodiment, R^{SO} is C₅₋₂₀heterocyclyl; and is optionally substituted.

In one embodiment, R^{SO} is C₅₋₁₅heterocyclyl; and is optionally substituted.

In one embodiment, R^{SO} is C₅₋₁₂heterocyclyl; and is optionally substituted.

10 In one embodiment, R^{SO} is C₅₋₁₀heterocyclyl; and is optionally substituted.

In one embodiment, R^{SO} is C₅₋₉heterocyclyl; and is optionally substituted.

In one embodiment, R^{SO} is C₅₋₇heterocyclyl; and is optionally substituted.

In one embodiment, R^{SO} is C₅₋₆heterocyclyl; and is optionally substituted.

15 In one embodiment, R^{SO} is substituted.

In one embodiment, R^{SO} is unsubstituted.

Examples of substituents are described below, for example, as defined for R^P.

20 The Sulfonyl Substituent, R^{SO}: Aryl Sulfonyl

In one embodiment, R^{SO} is C₅₋₂₀aryl; and is optionally substituted.

In one embodiment, R^{SO} is C₅₋₂₀carboaryl; and is optionally substituted.

25 In one embodiment, R^{SO} is C₅₋₁₀aryl; and is optionally substituted.

In one embodiment, R^{SO} is C₅₋₁₀carboryl; and is optionally substituted.

In one embodiment, R^{SO} is naphthyl or phenyl; and is optionally substituted.

In one embodiment, R^{SO} is naphthyl; and is optionally substituted.

30 In one embodiment, R^{SO} is C₅₋₆aryl; and is optionally substituted.

In one embodiment, R^{SO} is C₅₋₆carboaryl; and is optionally substituted.

In one embodiment, R^{SO} is phenyl; and is optionally substituted.

- 27 -

In one embodiment, R^{SO} is unsubstituted.


In one embodiment, R^{SO} is substituted.

Examples of substituents are described below, for example, as defined for R^P .

5

The Sulfonyl Substituent, R^{SO} : Phenyl Sulfonyl

In one embodiment, R^{SO} is (an optionally substituted phenyl group):



10 wherein p is an integer from 0 to 5, and each R^P is a phenyl substituent.

In one embodiment, R^{SO} is an unsubstituted phenyl group.

In one embodiment, R^{SO} is a substituted phenyl group.

15 In one embodiment, p is 0, 1, 2, 3, 4 or 5.

In one embodiment, p is 0, 1, 2, 3, or 4.

In one embodiment, p is 0, 1, 2 or 3.

In one embodiment, p is 0, 1 or 2.

In one embodiment, p is 0 or 1.

20

In one embodiment, p is 1, 2, 3, 4 or 5.

In one embodiment, p is 1, 2, 3, or 4.

In one embodiment, p is 1, 2 or 3.

In one embodiment, p is 1 or 2.

25

In one embodiment, p is 0.

In one embodiment, p is 1.

In one embodiment, p is 2.

In one embodiment, p is 3.

30

In one embodiment, p is 4.

In one embodiment, p is 5.

If the phenyl group has less than the full complement of substituents, they may be arranged in any combination. For example, if the phenyl group has a single substituent other than hydrogen, it may be in the 2-, 3-, or 4-position. Similarly, if the phenyl group has two substituents other than hydrogen, they may be in the 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-positions. If the phenyl group has three substituents other than hydrogen, they may be in, for example, the 2,3,4-, 2,3,5-, 2,3,6-, 2,4,5-, 2,5,6-, or 3,4,5-positions. If the phenyl group has four substituents other than hydrogen, they may be in, for example, the 3,4,5,6-, 2,4,5,6-, 2,3,5,6-, 2,3,4,6-, or 2,3,4,5-positions.

In one embodiment, p is 3 and the R^P groups are in the 2-, 4-, and 6-positions.
In one embodiment, p is 3 and the R^P groups are in the 3-, 4-, and 5-positions.

In one embodiment, p is 2 and the R^P groups are in the 2- and 4-positions.
In one embodiment, p is 2 and the R^P groups are in the 2- and 5-positions.
In one embodiment, p is 2 and the R^P groups are in the 2- and 6-positions.
In one embodiment, p is 2 and the R^P groups are in the 3- and 4-positions.
In one embodiment, p is 2 and the R^P groups are in the 3- and 5-positions.


In one embodiment, p is 1 and R^P is in the 2-, 3-, or 4-position.
In one embodiment, p is 1 and R^P is in the 2- or 4-position.
In one embodiment, p is 1 and R^P is in the 2-position.
In one embodiment, p is 1 and R^P is in the 3-position.
In one embodiment, p is 1 and R^P is in the 4-position.

Examples of substituents are described below.

When R^{SO} is -Ph, the sulfonyl group, $-SO_2R^{SO}$, is "besyl."
When R^{SO} is 4-Me, the sulfonyl group, $-SO_2R^{SO}$, is "tosyl."
When R^{SO} is 4-Cl, the sulfonyl group, $-SO_2R^{SO}$, is "closyl."
When R^{SO} is 4-Br, the sulfonyl group, $-SO_2R^{SO}$, is "brosyl."
When R^{SO} is 4-NO₂, the sulfonyl group, $-SO_2R^{SO}$, is "nosyl."

The Sulfonyl Substituent, R^{SO} : Naphthyl Sulfonyl

In one embodiment, R^{SO} is (an optionally substituted naphth-1-yl group or naphth-2-yl group):



wherein q is an integer from 0 to 3; r is an integer from 0 to 4; and each R^P is a naphthyl substituent.

In one embodiment, R^{SO} is an unsubstituted naphth-1-yl group or naphth-2-yl group.

In one embodiment, R^{SO} is a substituted naphth-1-yl group or naphth-2-yl group.

In one embodiment, R^{SO} is an optionally substituted naphth-1-yl group.

In one embodiment, R^{SO} is an unsubstituted naphth-1-yl group.

In one embodiment, R^{SO} is a substituted naphth-1-yl group.

In one embodiment, R^{SO} is an optionally substituted naphth-2-yl group.

In one embodiment, R^{SO} is an unsubstituted naphth-2-yl group.

In one embodiment, R^{SO} is a substituted naphth-2-yl group.

In one embodiment, q is 0, 1, 2 or 3.

In one embodiment, q is 0, 1 or 2.

In one embodiment, q is 0 or 1.

In one embodiment, q is 1, 2 or 3.

In one embodiment, q is 1 or 2.

In one embodiment, q is 0.

In one embodiment, q is 1.

- 30 -

In one embodiment, q is 2.

In one embodiment, q is 3.

In one embodiment, r is 0, 1, 2, 3, or 4.

5 In one embodiment, r is 0, 1, 2 or 3.

In one embodiment, r is 0, 1 or 2.

In one embodiment, r is 0 or 1.

In one embodiment, r is 1, 2, 3, or 4.

10 In one embodiment, r is 1, 2 or 3.

In one embodiment, r is 1 or 2.

In one embodiment, r is 0.

In one embodiment, r is 1.

15 In one embodiment, r is 2.

In one embodiment, r is 3.

In one embodiment, r is 4.

Examples of substituents are described below.

20

When R^{SO} is 5-dimethylaminonaphth-1-yl, the sulfonyl group, $-SO_2R^{SO}$, is "dansyl."

The Sulfonyl Substituent, R^{SO} : Phenyl and Naphthyl Sulfonyl: Substituents R^P

25 In one embodiment, each R^P is independently selected from:

halo; hydroxy; ether (e.g., C_{1-7} alkoxy); formyl; acyl (e.g., C_{1-7} alkylacyl, C_{5-20} arylacyl); carboxy; ester; acyloxy; amido; acylamido; thioamido; tetrazolyl; amino; nitro; azido; cyano; cyanato; thiocyno; isothiocyno; sulfhydryl; thioether (e.g., C_{1-7} alkylthio); sulfonic acid; sulfonate; sulfonyl; sulfonyloxy; sulfinyloxy; 30 sulfamino; sulfonamino; sulfinamino; sulfamyl; sulfonamido; C_{1-7} alkyl (including, e.g., unsubstituted C_{1-7} alkyl, C_{1-7} haloalkyl, C_{1-7} hydroxyalkyl, C_{1-7} carboxyalkyl, C_{1-7} aminoalkyl, C_{5-20} aryl- C_{1-7} alkyl); C_{3-20} heterocyclyl; and C_{5-20} aryl (including, e.g., C_{5-20} carboaryl, C_{5-20} heteroaryl, C_{1-7} alkyl- C_{5-20} aryl and C_{5-20} haloaryl).

In one embodiment, each R^P is independently selected from:

hydroxy (-OH);

halo;

5 cyano (-CN);

carboxy (-COOH);

azido;

ester;

amino, including e.g.,

10 C₁₋₇alkyl-amino;

amino-C₁₋₇alkyl-amino (e.g., -NH(CH₂)_w-amino);

C₁₋₇alkyl, including, e.g.,

halo-C₁₋₇alkyl;

amino-C₁₋₇alkyl (e.g., -(CH₂)_w-amino);

15 carboxy-C₁₋₇alkyl (e.g., -(CH₂)_w-COOH);

hydroxy-C₁₋₇alkyl (e.g., -(CH₂)_w-OH);

C₅₋₂₀aryl-C₁₋₇alkyl;

ether, including, e.g.,

C₁₋₇alkoxy;

20 halo-C₁₋₇alkoxy;

amino-C₁₋₇alkoxy (e.g., -O(CH₂)_w-amino);

carboxy-C₁₋₇alkoxy (e.g., -O(CH₂)_w-COOH);

hydroxy-C₁₋₇alkoxy (e.g., -O(CH₂)_w-OH);

C₅₋₂₀aryl-C₁₋₇alkoxy;

25 acyl, including, e.g.,

C₁₋₇alkyl-acyl;

halo-C₁₋₇alkyl-acyl;

amino-C₁₋₇alkyl-acyl (e.g., -C(=O)(CH₂)_w-amino);

carboxy-C₁₋₇alkyl-acyl (e.g., -C(=O)(CH₂)_w-COOH);

30 hydroxy-C₁₋₇alkyl-acyl (e.g., -C(=O)(CH₂)_w-OH);

C₅₋₂₀aryl-C₁₋₇alkyl-acyl;

C₅₋₂₀aryl-acyl;

C₅₋₂₀aryl;

wherein w is an integer from 1 to 7, preferably 1 to 4, preferably 1, 2, or 3.

In one embodiment, each R^P is independently selected from:

- 5 -OH;
 -F, -Cl, -Br, -I;
 -CN;
 -COOH;
 -N₃;
10 -COOMe, -COOEt, -COOtBu, -COOPh, -COOCH₂Ph;

 -NH₂, -NHMe, -NH₂Et, -NMe₂, -NEt₂;
 piperidino, morpholino, piperazino, N-methyl-piperazino;
 -NH(CH₂)_w-NH₂, -NH(CH₂)_w-NHMe, -NH(CH₂)_w-NMe₂, -NH(CH₂)_w-NEt₂;
15
 -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu;
 -CH₂F, -CH₂Cl, -CF₃, -CCl₃, -CF₂CF₃, -CH₂CF₃, -C(CF₃)₃;
 -(CH₂)_w-NH₂, -(CH₂)_w-NHMe, -(CH₂)_w-NMe₂, -(CH₂)_w-NEt₂;
 -(CH₂)_w-COOH;
20 -(CH₂)_w-OH;
 -CH₂Ph;

 -OMe, -OEt, -OnPr, -OiPr, -OnBu, -OiBu, -OsBu, -OtBu;
 -OCH₂F, -OCH₂Cl, -OCF₃, -OCCl₃, -OCF₂CF₃, -OCH₂CF₃, -OC(CF₃)₃;
25 -O(CH₂)_w-NH₂, -O(CH₂)_w-NHMe, -O(CH₂)_w-NMe₂, -O(CH₂)_w-NEt₂;
 -O(CH₂)_w-COOH;
 -O(CH₂)_w-OH;
 -OCH₂Ph;

30 -C(=O)Me, -C(=O)Et, -C(=O)-nPr, -C(=O)-iPr, -C(=O)-nBu, -C(=O)-iBu,
 -C(=O)-sBu, -C(=O)-tBu;
 -C(=O)CH₂F, -C(=O)CH₂Cl, -C(=O)CF₃, -C(=O)CCl₃, -C(=O)CF₂CF₃,
 -C(=O)CH₂CF₃, -C(=O)C(CF₃)₃;

- 33 -

-C(=O) (CH₂)_w-NH₂, -C(=O) (CH₂)_w-NHMe, -C(=O) (CH₂)_w-NMe₂,
-C(=O)(CH₂)_w-NEt₂;
-C(=O) (CH₂)_w-COOH;
-C(=O) (CH₂)_w-OH;
5 -C(=O)CH₂Ph;

-Ph;

wherein w is an integer from 1 to 7, preferably 1 to 4, preferably 1, 2, or 3.

In one embodiment, each R^P is independently selected from:

hydroxy (-OH);
halo;
C₁₋₇alkyl;
15 halo-C₁₋₇alkyl;
C₁₋₇alkoxy;
halo-C₁₋₇alkyl.

In one embodiment, each R^P is independently selected from:

20 -OH;
-F, -Cl, -Br, -I;
-Me, -Et;
-CF₃, -CH₂CF₃, -C₄F₉;
-OMe, -OEt;
25 -OCF₃, -OCH₂CF₃, -OC₄F₉.

In one embodiment, each R^P is independently selected from:

halo;
C₁₋₇alkyl;
30 C₁₋₇alkoxy.

In one embodiment, each R^P is independently selected from:

-F, -Cl, -Br, -I, -Me, -Et, -OMe, -OEt.

In one embodiment, each R^P is independently selected from:

-F, -Me, -OMe.

5 The Indol-2-yl Ring Substituents: R^{3N} , R^{4N} , R^{5N} , R^{6N} , and R^{7N}

In one embodiment, each of R^{3N} , R^{4N} , R^{5N} , R^{6N} , and R^{7N} is independently -H, or as defined above for R^P .

10 In one embodiment, each of R^{3N} , R^{4N} , R^{5N} , R^{6N} , and R^{7N} is independently -H, or selected from:

hydroxy (-OH);

halo;

C_{1-7} alkyl;

15 C_{1-7} alkoxy.

In one embodiment, each of R^{3N} , R^{4N} , R^{5N} , R^{6N} , and R^{7N} is independently selected from:

-H, -OH, -F, -Cl, -Br, -I, -Me, -Et, -OMe, -OEt.

20 In one embodiment, each of R^{3N} , R^{4N} , R^{5N} , R^{6N} , and R^{7N} is independently -H, or selected from:

halo;

C_{1-7} alkyl;

25 C_{1-7} alkoxy.

In one embodiment, each of R^{3N} , R^{4N} , R^{5N} , R^{6N} , and R^{7N} is independently selected from:

-H, -F, -Cl, -Br, -I, -Me, -Et, -OMe, -OEt.

30 In one embodiment, each of R^{3N} , R^{4N} , R^{5N} , R^{6N} , and R^{7N} is independently selected from:

-H, -F, -OMe.

In one embodiment, R^{3N} is -H.

In one embodiment, each of R^{4N} and R^{7N} is -H.

5 In one embodiment, each of R^{3N} , R^{4N} and R^{7N} is -H.

In one embodiment, each of R^{4N} , R^{6N} , and R^{7N} is -H.

In one embodiment, each of R^{3N} , R^{4N} , R^{6N} , and R^{7N} is -H.

10 In one embodiment, each of R^{4N} , R^{5N} , and R^{7N} is -H.

In one embodiment, each of R^{3N} , R^{4N} , R^{5N} , and R^{7N} is -H.

In one embodiment, each of R^{5N} , R^{6N} , and R^{7N} is -H.

In one embodiment, each of R^{3N} , R^{5N} , R^{6N} , and R^{7N} is -H.

15

In one embodiment, each of R^{4N} , R^{5N} , and R^{6N} is -H.

In one embodiment, each of R^{3N} , R^{4N} , R^{5N} , and R^{6N} is -H.


In one embodiment, each of R^{3N} , R^{4N} , R^{5N} , R^{6N} , and R^{7N} is -H.






20





Examples of Specific Embodiments


Some individual embodiments of the present invention include the following compounds:

25






	SIQ-02
	SIQ-03
	SIQ-04
	SIQ-05
	SIQ-06

	SIQ-07
	SIQ-08
	SIQ-09
	SIQ-10



Examples of additional individual embodiments of the present invention include the following compounds:



	SIQ-15
	SIQ-16

Chemical Terms

5 The term "carbo," "carbyl," "hydrocarbo," and "hydrocarbyl," as used herein, pertain to compounds and/or groups which have only carbon and hydrogen atoms (but see "carbocyclic" below).

10 The term "hetero," as used herein, pertains to compounds and/or groups which have at least one heteroatom, for example, multivalent heteroatoms (which are also suitable as ring heteroatoms) such as boron, silicon, nitrogen, phosphorus, oxygen, sulfur, and selenium (more commonly nitrogen, oxygen, and sulfur) and monovalent heteroatoms, such as fluorine, chlorine, bromine, and iodine.

15 The term "saturated," as used herein, pertains to compounds and/or groups which do not have any carbon-carbon double bonds or carbon-carbon triple bonds.

The term "unsaturated," as used herein, pertains to compounds and/or groups which have at least one carbon-carbon double bond or carbon-carbon triple bond. Compounds and/or groups may be partially unsaturated or fully unsaturated.

- 5 The term "aliphatic," as used herein, pertains to compounds and/or groups which are linear or branched, but not cyclic (also known as "acyclic" or "open-chain" groups).

- 10 The term "ring," as used herein, pertains to a closed ring of from 3 to 10 covalently linked atoms, more preferably 3 to 8 covalently linked atoms, yet more preferably 5 to 6 covalently linked atoms. A ring may be an alicyclic ring or an aromatic ring. The term "alicyclic ring," as used herein, pertains to a ring which is not an aromatic ring.

- 15 The term "carbocyclic ring," as used herein, pertains to a ring wherein all of the ring atoms are carbon atoms.

- The term "carboaromatic ring," as used herein, pertains to an aromatic ring wherein all of the ring atoms are carbon atoms.

- 20 The term "heterocyclic ring," as used herein, pertains to a ring wherein at least one of the ring atoms is a multivalent ring heteroatom, for example, nitrogen, phosphorus, silicon, oxygen, or sulfur, though more commonly nitrogen, oxygen, or sulfur. Preferably, the heterocyclic ring has from 1 to 4 heteroatoms.

- 25 The term "cyclic compound," as used herein, pertains to a compound which has at least one ring. The term "cyclyl," as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from a ring atom of a cyclic compound.

- 30 Where a cyclic compound has two or more rings, they may be fused (e.g., as in naphthalene, decalin, etc.), bridged (e.g., as in norbornane, adamantane, etc.), spiro (e.g., as in spiro[3.3]heptane), or a combination thereof. Cyclic compounds with one ring may be referred to as "monocyclic" or "mononuclear," whereas cyclic

compounds with two or more rings may be referred to as "polycyclic" or "polynuclear."

5 The term "carbocyclic compound," as used herein, pertains to a cyclic compound which has only carbocyclic ring(s).

The term "heterocyclic compound," as used herein, pertains to a cyclic compound which has at least one heterocyclic ring.

10 The term "aromatic compound," as used herein, pertains to a cyclic compound which has at least one aromatic ring.

The term "carboaromatic compound," as used herein, pertains to a cyclic compound which has only carboaromatic ring(s).

15 The term "heteroaromatic compound," as used herein, pertains to a cyclic compound which has at least one heteroaromatic ring.

20 The term "monodentate substituents," as used herein, pertains to substituents which have one point of covalent attachment.

The term "monovalent monodentate substituents," as used herein, pertains to substituents which have one point of covalent attachment, via a single bond. Examples of such substituents include halo, hydroxy, and alkyl.

25 The term "multivalent monodentate substituents," as used herein, pertains to substituents which have one point of covalent attachment, but through a double bond or triple bond. Examples of such substituents include oxo, imino, alkylidene, and alkidyne.

30 The term "bidentate substituents," as used herein, pertains to substituents which have two points of covalent attachment, and which act as a linking group between two other moieties. Examples of such substituents include alkylene and arylene.

Substituents

5 The phrase "optionally substituted," as used herein, pertains to a parent group which may be unsubstituted or which may be substituted.

10 Unless otherwise specified, the term "substituted," as used herein, pertains to a parent group which bears one or more substituents. The term "substituent" is used herein in the conventional sense and refers to a chemical moiety which is covalently attached to, or if appropriate, fused to, a parent group. A wide variety of substituents are well known, and methods for their formation and introduction into a variety of parent groups are also well known.

15 Examples of substituents are described in more detail below.

20 Alkyl: The term "alkyl," as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from a carbon atom of a hydrocarbon compound having from 1 to 20 carbon atoms (unless otherwise specified), which may be aliphatic or alicyclic, and which may be saturated or unsaturated (e.g., partially unsaturated, fully unsaturated). Thus, the term "alkyl" includes the sub-classes alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, etc., discussed below.

25 In the context of alkyl groups, the prefixes (e.g., C₁₋₄, C₁₋₇, C₁₋₂₀, C₂₋₇, C₃₋₇, etc.) denote the number of carbon atoms, or range of number of carbon atoms. For example, the term "C₁₋₄alkyl," as used herein, pertains to an alkyl group having from 1 to 4 carbon atoms. Examples of groups of alkyl groups include C₁₋₄alkyl ("lower alkyl"), C₁₋₇alkyl, and C₁₋₂₀alkyl. Note that the first prefix may vary according to other limitations; for example, for unsaturated alkyl groups, the first prefix must be at least 2; for cyclic alkyl groups, the first prefix must be at least 3; etc.

30 Examples of (unsubstituted) saturated alkyl groups include, but are not limited to, methyl (C₁), ethyl (C₂), propyl (C₃), butyl (C₄), pentyl (C₅), hexyl (C₆), heptyl (C₇),

octyl (C₈), nonyl (C₉), decyl (C₁₀), undecyl (C₁₁), dodecyl (C₁₂), tridecyl (C₁₃), tetradecyl (C₁₄), pentadecyl (C₁₅), and eicoddecyl (C₂₀).

5 Examples of (unsubstituted) saturated linear alkyl groups include, but are not limited to, methyl (C₁), ethyl (C₂), n-propyl (C₃), n-butyl (C₄), n-pentyl (amyl) (C₅), n-hexyl (C₆), and n-heptyl (C₇).

10 Examples of (unsubstituted) saturated branched alkyl groups include iso-propyl (C₃), iso-butyl (C₄), sec-butyl (C₄), tert-butyl (C₄), iso-pentyl (C₅), and neo-pentyl (C₅).

15 Alkenyl: The term "alkenyl," as used herein, pertains to an alkyl group having one or more carbon-carbon double bonds. Examples of groups of alkenyl groups include C₂₋₄alkenyl, C₂₋₇alkenyl, C₂₋₂₀alkenyl.

20 Examples of (unsubstituted) unsaturated alkenyl groups include, but are not limited to, ethenyl (vinyl, -CH=CH₂), 1-propenyl (-CH=CH-CH₃), 2-propenyl (allyl, -CH-CH=CH₂), isopropenyl (1-methylvinyl, -C(CH₃)=CH₂), butenyl (C₄), pentenyl (C₅), and hexenyl (C₆).

25 Alkynyl: The term "alkynyl," as used herein, pertains to an alkyl group having one or more carbon-carbon triple bonds. Examples of groups of alkynyl groups include C₂₋₄alkynyl, C₂₋₇alkynyl, C₂₋₂₀alkynyl.

30 Examples of (unsubstituted) unsaturated alkynyl groups include, but are not limited to, ethynyl (ethinyl, -C≡CH) and 2-propynyl (propargyl, -CH₂-C≡CH).

Cycloalkyl: The term "cycloalkyl," as used herein, pertains to an alkyl group which is also a cyclyl group; that is, a monovalent moiety obtained by removing a hydrogen atom from an alicyclic ring atom of a carbocyclic ring of a carbocyclic compound, which carbocyclic ring may be saturated or unsaturated (e.g., partially unsaturated, fully unsaturated), which moiety has from 3 to 20 carbon atoms (unless otherwise specified), including from 3 to 20 ring atoms. Thus, the term

"cycloalkyl" includes the sub-classes cycloalkylenyl and cycloalkynyl. Preferably, each ring has from 3 to 7 ring atoms. Examples of groups of cycloalkyl groups include C₃₋₂₀cycloalkyl, C₃₋₁₅cycloalkyl, C₃₋₁₀cycloalkyl, C₃₋₇cycloalkyl.

5 Examples of cycloalkyl groups include, but are not limited to, those derived from:
saturated monocyclic hydrocarbon compounds:

cyclopropane (C₃), cyclobutane (C₄), cyclopentane (C₅), cyclohexane (C₆),
cycloheptane (C₇), methylcyclopropane (C₄), dimethylcyclopropane (C₅),
methylcyclobutane (C₅), dimethylcyclobutane (C₆), methylcyclopentane (C₆),
10 dimethylcyclopentane (C₇), methylcyclohexane (C₇), dimethylcyclohexane (C₈),
menthane (C₁₀);

unsaturated monocyclic hydrocarbon compounds:

cyclopropene (C₃), cyclobutene (C₄), cyclopentene (C₅), cyclohexene (C₆),
methylcyclopropene (C₄), dimethylcyclopropene (C₅), methylcyclobutene (C₅),
15 dimethylcyclobutene (C₆), methylcyclopentene (C₆), dimethylcyclopentene (C₇),
methylcyclohexene (C₇), dimethylcyclohexene (C₈);

saturated polycyclic hydrocarbon compounds:

thujane (C₁₀), carane (C₁₀), pinane (C₁₀), bornane (C₁₀), norcarane (C₇), norpinane
(C₇), norbornane (C₇), adamantane (C₁₀), decalin (decahydronaphthalene) (C₁₀);

20 unsaturated polycyclic hydrocarbon compounds:

camphene (C₁₀), limonene (C₁₀), pinene (C₁₀);

polycyclic hydrocarbon compounds having an aromatic ring:

indene (C₉), indane (e.g., 2,3-dihydro-1H-indene) (C₉), tetraline
(1,2,3,4-tetrahydronaphthalene) (C₁₀), acenaphthene (C₁₂), fluorene (C₁₃),
25 phenalene (C₁₃), acephenanthrene (C₁₅), aceanthrene (C₁₆), cholanthrene (C₂₀).

Alkylidene: The term "alkylidene," as used herein, pertains to a divalent
monodentate moiety obtained by removing two hydrogen atoms from an aliphatic
or alicyclic carbon atom of a hydrocarbon compound having from 1 to 20 carbon
30 atoms (unless otherwise specified). Examples of groups of alkylidene groups
include C₁₋₂₀alkylidene, C₁₋₇alkylidene, C₁₋₄alkylidene.

Examples of alkylidene groups include, but are not limited to, methyldene ($=CH_2$), ethylidene ($=CH-CH_3$), vinylidene ($=C=CH_2$), isopropylidene ($=C(CH_3)_2$), cyclopentylidene. An example of a substituted alkylidene group is benzylidene ($=CH-Ph$).

5

Alkylidyne: The term "alkylidyne," as used herein, pertains to a trivalent monodentate moiety obtained by removing three hydrogen atoms from an aliphatic or alicyclic carbon atom of a hydrocarbon compound having from 1 to 20 carbon atoms (unless otherwise specified). Examples of groups of alkylidyne groups include C_{1-20} alkylidyne, C_{1-7} alkylidyne, C_{1-4} alkylidyne.

10

Examples of alkylidyne groups include, but are not limited to, methylidyne ($\equiv CH$) and ethylidyne ($\equiv C-CH_3$). An example of a substituted alkylidene group is benzylidyne ($\equiv C-Ph$).

15

Carbocyclyl: The term "carbocyclyl," as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from a ring atom of a carbocyclic compound, which moiety has from 3 to 20 ring atoms (unless otherwise specified). Preferably, each ring has from 3 to 7 ring atoms.

20

In this context, the prefixes (e.g., C_{3-20} , C_{3-7} , C_{5-6} , etc.) denote the number of ring atoms, or range of number of ring atoms. For example, the term " C_{5-6} carbocyclyl," as used herein, pertains to a carbocyclyl group having 5 or 6 ring atoms.

Examples of groups of carbocyclyl groups include C_{3-20} carbocyclyl,

25

C_{3-10} carbocyclyl, C_{5-10} carbocyclyl, C_{3-7} carbocyclyl, and C_{5-7} carbocyclyl.

Examples of carbocyclic groups include, but are not limited to, those described above as cycloalkyl groups; and those described below as carboaryl groups.

30

Heterocyclyl: The term "heterocyclyl," as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from a ring atom of a heterocyclic compound, which moiety has from 3 to 20 ring atoms (unless otherwise specified),

of which from 1 to 10 are ring heteroatoms. Preferably, each ring has from 3 to 7 ring atoms, of which from 1 to 4 are ring heteroatoms.

In this context, the prefixes (e.g., C₃₋₂₀, C₃₋₇, C₅₋₆, etc.) denote the number of ring atoms, or range of number of ring atoms, whether carbon atoms or heteroatoms. For example, the term "C₅₋₆heterocyclyl," as used herein, pertains to a heterocyclyl group having 5 or 6 ring atoms. Examples of groups of heterocyclyl groups include C₃₋₂₀heterocyclyl, C₅₋₂₀heterocyclyl, C₃₋₁₅heterocyclyl, C₅₋₁₅heterocyclyl, C₃₋₁₂heterocyclyl, C₅₋₁₂heterocyclyl, C₃₋₁₀heterocyclyl, C₅₋₁₀heterocyclyl, C₃₋₇heterocyclyl, C₅₋₇heterocyclyl, and C₅₋₆heterocyclyl.

Examples of (non-aromatic) monocyclic heterocyclyl groups include, but are not limited to, those derived from:

N₁: aziridine (C₃), azetidine (C₄), pyrrolidine (tetrahydropyrrole) (C₅), pyrroline (e.g., 3-pyrroline, 2,5-dihydropyrrole) (C₅), 2H-pyrrole or 3H-pyrrole (isopyrrole, isoazole) (C₅), piperidine (C₆), dihydropyridine (C₆), tetrahydropyridine (C₆), azepine (C₇);

O₁: oxirane (C₃), oxetane (C₄), oxolane (tetrahydrofuran) (C₅), oxole (dihydrofuran) (C₅), oxane (tetrahydropyran) (C₆), dihydropyran (C₆), pyran (C₆), oxepin (C₇);

S₁: thiirane (C₃), thietane (C₄), thiolane (tetrahydrothiophene) (C₅), thiane (tetrahydrothiopyran) (C₆), thiepane (C₇);

O₂: dioxolane (C₅), dioxane (C₆), and dioxepane (C₇);

O₃: trioxane (C₆);

N₂: imidazolidine (C₅), pyrazolidine (diazolidine) (C₅), imidazoline (C₅), pyrazoline (dihydropyrazole) (C₅), piperazine (C₆);

N₁O₁: tetrahydrooxazole (C₅), dihydrooxazole (C₅), tetrahydroisoxazole (C₅), dihydroisoxazole (C₅), morpholine (C₆), tetrahydrooxazine (C₆), dihydrooxazine (C₆), oxazine (C₆);

5 N₁S₁: thiazoline (C₅), thiazolidine (C₅), thiomorpholine (C₆);

N₂O₁: oxadiazine (C₆);

O₁S₁: oxathiole (C₅) and oxathiane (thioxane) (C₆); and,

10

N₁O₁S₁: oxathiazine (C₆).

Examples of substituted (non-aromatic) monocyclic heterocyclyl groups include those derived from saccharides, in cyclic form, for example, furanoses (C₅), such as arabinofuranose, lyxofuranose, ribofuranose, and xylofuranse, and pyranoses (C₆), such as allopyranose, altropyranose, glucopyranose, mannopyranose, gulopyranose, idopyranose, galactopyranose, and talopyranose.

15

Examples of heterocyclyl groups which are also heteroaryl groups are described below with aryl groups.

20

Aryl: The term "aryl," as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from an aromatic ring atom of an aromatic compound, which moiety has from 3 to 20 ring atoms (unless otherwise specified). Preferably, each ring has from 5 to 7 ring atoms.

25

In this context, the prefixes (e.g., C₃₋₂₀, C₅₋₇, C₅₋₆, etc.) denote the number of ring atoms, or range of number of ring atoms, whether carbon atoms or heteroatoms. For example, the term "C₅₋₆aryl," as used herein, pertains to an aryl group having 5 or 6 ring atoms. Examples of groups of aryl groups include C₃₋₂₀aryl, C₅₋₂₀aryl, C₅₋₁₅aryl, C₅₋₁₂aryl, C₅₋₁₀aryl, C₅₋₇aryl, C₅₋₆aryl, C₅aryl, and C₆aryl.

30

The ring atoms may be all carbon atoms, as in "carboaryl groups." Examples of carboaryl groups include C₃₋₂₀carboaryl, C₅₋₂₀carboaryl, C₅₋₁₅carboaryl, C₅₋₁₂carboaryl, C₅₋₁₀carboaryl, C₅₋₇carboaryl, C₅₋₆carboaryl, C₅carboaryl, and C₆carboaryl.

5

Examples of carboaryl groups include, but are not limited to, those derived from benzene (i.e., phenyl) (C₆), naphthalene (C₁₀), azulene (C₁₀), anthracene (C₁₄), phenanthrene (C₁₄), naphthacene (C₁₈), and pyrene (C₁₆).

10 Examples of aryl groups which comprise fused rings, at least one of which is an aromatic ring, include, but are not limited to, groups derived from indane (e.g., 2,3-dihydro-1H-indene) (C₉), indene (C₉), isoindene (C₉), tetraline (1,2,3,4-tetrahydronaphthalene (C₁₀), acenaphthene (C₁₂), fluorene (C₁₃), phenalene (C₁₃), acephenanthrene (C₁₅), and aceanthrene (C₁₆).

15

Alternatively, the ring atoms may include one or more heteroatoms, as in "heteroaryl groups." Examples of heteroaryl groups include C₃₋₂₀heteroaryl, C₅₋₂₀heteroaryl, C₅₋₁₅heteroaryl, C₅₋₁₂heteroaryl, C₅₋₁₀heteroaryl, C₅₋₇heteroaryl, C₅₋₆heteroaryl, C₅heteroaryl, and C₆heteroaryl.

20

Examples of monocyclic heteroaryl groups include, but are not limited to, those derived from:

N₁: pyrrole (azole) (C₅), pyridine (azine) (C₆);

O₁: furan (oxole) (C₅);

25 S₁: thiophene (thiole) (C₅);

N₁O₁: oxazole (C₅), isoxazole (C₅), isoxazine (C₆);

N₂O₁: oxadiazole (furazan) (C₅);

N₃O₁: oxatriazole (C₅);

N₁S₁: thiazole (C₅), isothiazole (C₅);

30 N₂: imidazole (1,3-diazole) (C₅), pyrazole (1,2-diazole) (C₅), pyridazine (1,2-diazine) (C₆), pyrimidine (1,3-diazine) (C₆) (e.g., cytosine, thymine, uracil), pyrazine (1,4-diazine) (C₆);

N₃: triazole (C₅), triazine (C₆); and,

N₄: tetrazole (C₅).

Examples of heterocyclic groups (some of which are also heteroaryl groups) which comprise fused rings, include, but are not limited to:

5 C₉heterocyclic groups (with 2 fused rings) derived from benzofuran (O₁), isobenzofuran (O₁), indole (N₁), isoindole (N₁), indolizine (N₁), indoline (N₁), isoindoline (N₁), purine (N₄) (e.g., adenine, guanine), benzimidazole (N₂), indazole (N₂), benzoxazole (N₁O₁), benzisoxazole (N₁O₁), benzodioxole (O₂), benzofurazan (N₂O₁), benzotriazole (N₃), benzothiofuran (S₁), benzothiazole (N₁S₁),
10 benzothiadiazole (N₂S);

 C₁₀heterocyclic groups (with 2 fused rings) derived from chromene (O₁), isochromene (O₁), chroman (O₁), isochroman (O₁), benzodioxan (O₂), quinoline (N₁), isoquinoline (N₁), quinolizine (N₁), benzoxazine (N₁O₁), benzodiazine (N₂), pyridopyridine (N₂), quinoxaline (N₂), quinazoline (N₂), cinnoline (N₂), phthalazine
15 (N₂), naphthyridine (N₂), pteridine (N₄);

 C₁₁heterocyclic groups (with 2 fused rings) derived from benzodiazepine (N₂);

 C₁₃heterocyclic groups (with 3 fused rings) derived from carbazole (N₁), dibenzofuran (O₁), dibenzothiophene (S₁), carboline (N₂), perimidine (N₂),
20 pyridoindole (N₂); and,

 C₁₄heterocyclic groups (with 3 fused rings) derived from acridine (N₁), xanthene (O₁), thioxanthene (S₁), oxanthrene (O₂), phenoxathiin (O₁S₁), phenazine (N₂), phenoxazine (N₁O₁), phenothiazine (N₁S₁), thianthrene (S₂), phenanthridine (N₁), phenanthroline (N₂), phenazine (N₂).

25

Heterocyclic groups (including heteroaryl groups) which have a nitrogen ring atom in the form of an -NH- group may be N-substituted, that is, as -NR-. For example, pyrrole may be N-methyl substituted, to give N-methylpyrrole. Examples of N-substitutents include, but are not limited to C₁₋₇alkyl, C₃₋₂₀heterocyclyl, C₅₋₂₀aryl, and acyl groups.
30

Heterocyclic groups (including heteroaryl groups) which have a nitrogen ring atom in the form of an -N= group may be substituted in the form of an N-oxide, that is,

as $-N(\rightarrow O)=$ (also denoted $-N^+(\rightarrow O^-)=$). For example, quinoline may be substituted to give quinoline N-oxide; pyridine to give pyridine N-oxide; benzofurazan to give benzofurazan N-oxide (also known as benzofuroxan).

- 5 Cyclic groups may additionally bear one or more oxo ($=O$) groups on ring carbon atoms.

Monocyclic examples of such groups include, but are not limited to, those derived from:

- 10 C_5 : cyclopentanone, cyclopentenone, cyclopentadienone;
 C_6 : cyclohexanone, cyclohexenone, cyclohexadienone;
 O_1 : furanone (C_5), pyrone (C_6);
 N_1 : pyrrolidone (pyrrolidinone) (C_5), piperidinone (piperidone) (C_6), piperidinedione (C_6);
15 N_2 : imidazolidone (imidazolidinone) (C_5), pyrazolone (pyrazolinone) (C_5),
 piperazinone (C_6), piperazinedione (C_6), pyridazinone (C_6), pyrimidinone (C_6)
 (e.g., cytosine), pyrimidinedione (C_6) (e.g., thymine, uracil), barbituric acid (C_6);
 N_1S_1 : thiazolone (C_5), isothiazolone (C_5);
 N_1O_1 : oxazolinone (C_5).

- 20 Polycyclic examples of such groups include, but are not limited to, those derived from:

- C_9 : indenedione;
 C_{10} : tetralone, decalone;
25 C_{14} : anthrone, phenanthrone;
 N_1 : oxindole (C_9);
 O_1 : benzopyrone (e.g., coumarin, isocoumarin, chromone) (C_{10});
 N_1O_1 : benzoxazolinone (C_9), benzoxazolinone (C_{10});
 N_2 : quinazolinedione (C_{10}); benzodiazepinone (C_{11}); benzodiazepinedione (C_{11});
30 N_4 : purinone (C_9) (e.g., guanine).

Still more examples of cyclic groups which bear one or more oxo ($=O$) groups on ring carbon atoms include, but are not limited to, those derived from:

- 51 -

cyclic anhydrides (-C(=O)-O-C(=O)- in a ring), including but not limited to maleic anhydride (C₅), succinic anhydride (C₅), and glutaric anhydride (C₆);

cyclic carbonates (-O-C(=O)-O- in a ring), such as ethylene carbonate (C₅) and 1,2-propylene carbonate (C₅);

5 imides (-C(=O)-NR-C(=O)- in a ring), including but not limited to, succinimide (C₅), maleimide (C₅), phthalimide, and glutarimide (C₆);

lactones (cyclic esters, -O-C(=O)- in a ring), including, but not limited to, β-propiolactone, γ-butyrolactone, δ-valerolactone (2-piperidone), and ε-caprolactone;

10 lactams (cyclic amides, -NR-C(=O)- in a ring), including, but not limited to, β-propiolactam (C₄), γ-butyrolactam (2-pyrrolidone) (C₅), δ-valerolactam (C₆), and ε-caprolactam (C₇);

cyclic carbamates (-O-C(=O)-NR- in a ring), such as 2-oxazolidone (C₅);

15 cyclic ureas (-NR-C(=O)-NR- in a ring), such as 2-imidazolidone (C₅) and pyrimidine-2,4-dione (e.g., thymine, uracil) (C₆).

The above alkyl, alkylidene, alkylidyne, heterocyclyl, and aryl groups, whether alone or part of another substituent, may themselves optionally be substituted with one or more groups selected from themselves and the additional substituents
20 listed below.

Hydrogen: -H. Note that if the substituent at a particular position is hydrogen, it may be convenient to refer to the compound as being "unsubstituted" at that position.

25

Halo: -F, -Cl, -Br, and -I.

Hydroxy: -OH.

30

Ether: -OR, wherein R is an ether substituent, for example, a C₁₋₇alkyl group (also referred to as a C₁₋₇alkoxy group, discussed below), a C₃₋₂₀heterocyclyl group (also referred to as a C₃₋₂₀heterocyclyloxy group), or a C₅₋₂₀aryl group (also referred to as a C₅₋₂₀aryloxy group), preferably a C₁₋₇alkyl group.

C₁₋₇alkoxy: -OR, wherein R is a C₁₋₇alkyl group. Examples of C₁₋₇alkoxy groups include, but are not limited to, -OMe (methoxy), -OEt (ethoxy), -O(nPr) (n-propoxy), -O(iPr) (isopropoxy), -O(nBu) (n-butoxy), -O(sBu) (sec-butoxy), -O(iBu) (isobutoxy), and -O(tBu) (tert-butoxy).

Acetal: -CH(OR¹)(OR²), wherein R¹ and R² are independently acetal substituents, for example, a C₁₋₇alkyl group, a C₃₋₂₀heterocyclyl group, or a C₅₋₂₀aryl group, preferably a C₁₋₇alkyl group, or, in the case of a "cyclic" acetal group, R¹ and R², taken together with the two oxygen atoms to which they are attached, and the carbon atoms to which they are attached, form a heterocyclic ring having from 4 to 8 ring atoms. Examples of acetal groups include, but are not limited to, -CH(OMe)₂, -CH(OEt)₂, and -CH(OMe)(OEt).

Hemiacetal: -CH(OH)(OR¹), wherein R¹ is a hemiacetal substituent, for example, a C₁₋₇alkyl group, a C₃₋₂₀heterocyclyl group, or a C₅₋₂₀aryl group, preferably a C₁₋₇alkyl group. Examples of hemiacetal groups include, but are not limited to, -CH(OH)(OMe) and -CH(OH)(OEt).

Ketal: -CR(OR¹)(OR²), where R¹ and R² are as defined for acetals, and R is a ketal substituent other than hydrogen, for example, a C₁₋₇alkyl group, a C₃₋₂₀heterocyclyl group, or a C₅₋₂₀aryl group, preferably a C₁₋₇alkyl group. Examples ketal groups include, but are not limited to, -C(Me)(OMe)₂, -C(Me)(OEt)₂, -C(Me)(OMe)(OEt), -C(Et)(OMe)₂, -C(Et)(OEt)₂, and -C(Et)(OMe)(OEt).

Hemiketal: -CR(OH)(OR¹), where R¹ is as defined for hemiacetals, and R is a hemiketal substituent other than hydrogen, for example, a C₁₋₇alkyl group, a C₃₋₂₀heterocyclyl group, or a C₅₋₂₀aryl group, preferably a C₁₋₇alkyl group.

Examples of hemiacetal groups include, but are not limited to, -C(Me)(OH)(OMe), -C(Et)(OH)(OMe), -C(Me)(OH)(OEt), and -C(Et)(OH)(OEt).

Oxo (keto, -one): =O.

Thione (thioketone): $=S$.

5 Imino (imine): $=NR$, wherein R is an imino substituent, for example, hydrogen, C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably hydrogen or a C_{1-7} alkyl group. Examples of ester groups include, but are not limited to, $=NH$, $=NMe$, $=NEt$, and $=NPh$.

10 Formyl (carbaldehyde, carboxaldehyde): $-C(=O)H$.

Acyl (keto): $-C(=O)R$, wherein R is an acyl substituent, for example, a C_{1-7} alkyl group (also referred to as C_{1-7} alkylacyl or C_{1-7} alkanoyl), a C_{3-20} heterocyclyl group (also referred to as C_{3-20} heterocyclylacyl), or a C_{5-20} aryl group (also referred to as C_{5-20} arylacyl), preferably a C_{1-7} alkyl group. Examples of acyl groups include, but are not limited to, $-C(=O)CH_3$ (acetyl), $-C(=O)CH_2CH_3$ (propionyl), $-C(=O)C(CH_3)_3$ (t-butyryl), and $-C(=O)Ph$ (benzoyl, phenone).

Carboxy (carboxylic acid): $-C(=O)OH$.

20 Thiocarboxy (thiocarboxylic acid): $-C(=S)SH$.

Thiolocarboxy (thiolocarboxylic acid): $-C(=O)SH$.

Thionocarboxy (thionocarboxylic acid): $-C(=S)OH$.

25 Imidic acid: $-C(=NH)OH$.

Hydroxamic acid: $-C(=NOH)OH$.

30 Ester (carboxylate, carboxylic acid ester, oxycarbonyl): $-C(=O)OR$, wherein R is an ester substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of ester groups include,




but are not limited to, $-\text{C}(=\text{O})\text{OCH}_3$, $-\text{C}(=\text{O})\text{OCH}_2\text{CH}_3$, $-\text{C}(=\text{O})\text{OC}(\text{CH}_3)_3$, and $-\text{C}(=\text{O})\text{OPh}$.

5 Acyloxy (reverse ester): $-\text{OC}(=\text{O})\text{R}$, wherein R is an acyloxy substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of acyloxy groups include, but are not limited to, $-\text{OC}(=\text{O})\text{CH}_3$ (acetoxyl), $-\text{OC}(=\text{O})\text{CH}_2\text{CH}_3$, $-\text{OC}(=\text{O})\text{C}(\text{CH}_3)_3$, $-\text{OC}(=\text{O})\text{Ph}$, and $-\text{OC}(=\text{O})\text{CH}_2\text{Ph}$.

10 Amido (carbamoyl, carbamyl, aminocarbonyl, carboxamide): $-\text{C}(=\text{O})\text{NR}^1\text{R}^2$, wherein R^1 and R^2 are independently amino substituents, as defined for amino groups. Examples of amido groups include, but are not limited to, $-\text{C}(=\text{O})\text{NH}_2$, $-\text{C}(=\text{O})\text{NHCH}_3$, $-\text{C}(=\text{O})\text{N}(\text{CH}_3)_2$, $-\text{C}(=\text{O})\text{NHCH}_2\text{CH}_3$, and $-\text{C}(=\text{O})\text{N}(\text{CH}_2\text{CH}_3)_2$, as well as amido groups in which R^1 and R^2 , together with the nitrogen atom to which
15 they are attached, form a heterocyclic structure as in, for example, piperidinocarbonyl, morpholinocarbonyl, thiomorpholinocarbonyl, and piperazinocarbonyl.

20 Acylamido (acylamino): $-\text{NR}^1\text{C}(=\text{O})\text{R}^2$, wherein R^1 is an amide substituent, for example, hydrogen, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably hydrogen or a C_{1-7} alkyl group, and R^2 is an acyl substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably hydrogen or a C_{1-7} alkyl group. Examples of acylamide groups include, but are not limited to, $-\text{NHC}(=\text{O})\text{CH}_3$, $-\text{NHC}(=\text{O})\text{CH}_2\text{CH}_3$, and $-\text{NHC}(=\text{O})\text{Ph}$.

25 R^1 and R^2 may together form a cyclic structure, as in, for example, succinimidyl, maleimidyl, and phthalimidyl:




- 55 -

Thioamido (thiocarbamyl): $-C(=S)NR^1R^2$, wherein R^1 and R^2 are independently amino substituents, as defined for amino groups. Examples of amido groups include, but are not limited to, $-C(=S)NH_2$, $-C(=S)NHCH_3$, $-C(=S)N(CH_3)_2$, and $-C(=S)NHCH_2CH_3$.

5 Ureido: $-N(R^1)CONR^2R^3$ wherein R^2 and R^3 are independently amino substituents, as defined for amino groups, and R^1 is a ureido substituent, for example, hydrogen, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably hydrogen or a C_{1-7} alkyl group. Examples of ureido groups
10 include, but are not limited to, $-NHCONH_2$, $-NHCONHMe$, $-NHCONHEt$, $-NHCONMe_2$, $-NHCONEt_2$, $-NMeCONH_2$, $-NMeCONHMe$, $-NMeCONHEt$, $-NMeCONMe_2$, and $-NMeCONEt_2$.

15 Guanidino: $-NH-C(=NH)NH_2$.

Tetrazolyl: a five membered aromatic ring having four nitrogen atoms and one carbon atom,



20 Amino: $-NR^1R^2$, wherein R^1 and R^2 are independently amino substituents, for example, hydrogen, a C_{1-7} alkyl group (also referred to as C_{1-7} alkylamino or di- C_{1-7} alkylamino), a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably H or a C_{1-7} alkyl group, or, in the case of a "cyclic" amino group, R^1 and R^2 , taken together with the nitrogen atom to which they are attached, form a heterocyclic ring having
25 from 4 to 8 ring atoms. Amino groups may be primary ($-NH_2$), secondary ($-NHR^1$), or tertiary ($-NHR^1R^2$), and in cationic form, may be quaternary ($-^+NR^1R^2R^3$). Examples of amino groups include, but are not limited to; $-NH_2$, $-NHCH_3$, $-NHC(CH_3)_2$, $-N(CH_3)_2$, $-N(CH_2CH_3)_2$, and $-NHPh$. Examples of cyclic amino groups include, but are not limited to, aziridino, azetidino, pyrrolidino, piperidino,
30 piperazino, morpholino, and thiomorpholino.

Imino: $=NR$, wherein R is an imino substituent, for example, for example, hydrogen, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably H or a C_{1-7} alkyl group. Examples of imino groups include, but are not limited to, $=NH$, $=NMe$, and $=NEt$.

5

Amidine (amidino): $-C(=NR)NR_2$, wherein each R is an amidine substituent, for example, hydrogen, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably H or a C_{1-7} alkyl group. Examples of amidine groups include, but are not limited to, $-C(=NH)NH_2$, $-C(=NH)NMe_2$, and $-C(=NMe)NMe_2$.

10

Nitro: $-NO_2$.

Azido: $-N_3$.

15

Cyano (nitrile, carbonitrile): $-CN$.

Cyanato: $-OCN$.

Thiocyano (thiocyanato): $-SCN$.

20

Isothiocyano (isothiocyanato): $-NCS$.

Sulfhydryl (thiol, mercapto): $-SH$.

25

Thioether (sulfide): $-SR$, wherein R is a thioether substituent, for example, a C_{1-7} alkyl group (also referred to as a C_{1-7} alkylthio group), a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of C_{1-7} alkylthio groups include, but are not limited to, $-SCH_3$ and $-SCH_2CH_3$.

30

Disulfide: $-SS-R$, wherein R is a disulfide substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group (also referred to herein as C_{1-7} alkyl disulfide). Examples of C_{1-7} alkyl disulfide groups include, but are not limited to, $-SSCH_3$ and $-SSCH_2CH_3$.

Sulfonic acid (sulfo): $-\text{S}(=\text{O})_2\text{OH}$, $-\text{SO}_3\text{H}$.

5 Sulfonate (sulfonic acid ester): $-\text{S}(=\text{O})_2\text{OR}$, wherein R is a sulfonate substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of sulfonate groups include, but are not limited to, $-\text{S}(=\text{O})_2\text{OCH}_3$ and $-\text{S}(=\text{O})_2\text{OCH}_2\text{CH}_3$.

10 Sulfinic acid: $-\text{S}(=\text{O})\text{OH}$, $-\text{SO}_2\text{H}$.

15 Sulfinates (sulfinic acid ester): $-\text{S}(=\text{O})\text{OR}$; wherein R is a sulfinate substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of sulfinate groups include, but are not limited to, $-\text{S}(=\text{O})\text{OCH}_3$ and $-\text{S}(=\text{O})\text{OCH}_2\text{CH}_3$.

20 Sulfate: $-\text{OS}(=\text{O})_2\text{OR}$; wherein R is a sulfate substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of sulfate groups include, but are not limited to, $-\text{OS}(=\text{O})_2\text{OCH}_3$ and $-\text{SO}(=\text{O})_2\text{OCH}_2\text{CH}_3$.

25 Sulfone (sulfonyl): $-\text{S}(=\text{O})_2\text{R}$, wherein R is a sulfone substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group, for example, a fluorinated or perfluorinated C_{1-7} alkyl group. Examples of sulfone groups include, but are not limited to, $-\text{S}(=\text{O})_2\text{CH}_3$ (methanesulfonyl, mesyl), $-\text{S}(=\text{O})_2\text{CF}_3$ (triflyl), $-\text{S}(=\text{O})_2\text{CH}_2\text{CH}_3$ (esyl), $-\text{S}(=\text{O})_2\text{C}_4\text{F}_9$ (nonafllyl), $-\text{S}(=\text{O})_2\text{CH}_2\text{CF}_3$ (tresyl), $-\text{S}(=\text{O})_2\text{Ph}$ (phenylsulfonyl, besyl), 4-methylphenylsulfonyl (tosyl), 4-chlorophenylsulfonyl (closyl), 4-bromophenylsulfonyl (brosyl), 4-nitrophenyl (nosyl), 2-naphthalenesulfonate (napsyl), and 5-dimethylamino-naphthalen-1-ylsulfonate (dansyl).

30 Sulfine (sulfinyl, sulfoxide): $-\text{S}(=\text{O})\text{R}$, wherein R is a sulfine substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group,

preferably a C₁₋₇alkyl group. Examples of sulfine groups include, but are not limited to, -S(=O)CH₃ and -S(=O)CH₂CH₃.

5 Sulfonyloxy: -OS(=O)₂R, wherein R is a sulfonyloxy substituent, for example, a C₁₋₇alkyl group, a C₃₋₂₀heterocyclyl group, or a C₅₋₂₀aryl group, preferably a C₁₋₇alkyl group. Examples of sulfonyloxy groups include, but are not limited to, -OS(=O)₂CH₃ (mesylate) and -OS(=O)₂CH₂CH₃ (esylate).

10 Sulfinyloxy: -OS(=O)R, wherein R is a sulfinyloxy substituent, for example, a C₁₋₇alkyl group, a C₃₋₂₀heterocyclyl group, or a C₅₋₂₀aryl group, preferably a C₁₋₇alkyl group. Examples of sulfinyloxy groups include, but are not limited to, -OS(=O)CH₃ and -OS(=O)CH₂CH₃.

15 Sulfamino: -NR¹S(=O)₂OH, wherein R¹ is an amino substituent, as defined for amino groups. Examples of sulfamino groups include, but are not limited to, -NHS(=O)₂OH and -N(CH₃)S(=O)₂OH.

20 Sulfonamino: -NR¹S(=O)₂R, wherein R¹ is an amino substituent, as defined for amino groups, and R is a sulfonamino substituent, for example, a C₁₋₇alkyl group, a C₃₋₂₀heterocyclyl group, or a C₅₋₂₀aryl group, preferably a C₁₋₇alkyl group. Examples of sulfonamino groups include, but are not limited to, -NHS(=O)₂CH₃ and -N(CH₃)S(=O)₂C₆H₅.

25 Sulfinamino: -NR¹S(=O)R, wherein R¹ is an amino substituent, as defined for amino groups, and R is a sulfinamino substituent, for example, a C₁₋₇alkyl group, a C₃₋₂₀heterocyclyl group, or a C₅₋₂₀aryl group, preferably a C₁₋₇alkyl group. Examples of sulfinamino groups include, but are not limited to, -NHS(=O)CH₃ and -N(CH₃)S(=O)C₆H₅.

30 Sulfamyl: -S(=O)NR¹R², wherein R¹ and R² are independently amino substituents, as defined for amino groups. Examples of sulfamyl groups include, but are not limited to, -S(=O)NH₂, -S(=O)NH(CH₃), -S(=O)N(CH₃)₂, -S(=O)NH(CH₂CH₃), -S(=O)N(CH₂CH₃)₂, and -S(=O)NHPh.

Sulfonamido: $-S(=O)_2NR^1R^2$, wherein R^1 and R^2 are independently amino substituents, as defined for amino groups. Examples of sulfonamido groups include, but are not limited to, $-S(=O)_2NH_2$, $-S(=O)_2NH(CH_3)$, $-S(=O)_2N(CH_3)_2$,
5 $-S(=O)_2NH(CH_2CH_3)$, $-S(=O)_2N(CH_2CH_3)_2$, and $-S(=O)_2NHPh$.

In many cases, substituents are themselves substituted.

For example, a C_{1-7} alkyl group may be substituted with, for example:

- 10 hydroxy (also referred to as a hydroxy- C_{1-7} alkyl group);
halo (also referred to as a halo- C_{1-7} alkyl group);
amino (also referred to as a amino- C_{1-7} alkyl group);
carboxy (also referred to as a carboxy- C_{1-7} alkyl group);
 C_{1-7} alkoxy (also referred to as a C_{1-7} alkoxy- C_{1-7} alkyl group);
15 C_{5-20} aryl (also referred to as a C_{5-20} aryl- C_{1-7} alkyl group).

Similarly, a C_{5-20} aryl group may be substituted with, for example:

- hydroxy (also referred to as a hydroxy- C_{5-20} aryl group);
halo (also referred to as a halo- C_{5-20} aryl group);
20 amino (also referred to as an amino- C_{5-20} aryl group, e.g., as in aniline);
carboxy (also referred to as an carboxy- C_{5-20} aryl group, e.g., as in benzoic acid);
 C_{1-7} alkyl (also referred to as a C_{1-7} alkyl- C_{5-20} aryl group, e.g., as in toluene);
 C_{1-7} alkoxy (also referred to as a C_{1-7} alkoxy- C_{5-20} aryl group, e.g., as in anisole);
 C_{5-20} aryl (also referred to as a C_{5-20} aryl- C_{5-20} aryl, e.g., as in biphenyl).

25 These and other specific examples of such substituted-substituents are described below.

Hydroxy- C_{1-7} alkyl: The term "hydroxy- C_{1-7} alkyl," as used herein, pertains to a
30 C_{1-7} alkyl group in which at least one hydrogen atom (e.g., 1, 2, 3) has been replaced with a hydroxy group. Examples of such groups include, but are not limited to, $-CH_2OH$, $-CH_2CH_2OH$, and $-CH(OH)CH_2OH$.

Halo-C₁₋₇alkyl group: The term "halo-C₁₋₇alkyl," as used herein, pertains to a C₁₋₇alkyl group in which at least one hydrogen atom (e.g., 1, 2, 3) has been replaced with a halogen atom (e.g., F, Cl, Br, I). If more than one hydrogen atom has been replaced with a halogen atom, the halogen atoms may independently be the same or different. Every hydrogen atom may be replaced with a halogen atom, in which case the group may conveniently be referred to as a C₁₋₇perhaloalkyl group." Examples of such groups include, but are not limited to, -CF₃, -CHF₂, -CH₂F, -CCl₃, -CBr₃, -CH₂CH₂F, -CH₂CHF₂, and -CH₂CF₃.

10 Amino-C₁₋₇alkyl: The term "amino-C₁₋₇alkyl," as used herein, pertains to a C₁₋₇alkyl group in which at least one hydrogen atom (e.g., 1, 2, 3) has been replaced with an amino group. Examples of such groups include, but are not limited to, -CH₂NH₂, -CH₂CH₂NH₂, and -CH₂CH₂N(CH₃)₂.

15 Carboxy-C₁₋₇alkyl: The term "carboxy-C₁₋₇alkyl," as used herein, pertains to a C₁₋₇alkyl group in which at least one hydrogen atom (e.g., 1, 2, 3) has been replaced with a carboxy group. Examples of such groups include, but are not limited to, -CH₂COOH and -CH₂CH₂COOH.

20 C₁₋₇alkoxy-C₁₋₇alkyl: The term "C₁₋₇alkoxy-C₁₋₇alkyl," as used herein, pertains to a C₁₋₇alkyl group in which at least one hydrogen atom (e.g., 1, 2, 3) has been replaced with a C₁₋₇alkoxy group. Examples of such groups include, but are not limited to, -CH₂OCH₃, -CH₂CH₂OCH₃, and -CH₂CH₂OCH₂CH₃.

25 C₅₋₂₀aryl-C₁₋₇alkyl: The term "C₅₋₂₀aryl-C₁₋₇alkyl," as used herein, pertains to a C₁₋₇alkyl group in which at least one hydrogen atom (e.g., 1, 2, 3) has been replaced with a C₅₋₂₀aryl group. Examples of such groups include, but are not limited to, benzyl (phenylmethyl, PhCH₂-), benzhydryl (Ph₂CH-), trityl (triphenylmethyl, Ph₃C-), phenethyl (phenylethyl, Ph-CH₂CH₂-), styryl (Ph-CH=CH-), cinnamyl (Ph-CH=CH-CH₂-).

30 Hydroxy-C₅₋₂₀aryl: The term "hydroxy-C₅₋₂₀aryl," as used herein, pertains to a C₅₋₂₀aryl group in which at least one hydrogen atom (e.g., 1, 2, 3) has been

substituted with an hydroxy group. Examples of such groups include, but are not limited to, those derived from: phenol, naphthol, pyrocatechol, resorcinol, hydroquinone, pyrogallol, phloroglucinol.

5 Halo-C₅₋₂₀aryl: The term "halo-C₅₋₂₀aryl," as used herein, pertains to a C₅₋₂₀aryl group in which at least one hydrogen atom (e.g., 1, 2, 3) has been substituted with a halo (e.g., F, Cl, Br, I) group. Examples of such groups include, but are not limited to, halophenyl (e.g., fluorophenyl, chlorophenyl, bromophenyl, or iodophenyl, whether ortho-, meta-, or para-substituted), dihalophenyl, trihalophenyl, tetrahalophenyl, and pentahalophenyl.

15 C₁₋₇alkyl-C₅₋₂₀aryl: The term "C₁₋₇alkyl-C₅₋₂₀aryl," as used herein, pertains to a C₅₋₂₀aryl group in which at least one hydrogen atom (e.g., 1, 2, 3) has been substituted with a C₁₋₇alkyl group. Examples of such groups include, but are not limited to, tolyl (from toluene), xylyl (from xylene), mesityl (from mesitylene), and cumenyl (or cumyl, from cumene), and duryl (from durene).

20 Hydroxy-C₁₋₇alkoxy: -OR, wherein R is a hydroxy-C₁₋₇alkyl group. Examples of hydroxy-C₁₋₇alkoxy groups include, but are not limited to, -OCH₂OH, -OCH₂CH₂OH, and -OCH₂CH₂CH₂OH.

25 Halo-C₁₋₇alkoxy: -OR, wherein R is a halo-C₁₋₇alkyl group. Examples of halo-C₁₋₇alkoxy groups include, but are not limited to, -OCF₃, -OCHF₂, -OCH₂F, -OCCl₃, -OCBr₃, -OCH₂CH₂F, -OCH₂CHF₂, and -OCH₂CF₃.

Carboxy-C₁₋₇alkoxy: -OR, wherein R is a carboxy-C₁₋₇alkyl group. Examples of carboxy-C₁₋₇alkoxy groups include, but are not limited to, -OCH₂COOH, -OCH₂CH₂COOH, and -OCH₂CH₂CH₂COOH.

30 C₁₋₇alkoxy-C₁₋₇alkoxy: -OR, wherein R is a C₁₋₇alkoxy-C₁₋₇alkyl group. Examples of C₁₋₇alkoxy-C₁₋₇alkoxy groups include, but are not limited to, -OCH₂OCH₃, -OCH₂CH₂OCH₃, and -OCH₂CH₂OCH₂CH₃.

C₅₋₂₀aryl-C₁₋₇alkoxy: -OR, wherein R is a C₅₋₂₀aryl-C₁₋₇alkyl group. Examples of such groups include, but are not limited to, benzyloxy, benzhydryloxy, trityloxy, phenethoxy, styryloxy, and cimmamyloxy.

- 5 C₁₋₇alkyl-C₅₋₂₀aryloxy: -OR, wherein R is a C₁₋₇alkyl-C₅₋₂₀aryl group. Examples of such groups include, but are not limited to, tolyloxy, xylyloxy, mesityloxy, cumenyloxy, and duryloxy.

- 10 Amino-C₁₋₇alkyl-amino: The term "amino-C₁₋₇alkyl-amino," as used herein, pertains to an amino group, -NR¹R², in which one of the substituents, R¹ or R², is itself a amino-C₁₋₇alkyl group (-C₁₋₇alkyl-NR³R⁴). The amino-C₁₋₇alkylamino group may be represented, for example, by the formula -NR¹-C₁₋₇alkyl-NR³R⁴. Examples of such groups include, but are not limited to, groups of the formula -NR¹(CH₂)_nNR¹R², where n is 1 to 6 (for example, -NHCH₂NH₂, -NH(CH₂)₂NH₂, -NH(CH₂)₃NH₂,
15 -NH(CH₂)₄NH₂, -NH(CH₂)₅NH₂, -NH(CH₂)₆NH₂), -NHCH₂NH(Me), -NH(CH₂)₂NH(Me), -NH(CH₂)₃NH(Me), -NH(CH₂)₄NH(Me), -NH(CH₂)₅NH(Me), -NH(CH₂)₆NH(Me), -NHCH₂NH(Et), -NH(CH₂)₂NH(Et), -NH(CH₂)₃NH(Et), -NH(CH₂)₄NH(Et), -NH(CH₂)₅NH(Et), and -NH(CH₂)₆NH(Et).

20 Includes Other Forms

- Unless otherwise specified, included in the above are the well known ionic, salt, solvate, and protected forms of these substituents. For example, a reference to carboxylic acid (-COOH) also includes the anionic (carboxylate) form (-COO⁻), a
25 salt or solvate thereof, as well as conventional protected forms. Similarly, a reference to an amino group includes the protonated form (-N⁺HR¹R²), a salt or solvate of the amino group, for example, a hydrochloride salt, as well as conventional protected forms of an amino group. Similarly, a reference to a hydroxyl group also includes the anionic form (-O⁻), a salt or solvate thereof, as
30 well as conventional protected forms of a hydroxyl group.


Isomers, Salts, Solvates, Protected Forms, and Prodrugs

Certain compounds may exist in one or more particular geometric, optical, enantiomeric, diastereomeric, epimeric, stereoisomeric, tautomeric, conformational, or anomeric forms, including but not limited to, cis- and trans-forms; E- and Z-forms; c-, t-, and r- forms; endo- and exo-forms; R-, S-, and meso-forms; D- and L-forms; d- and l-forms; (+) and (-) forms; keto-, enol-, and enolate-forms; syn- and anti-forms; synclinal- and anticlinal-forms; α - and β -forms; axial and equatorial forms; boat-, chair-, twist-, envelope-, and halfchair-forms; and combinations thereof, hereinafter collectively referred to as "isomers" (or "isomeric forms").

Note that, except as discussed below for tautomeric forms, specifically excluded from the term "isomers," as used herein, are structural (or constitutional) isomers (i.e., isomers which differ in the connections between atoms rather than merely by the position of atoms in space). For example, a reference to a methoxy group, -OCH₃, is not to be construed as a reference to its structural isomer, a hydroxymethyl group, -CH₂OH. Similarly, a reference to ortho-chlorophenyl is not to be construed as a reference to its structural isomer, meta-chlorophenyl.

However, a reference to a class of structures may well include structurally isomeric forms falling within that class (e.g., C₁₋₇alkyl includes n-propyl and isopropyl; butyl includes n-, iso-, sec-, and tert-butyl; methoxyphenyl includes ortho-, meta-, and para-methoxyphenyl).

The above exclusion does not pertain to tautomeric forms, for example, keto-, enol-, and enolate-forms, as in, for example, the following tautomeric pairs: keto/enol (illustrated below), imine/enamine, amide/imino alcohol, amidine/amidine, nitroso/oxime, thioketone/enethiol, N-nitroso/hydroxyazo, and nitro/aci-nitro.



- 64 -

Note that specifically included in the term "isomer" are compounds with one or more isotopic substitutions. For example, H may be in any isotopic form, including ^1H , ^2H (D), and ^3H (T); C may be in any isotopic form, including ^{12}C , ^{13}C , and ^{14}C ; O may be in any isotopic form, including ^{16}O and ^{18}O ; F may be in any isotopic form, including ^{18}F and ^{19}F ; and the like.

Unless otherwise specified, a reference to a particular compound includes all such isomeric forms, including (wholly or partially) racemic and other mixtures thereof. Methods for the preparation (e.g., asymmetric synthesis) and separation (e.g., fractional crystallisation and chromatographic means) of such isomeric forms are either known in the art or are readily obtained by adapting the methods taught herein, or known methods, in a known manner.

Unless otherwise specified, a reference to a particular compound also includes ionic, salt, solvate, and protected forms of thereof, for example, as discussed below.

It may be convenient or desirable to prepare, purify, and/or handle a corresponding salt of the active compound, for example, a pharmaceutically-acceptable salt. Examples of pharmaceutically acceptable salts are discussed in Berge et al., 1977, "Pharmaceutically Acceptable Salts," J. Pharm. Sci., Vol. 66, pp. 1-19.

For example, if the compound is anionic, or has a functional group which may be anionic (e.g., $-\text{COOH}$ may be $-\text{COO}^-$), then a salt may be formed with a suitable cation. Examples of suitable inorganic cations include, but are not limited to, alkali metal ions such as Na^+ and K^+ , alkaline earth cations such as Ca^{2+} and Mg^{2+} , and other cations such as Al^{+3} . Examples of suitable organic cations include, but are not limited to, ammonium ion (i.e., NH_4^+) and substituted ammonium ions (e.g., NH_3R^+ , NH_2R_2^+ , NHR_3^+ , NR_4^+). Examples of some suitable substituted ammonium ions are those derived from: ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and

tromethamine, as well as amino acids, such as lysine and arginine. An example of a common quaternary ammonium ion is $N(CH_3)_4^+$.

If the compound is cationic, or has a functional group which may be cationic (e.g., $-NH_2$ may be $-NH_3^+$), then a salt may be formed with a suitable anion. Examples of suitable inorganic anions include, but are not limited to, those derived from the following inorganic acids: hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfurous, nitric, nitrous, phosphoric, and phosphorous.

Examples of suitable organic anions include, but are not limited to, those derived from the following organic acids: 2-acetyoxybenzoic, acetic, ascorbic, aspartic, benzoic, camphorsulfonic, cinnamic, citric, edetic, ethanedisulfonic, ethanesulfonic, fumaric, glucheptonic, gluconic, glutamic, glycolic, hydroxymaleic, hydroxynaphthalene carboxylic, isethionic, lactic, lactobionic, lauric, maleic, malic, methanesulfonic, mucic, oleic, oxalic, palmitic, pamoic, pantothenic, phenylacetic, phenylsulfonic, propionic, pyruvic, salicylic, stearic, succinic, sulfanilic, tartaric, toluenesulfonic, and valeric. Examples of suitable polymeric organic anions include, but are not limited to, those derived from the following polymeric acids: tannic acid, carboxymethyl cellulose.

It may be convenient or desirable to prepare, purify, and/or handle a corresponding solvate of the active compound. The term "solvate" is used herein in the conventional sense to refer to a complex of solute (e.g., active compound, salt of active compound) and solvent. If the solvent is water, the solvate may be conveniently referred to as a hydrate, for example, a mono-hydrate, a di-hydrate, a tri-hydrate, etc.

It may be convenient or desirable to prepare, purify, and/or handle the active compound in a chemically protected form. The term "chemically protected form" is used herein in the conventional chemical sense and pertains to a compound in which one or more reactive functional groups are protected from undesirable chemical reactions under specified conditions (e.g., pH, temperature, radiation, solvent, and the like). In practice, well known chemical methods are employed to

reversibly render unreactive a functional group, which otherwise would be reactive, under specified conditions. In a chemically protected form, one or more reactive functional groups are in the form of a protected or protecting group (also known as a masked or masking group or a blocked or blocking group). By protecting a reactive functional group, reactions involving other unprotected reactive functional groups can be performed, without affecting the protected group; the protecting group may be removed, usually in a subsequent step, without substantially affecting the remainder of the molecule. See, for example, Protective Groups in Organic Synthesis (T. Green and P. Wuts; 3rd Edition; John Wiley and Sons, 1999).

A wide variety of such "protecting," "blocking," or "masking" methods are widely used and well known in organic synthesis. For example, a compound which has two nonequivalent reactive functional groups, both of which would be reactive under specified conditions, may be derivatized to render one of the functional groups "protected," and therefore unreactive, under the specified conditions; so protected, the compound may be used as a reactant which has effectively only one reactive functional group. After the desired reaction (involving the other functional group) is complete, the protected group may be "deprotected" to return it to its original functionality.

For example, a hydroxy group may be protected as an ether (-OR) or an ester (-OC(=O)R), for example, as: a t-butyl ether; a benzyl, benzhydryl (diphenylmethyl), or trityl (triphenylmethyl) ether; a trimethylsilyl or t-butyldimethylsilyl ether; or an acetyl ester (-OC(=O)CH₃, -OAc).

For example, an aldehyde or ketone group may be protected as an acetal (R-CH(OR)₂) or ketal (R₂C(OR)₂), respectively, in which the carbonyl group (>C=O) is converted to a diether (>C(OR)₂), by reaction with, for example, a primary alcohol. The aldehyde or ketone group is readily regenerated by hydrolysis using a large excess of water in the presence of acid.

- 67 -

For example, an amine group may be protected, for example, as an amide (-NRCO-R) or a urethane (-NRCO-OR), for example, as: a methyl amide (-NHCO-CH₃); a benzyloxy amide (-NHCO-OCH₂C₆H₅, -NH-Cbz); as a t-butoxy amide (-NHCO-OC(CH₃)₃, -NH-Boc); a 2-biphenyl-2-propoxy amide (-NHCO-OC(CH₃)₂C₆H₄C₆H₅, -NH-Bpoc), as a 9-fluorenylmethoxy amide (-NH-Fmoc), as a 6-nitroveratryloxy amide (-NH-Nvoc), as a 2-trimethylsilylethyloxy amide (-NH-Teoc), as a 2,2,2-trichloroethyloxy amide (-NH-Troc), as an allyloxy amide (-NH-Alloc), as a 2-(phenylsulphonyl)ethyloxy amide (-NH-Psec); or, in suitable cases (e.g., cyclic amines), as a nitroxide radical (>N-O•).

For example, a carboxylic acid group may be protected as an ester for example, as: an C₁₋₇alkyl ester (e.g., a methyl ester; a t-butyl ester); a C₁₋₇haloalkyl ester (e.g., a C₁₋₇trihaloalkyl ester); a triC₁₋₇alkylsilyl-C₁₋₇alkyl ester; or a C₅₋₂₀aryl-C₁₋₇alkyl ester (e.g., a benzyl ester; a nitrobenzyl ester); or as an amide, for example, as a methyl amide.

For example, a thiol group may be protected as a thioether (-SR), for example, as: a benzyl thioether; an acetamidomethyl ether (-S-CH₂NHC(=O)CH₃).

It may be convenient or desirable to prepare, purify, and/or handle the active compound in the form of a prodrug. The term "prodrug," as used herein, pertains to a compound which, when metabolised (e.g., in vivo), yields the desired active compound. Typically, the prodrug is inactive, or less active than the active compound, but may provide advantageous handling, administration, or metabolic properties.

For example, some prodrugs are esters of the active compound (e.g., a physiologically acceptable metabolically labile ester). During metabolism, the ester group (-C(=O)OR) is cleaved to yield the active drug. Such esters may be formed by esterification, for example, of any of the carboxylic acid groups (-C(=O)OH) in the parent compound, with, where appropriate, prior protection of

any other reactive groups present in the parent compound, followed by deprotection if required.

Examples of such metabolically labile esters include those of the formula

5 -C(=O)OR wherein R is:

C₁₋₇alkyl

(e.g., -Me, -Et, -nPr, -iPr, -nBu, -sBu, -iBu, -tBu);

C₁₋₇aminoalkyl

(e.g., aminoethyl; 2-(N,N-diethylamino)ethyl; 2-(4-morpholino)ethyl); and

10 acyloxy-C₁₋₇alkyl

(e.g., acyloxymethyl;

acyloxyethyl;

pivaloyloxymethyl;

acetoxymethyl;

15 1-acetoxyethyl;

1-(1-methoxy-1-methyl)ethyl-carboxyloxyethyl;

1-(benzoyloxy)ethyl; isopropoxy-carboxyloxymethyl;

1-isopropoxy-carboxyloxyethyl; cyclohexyl-carboxyloxymethyl;

1-cyclohexyl-carboxyloxyethyl;

20 cyclohexyloxy-carboxyloxymethyl;

1-cyclohexyloxy-carboxyloxyethyl;

(4-tetrahydropyranyloxy) carboxyloxymethyl;

1-(4-tetrahydropyranyloxy)carboxyloxyethyl;

(4-tetrahydropyranyl)carboxyloxymethyl; and

25 1-(4-tetrahydropyranyl)carboxyloxyethyl).

Also, some prodrugs are activated enzymatically to yield the active compound, or a compound which, upon further chemical reaction, yields the active compound.

For example, the prodrug may be a sugar derivative or other glycoside conjugate,
30 or may be an amino acid ester derivative.

Acronyms

For convenience, many chemical moieties are represented using well known abbreviations, including but not limited to, methyl (Me), ethyl (Et), n-propyl (nPr),
5 iso-propyl (iPr), n-butyl (nBu), sec-butyl (sBu), iso-butyl (iBu), tert-butyl (tBu),
n-hexyl (nHex), cyclohexyl (cHex), phenyl (Ph), biphenyl (biPh), benzyl (Bn),
naphthyl (naph), methoxy (MeO), ethoxy (EtO), benzoyl (Bz), and acetyl (Ac).

For convenience, many chemical compounds are represented using well known
10 abbreviations, including but not limited to, methanol (MeOH), ethanol (EtOH), iso-
propanol (i-PrOH), methyl ethyl ketone (MEK), ether or diethyl ether (Et₂O), acetic
acid (AcOH), dichloromethane (methylene chloride, DCM), acetonitrile (ACN),
trifluoroacetic acid (TFA), dimethylformamide (DMF), tetrahydrofuran (THF), and
dimethylsulfoxide (DMSO).

Synthesis

Several methods for the chemical synthesis of compounds of the present invention
are described herein. These methods may be modified and/or adapted in known
20 ways in order to facilitate the synthesis of additional compounds within the scope
of the present invention.

Method A

General Method for the Synthesis of 1-Sulfonyl-1H-Indoles

25 Treatment of the appropriate 1-unsubstituted-1H-indole with the appropriate
sulfonyl chloride compound (R-SO₂Cl), for example, in the presence of
tetrabutylammonium hydrogensulfate (TBAHS), for example, in toluene, and
aqueous sodium hydroxide, gives the corresponding 1-substituted 1H-indole.


30 An example of such a method is described below.

For example, to a vigorously stirred solution of 1-unsubstituted-1H-indole (8.5
mmol) and tetrabutylammonium hydrogensulfate (TBAHS) (1.28 mmol) in toluene

- 70 -

(25 mL) at 0°C is added 50% aqueous sodium hydroxide (25 mL) and sulfonyl chloride compound (12.8 mmol). The resultant solution is stirred at room temperature for 16 hours. After this time, the organic layer is separated and washed with 1N HCl (2 x 25 mL), saturated aqueous NaHCO₃ (2 x 25 mL), water (25 mL), and brine (25 mL), and is dried over MgSO₄, and is evaporated to dryness to yield the desired 1-sulfonyl-1H-indole.

Scheme 1



Method B

General Method for the Synthesis of 4,4-Dimethoxy-Cyclohexa-2,5-Dienones

Treatment of the appropriate 4-methoxyphenol with iodobenzene diacetate, for example, in methanol, under a nitrogen atmosphere, gives the corresponding 4,4-dimethoxy-cyclohexa-2,5-dienone. An example of such a method is described below.

For example, a solution of 4-methoxyphenol (40 mmol) and iodobenzene diacetate (14.3 g, 44 mmol) in methanol (150 mL) is stirred at 0°C, under a nitrogen atmosphere for 15 minutes. The solution is allowed to warm to room temperature and stirring is continued for 30 minutes. Solvent is removed *in vacuo* to yield the desired product.

Scheme 2




Method C

General Method for the Synthesis of
4-(1-Sulfonyl-1H-Indol-2-yl)-4-(Hydroxy)-Cyclohexa-2,5-Dieneones

- 5 Treatment of the appropriate 1-sulfonyl-1H-indoles with n-butyl lithium, followed by the addition of the appropriate 4,4-dimethoxy-cyclohexa-2,5-dienone, gives the corresponding 4-(1-sulfonyl-1H-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dieneone. An example of such a method is described below.
- 10 For example, to a stirring solution of n-butyl lithium (3.3 mL, 1.6 M in hexanes, 5.2 mmol) in tetrahydrofuran (THF) (7 mL) at -78°C is added a solution of 1-sulphonyl-1H-indole (3.5 mmol) in THF (7 mL) dropwise, under a nitrogen atmosphere. Following addition, the solution is stirred at -78°C for 1.5 hours. After this time, the resultant solution is added via cannular to a stirring solution of freshly prepared
- 15 4,4-dimethoxy-cyclohexa-2,5-dienone (0.54 g, 3.5 mmol) in THF (14 mL) at -78°C. Following addition, the solution is stirred at -78°C for 2 hours. After this time, the resultant solution is poured into brine (25 mL) and extracted with CH₂Cl₂ (3 x 25 mL). The combined organic layer is washed with water (3 x 20 mL), brine (2 x 20 mL), and is dried over MgSO₄, and is filtered and evaporated to dryness. The
- 20 dark oil is redissolved in acetone (20 mL) and 10% aqueous acetic acid (20 mL) and heated at reflux for 1 hour. After this time, the solution is allowed to cool to room temperature and extracted with CH₂Cl₂ (3 x 25 mL). The combined organic layer is washed with water (3 x 20 mL), brine (2 x 20 mL), and is dried over MgSO₄, filtered and evaporated to dryness. The product is purified by flash
- 25 column chromatography (4:1 hexane : EtOAc) to yield the desired product.

- 72 -

Scheme 3Method D

5 General Method for the Synthesis of 4,4-Dimethoxy-4H-Naphthalen-1-One

Treatment of the appropriate 4-methoxynaphthol with iodobenzene diacetate, for example, in methanol, under a nitrogen atmosphere, gives the corresponding 4,4-dimethoxy-4H-naphthalen-1-one. An example of such a method is described


10 below.

For example, a solution of 4-methoxynaphthol (16 mmol) and iodobenzene diacetate (6.1 g, 19 mmol) in methanol (75 mL) is stirred at room temperature, under a nitrogen atmosphere for 1 hour. The resultant dark blue solution is

15 poured into a saturated solution of NaHCO₃ (75 mL), then evaporated to reduced volume. The blue oil is extracted with CH₂Cl₂ (3 x 75 mL) and the organic layer is washed with water (3 x 75 mL), brine (2 x 75 mL), and is dried over MgSO₄, and filtered and evaporated to dryness (bath temp. < 40°C) to yield the product as a dark blue semi-solid.

20

- 73 -

Scheme 4Method E

5

General Method for the Synthesis of

4-(1-Sulfonyl-1H-Indol-2-yl)-4-(Hydroxy)-Cyclohexa-2,5-Dieneones

10

Treatment of the appropriate 1-sulfonyl-1H-indoles with n-butyl lithium, followed by the addition of the appropriate 4,4-dimethoxy-4H-naphthalen-1-one, gives the corresponding 4-(1-sulfonyl-1H-indol-2-yl)-4-(hydroxy)-4H-naphthalen-1-one. An example of such a method is described below.

15


For example, to a stirring solution of n-butyl lithium (3.3 mL, 1.6 M in hexanes, 5.2 mmol) in THF (7 mL) at -78°C is added a solution of 1-sulphonyl-1H-indole (3.5 mmol) in THF (7 mL) dropwise, under a nitrogen atmosphere. Following addition, the solution is stirred at -78°C for 1.5 hours. After this time, the resultant solution is added via cannular to a stirring solution of freshly prepared 4,4-dimethoxy-4H-naphthalen-1-one (3.5 mmol) in THF (14 mL) at -78°C. Following addition, the solution is stirred at -78°C for 2 hours. After this time, the resultant solution is poured into brine (25 mL) and extracted with CH₂Cl₂ (3 x 25 mL). The combined organic layer is washed with water (3 x 20 mL), brine (2 x 20 mL), and dried over MgSO₄, and filtered and evaporated to dryness. The dark oil is redissolved in acetone (20 mL) and 10% aqueous acetic acid (20 mL) and heated at reflux for 1 hour. After this time, the solution is allowed to cool to room

20

temperature and extracted with CH₂Cl₂ (3 x 25 mL). The combined organic layer is washed with water (3 x 20 mL), brine (2 x 20 mL), and dried over MgSO₄, and filtered and evaporated to dryness. The product is purified by flash column chromatography (4:1 hexane : EtOAc) to yield the desired product.


25

- 74 -

Scheme 5Method F

General Method for Preparation of Substituted Arylsulfonyl Chlorides

Appropriate substituted arylsulfonyl chlorides, suitable for use in the above methods, may be prepared, for example, by reaction of the appropriate substituted aromatic compound with chlorosulfonic acid. An example of such a method is described below.


Scheme 6Method G

General Method for Preparation of Oxy-Substituted Compounds

Oxy-substituted-sulfonyl compounds may be prepared from the corresponding methoxy compound. For example, the methoxy compound may be demethylated,

- 75 -

e.g., with boron tribromide in methylene chloride, and the resulting hydroxy compound may be reacted with a suitable alkyl halide compound, including substituted alkyl halides, such as iodoacetic acid, to give the corresponding oxy-substituted-sulfonyl compound. An example of such a method is described below.


Scheme 7Method H

General Method for Preparation of Amino-Substituted Compounds

Amino-substituted-sulfonyl compounds may be prepared from the corresponding acetyl-amino compound, which may itself be prepared from commercially available acetylaminobenzene sulfonylchloride, using methods described above. For example, the acetyl-amino compound may be converted to the free amino, e.g., by hydrolysis with hot dilute HCl, and the resulting hydroxy compound may be reacted with a suitable alkyl halide compound, including substituted alkyl halides,

such as aminoalkyl iodide, to give the corresponding amino-substituted-sulfonyl compound. An example of such a method is described below.

Scheme 8



5


Method I

General method for the synthesis of bis-thiol adducts.

- 10 Treatment of the appropriate 1-sulfonyl-1H-indol-2-yl-quinol with the appropriate thiol (RSH), for example in ethanol in the presence of triethylamine, gives the corresponding di-thiol adduct. An example of such a method is described below.

- 15 To a solution of the quinol (0.1 g) in ethanol (5 mL) is added the thiol (2.0 equivalents) followed by triethylamine (0.1 equivalents). After two hours the solvent is removed under vacuum and the residue stirred with diethylether:hexane (1:1, 5 mL). The precipitate is collected on a filter and dried under vacuum.

- 77 -

Scheme 9Method J

5


General method for the synthesis of mono-thiol adducts.

Treatment of the appropriate 1-sulfonyl-1H-indol-2-yl-quinol with the appropriate thiol (RSH), for example in ethanol, gives the corresponding mono-thiol adduct. An example of such a method is described below.

10

To a solution of the quinol (0.1 g) in ethanol (5 mL) was added the thiol (2.0 equivalents). After two hours the solvent was removed under vacuum and the residue dissolved in diethylether (1 mL) and purified by column chromatography (silica gel, EtOAc:hexane 2:8).

15

Scheme 10Uses

20

The present invention provides active compounds, specifically, active antiproliferative agents, anticancer agents, and/or thioredoxin/thioredoxin reductase inhibitors.

25

The term "active," as used herein, pertains to compounds which are capable of, e.g., inhibiting cell proliferation, treating cancer, inhibiting thioredoxin/thioredoxin reductase, and specifically includes both compounds with intrinsic activity (drugs)

as well as prodrugs of such compounds, which prodrugs may themselves exhibit little or no intrinsic activity.

One of ordinary skill in the art is readily able to determine whether or not a candidate compound is active. For example, assays which may conveniently be used in order to assess the activity offered by a particular compound are described in the examples below.

Antiproliferative Applications

The present invention also provides active compounds which (a) regulate (e.g., inhibit) cell proliferation; (b) inhibit cell cycle progression; (c) promote apoptosis; or (d) a combination of one or more of these.

Thus, the present invention also provides methods of (a) regulating (e.g., inhibiting) cell proliferation; (b) inhibiting cell cycle progression; (c) promoting apoptosis; or (d) a combination of one or more of these, *in vitro* or *in vivo*, comprising contacting a cell with (e.g., exposing a cell to) an effective amount of an active compound, as described herein.

One of ordinary skill in the art is readily able to determine whether or not a candidate compound regulate (e.g., inhibit) cell proliferation, etc. For example, assays which may conveniently be used to assess the activity offered by a particular compound are described in the examples below.

For example, a sample of cells (e.g., from a tumour) may be grown *in vitro* and an active compound brought into contact with said cells, and the effect of the compound on those cells observed. As an example of "effect," the morphological status of the cells (e.g., alive or dead, etc.) may be determined. Where the active compound is found to exert an influence on the cells, this may be used as a prognostic or diagnostic marker of the efficacy of the compound in methods of treating a patient carrying cells of the same cellular type.

The present invention further provides antiproliferative agents. The term "antiproliferative agent" as used herein, pertains to a compound which treats a proliferative condition (i.e., a compound which is useful in the treatment of a proliferative condition).

5

One of ordinary skill in the art is readily able to determine whether or not a candidate compound treats a proliferative condition for any particular cell type. For example, assays which may conveniently be used to assess the activity offered by a particular compound are described in the examples below.

10

The terms "cell proliferation," "proliferative condition," "proliferative disorder," and "proliferative disease," are used interchangeably herein and pertain to an unwanted or uncontrolled cellular proliferation of excessive or abnormal cells which is undesired, such as, neoplastic or hyperplastic growth, whether *in vitro* or *in vivo*.

15

Examples of proliferative conditions include, but are not limited to, benign, pre-malignant, and malignant cellular proliferation, including but not limited to, neoplasms and tumours (e.g., histocytoma, glioma, astrocyoma, osteoma), cancers (e.g., lung cancer, small cell lung cancer, gastrointestinal cancer, bowel cancer, colon cancer, breast carcinoma, ovarian carcinoma, prostate cancer, testicular cancer, liver cancer, kidney cancer, bladder cancer, pancreas cancer, brain cancer, sarcoma, osteosarcoma, Kaposi's sarcoma, melanoma), leukemias, psoriasis, bone diseases, fibroproliferative disorders (e.g., of connective tissues), and atherosclerosis.

20

25

In one embodiment, the proliferative condition is colon cancer or renal cancer.

In one embodiment, the proliferative condition is colon cancer.

In one embodiment, the proliferative condition is renal cancer.

30

In one embodiment, the proliferative condition is melanoma.

Any type of cell may be treated, including but not limited to, lung, gastrointestinal (including, e.g., bowel, colon), breast (mammary), ovarian, prostate, liver (hepatic), kidney (renal), bladder, pancreas, brain, and skin.

5 In one embodiment, the cell is a colon cell (e.g., colon tumour cell, colon cancer cell) or a renal cell (e.g., renal tumour cell, renal cancer cell).

In one embodiment, the cell is a colon cell (e.g., colon tumour cell, colon cancer cell).

10 In one embodiment, the cell is a renal cell (e.g., renal tumour cell, renal cancer cell).

In one embodiment, the cell is a melanoma cell.

Anticancer Applications

15 Antiproliferative compounds of the present invention have application in the treatment of cancer, and so the present invention further provides anticancer agents.

20 The term "anticancer agent" as used herein, pertains to a compound which treats a cancer (i.e., a compound which is useful in the treatment of a cancer).

25 One of ordinary skill in the art is readily able to determine whether or not a candidate compound treats a cancerous condition for any particular cell type. For example, assays which may conveniently be used to assess the activity offered by a particular compound are described in the examples below.

30 The anti-cancer effect may arise through one or more mechanisms, including but not limited to, the regulation of cell proliferation, the inhibition of cell cycle progression, the inhibition of angiogenesis (the formation of new blood vessels), the inhibition of metastasis (the spread of a tumour from its origin), the inhibition of invasion (the spread of tumour cells into neighbouring normal structures), or the promotion of apoptosis (programmed cell death).

Thioredoxin/Thioredoxin Reductase Applications

The present invention also provides active compounds which inhibit thioredoxin/thioredoxin reductase activity.

5

The term "inhibiting thioredoxin/thioredoxin reductase," as used herein, includes: inhibiting thioredoxin/thioredoxin reductase activity; inhibiting the formation of thioredoxin/thioredoxin reductase complexes; and inhibiting the activity of thioredoxin/thioredoxin reductase complexes.

10

One of ordinary skill in the art is readily able to determine whether or not a candidate compound inhibits thioredoxin/thioredoxin reductase activity. For example, one assay which may conveniently be used in order to assess the thioredoxin/thioredoxin reductase inhibition offered by a particular compound is described in the examples below.

15

Thus, the present invention also provides methods of inhibiting thioredoxin/thioredoxin reductase in a cell, comprising contacting said cell with (e.g., exposing said cell to) an effective amount of an active compound. Such a method may be practised *in vitro* or *in vivo*. In one embodiment, the method is performed *in vitro*. In one embodiment, the method is performed *in vivo*. Preferably, the active compound is provided in the form of a pharmaceutically acceptable composition.

20

The present invention also provides active compounds which are anti-thioredoxin/thioredoxin reductase agents, and which treat a condition mediated by thioredoxin/thioredoxin reductase.

25

The term "a condition mediated by thioredoxin/thioredoxin reductase," as used herein pertains to a condition in which thioredoxin/thioredoxin reductase and/or the action of thioredoxin/thioredoxin reductase is important or necessary, e.g., for the onset, progress, expression, etc. of that condition, or a condition which is known to be treated by thioredoxin/thioredoxin reductase inhibitors.

30

The thioredoxins are ubiquitous proteins containing a conserved -Trp-Cys-Gly-Pro-Cys-Lys- redox catalytic site. Mammalian thioredoxin family members include thioredoxin-1 (Trx1), mitochondrial thioredoxin-2 (Trx2), and a larger thioredoxin-like protein, p32^{TrxL}. Thioredoxin is reduced by NADPH and thioredoxin reductase and, in turn reduces oxidized cysteine groups on proteins. When thioredoxin levels are elevated there is increased cell growth and resistance to the normal mechanism of programmed cell death. An increase in thioredoxin levels seen in many human primary cancers compared to normal tissue appears to contribute to increased cancer cell growth and resistance to chemotherapy. Mechanisms by which thioredoxin increases cell growth include an increased supply of reducing equivalents for DNA synthesis, activation of transcription factors that regulate cell growth, and an increase in the sensitivity of cells to other cytokines and growth factors. The mechanisms for the inhibition of apoptosis by thioredoxin are just now being elucidated. Because of its role in stimulating cancer cell growth and as an inhibitor of apoptosis, thioredoxin offers a target for the development of drugs to treat and prevent cancer. See, for example, the review article by Powis et al., 2000, and references cited therein.

Thioredoxin was first described in 1964 as a small redox protein from *Escherichia coli*. Mammalian thioredoxin was reported in 1967 as a redox protein present in rat Novikoff hepatoma cells. Thioredoxin was subsequently rediscovered under other names, including: (i) adult T cell leukemia-derived factor (ADF), an interleukin-2 (IL-2) receptor-inducing factor produced by human T-lymphotrophic virus type 1 (HTLV 1)-infected T cells; and, (ii) early pregnancy factor, part of a complex in the serum of pregnant animals that increases the complement-dependent inhibition of lymphocyte binding to heterologous blood cells. These proteins were shown to be identical when the correct predicted amino acid sequence of thioredoxin was published, and they are all now referred to as thioredoxin (Trx). A truncated form of thioredoxin, eosinophil cytotoxicity enhancing factor, has also been described.

Members of the thioredoxin family of proteins have as a conserved catalytic site - Trp-Cys-Gly-Pro-Cys-Lys- that undergoes reversible oxidation to the cysteine-

- 83 -

disulfide (Trx-S₂) form through the transfer of reducing equivalents to a disulfide substrate (X-S₂). The oxidized thioredoxin is reduced back to the cysteine-thiol form [Trx-(SH)₂] by the NADPH-dependent flavoprotein thioredoxin reductase (TR).



5

Mammalian thioredoxin reductases are homodimeric, flavin adenine dinucleotide-containing proteins with a penultimate C-terminal selenocysteine (SeCys) residue. The conserved redox catalytic site of thioredoxin reductase, -Cys-Val-Asn-Val-Gly-
10 Cys-, undergoes reversible oxidation reduction in much the same way as thioredoxin. Although selenocysteine is essential for the full activity of mammalian thioredoxin reductases, human thioredoxin can be relatively efficiently reduced by the nonselenocysteine-containing bacterial thioredoxin reductase. To date, two
15 human thioredoxin reductases have been cloned, TR1, found predominantly in the cytosol, and TR2, which has a putative mitochondrial import sequence.

Two forms of thioredoxin have been cloned, thioredoxin-1 (Trx-1) and thioredoxin 2 (Trx-2). Human Trx-1 is a 104 amino acid protein with a molecular weight of 12 kDa that contains two catalytic site Cys residues -Trp-Cys³²-Gly-Pro-Cys³⁵-Lys-
20 found in all thioredoxin proteins, as well as three additional Cys residues, Cys⁶², Cys⁶⁹, and Cys⁷³, that are not found in bacterial thioredoxins. Trx-1's from a number of other mammalian species, including chicken, rat, mouse, and bovine, have been cloned.

25 Thioredoxin variously acts as a growth factor, and antioxidant, a cofactor, as a transcription factor regulator, and as an inhibitor of apoptosis.

Studies with a variety of human primary tumors have shown that thioredoxin is overexpressed in the tumor compared to levels in the corresponding normal
30 tissue. Recent immunohistochemical studies using paraffin-embedded tissue sections have shown that thioredoxin expression is increased in more than half of

human primary gastric cancers. The thioredoxin levels showed a highly significant positive correlation ($p < 0.001$) with cell proliferation measured by nuclear proliferation antigen and a highly significant negative correlation ($p < 0.001$) with apoptosis measured by the terminal deoxynucleotidyl transferase assay. A comparison of 49,000 human gene transcripts in human normal colon epithelium and colorectal cancer by the serial analysis of gene expression (SAGE) technique revealed 548 differentially expressed transcripts. Thioredoxin mRNA was increased 2-fold in colon cancer cell lines and 4-fold in colon tumors.

Plasma and serum levels of thioredoxin, which in normal individuals are between 10 and 80 ng/ml (0.86.6 nM), have been reported to be elevated almost 2-fold in patients with hepatocellular carcinoma and to decrease following surgical removal of the tumor. Serum thioredoxin was not elevated in patients with other forms of liver disease such as chronic hepatitis or liver cirrhosis.

The growth-stimulating and transforming effects of thioredoxin, together with the finding that it is overexpressed by a number of human primary tumors, raise the possibility that thioredoxin is a factor leading to aggressive tumor growth and poor patient prognosis. Because thioredoxin has also been shown to inhibit apoptosis caused by a number of anticancer drugs and to be a cause of resistance to the cytotoxic effects of some anticancer drugs, it is possible that increased thioredoxin could be a cause of resistance to chemotherapy. These findings make thioredoxin an attractive target for the development of drugs to inhibit cancer cell growth. Several such compounds have been identified. They include PX-12 (1-methylhydroxypropyl 2-imidazoloyl disulfide), which was identified as an inhibitor of thioredoxin binding to the Cys⁷³ residue. The median IC₅₀ for growth inhibition of a variety of cell lines by PX-12 is 8.1 μ M. PX-12 has been shown to have in vivo antitumor activity against human tumor xenografts in *scid* mice and chemopreventive activity in *min* (multiple intestinal neoplasia) mice, which have a germline mutation in the APC gene seen in familial adenomatous polyposis. The growth inhibition by compound PX-12 in the NCI 60 human tumor cell line panel was significantly correlated with the expression of thioredoxin mRNA. Several other inhibitors of thioredoxin have been identified by the COMPARE program

from over 50,000 compounds tested by the National Cancer Institute as having a pattern of cell killing activity in the 60 human tumor cell line panel similar to PX-12. One of these compounds, NSC-131233 (2,5-bis[(dimethylamino)methyl]cyclopentanone) is an irreversible inhibitor of thioredoxin with a K_i of 1.0 μ M.

5

The thioredoxins are a family of small redox proteins whose functions include the regulation of cell growth, programmed cell death, and the development of the organism. When thioredoxin levels are elevated in cells, there is increased cell growth and resistance to normal mechanisms of programmed cell death. An increase in thioredoxin levels seen in many human primary cancers compared to normal tissue may be a contributing factor leading to increased cancer cell growth and resistance to chemotherapeutic drugs. The mechanism for the increase in thioredoxin in cancer cells remains unknown at this time. Because of its role as a stimulator of cell growth and an inhibitor of apoptosis, thioredoxin is a target for the development of drugs to treat and, possibly, prevent cancer.

10

15

Methods of Treatment, Etc.

The invention further provides methods of treatment for example, of a proliferative condition, cancer, a condition mediated by thioredoxin/thioredoxin reductase, a condition known to be treated by thioredoxin/thioredoxin reductase inhibitors, or other condition as described herein, comprising administering to a subject in need of treatment a therapeutically-effective amount of an active compound, preferably in the form of a pharmaceutical composition.

20

25

The invention further provides active compounds for use in a method of treatment of the human or animal body, for example, in the treatment of a proliferative condition, cancer, a condition mediated by thioredoxin/thioredoxin reductase, a condition known to be treated by thioredoxin/thioredoxin reductase inhibitors, or other condition as described herein.

30

The invention further provides the use of an active compound for the manufacture of a medicament, for example, for the treatment of a proliferative conditions,

cancer, a condition mediated by thioredoxin/thioredoxin reductase, a condition known to be treated by thioredoxin/thioredoxin reductase inhibitors, or other condition as described herein.

5 Treatment

10 The term "treatment," as used herein in the context of treating a condition, pertains generally to treatment and therapy, whether of a human or an animal (e.g., in veterinary applications), in which some desired therapeutic effect is achieved, for example, the inhibition of the progress of the condition, and includes a reduction in the rate of progress, a halt in the rate of progress, amelioration of the condition, and cure of the condition. Treatment as a prophylactic measure (i.e., prophylaxis) is also included.

15 The term "therapeutically-effective amount," as used herein, pertains to that amount of an active compound, or a material, composition or dosage form comprising an active compound, which is effective for producing some desired therapeutic effect, commensurate with a reasonable benefit/risk ratio.

20 The term "treatment" includes combination treatments and therapies, in which two or more treatments or therapies are combined, for example, sequentially or simultaneously. Examples of treatments and therapies include, but are not limited to, chemotherapy (the administration of active agents, including, e.g., drugs, antibodies (e.g., as in immunotherapy), prodrugs (e.g., as in photodynamic
25 therapy, GDEPT, ADEPT, etc.); surgery; radiation therapy; and gene therapy.

For example, in one embodiment, the treatment is combination treatment employing a compound as described herein, with cisplatin.

30 Active compounds may also be used, as described above, in combination therapies, that is, in conjunction with other agents, for example, cytotoxic agents.

Additional Uses

Active compounds may also be used as cell culture additives to inhibit thioredoxin/thioredoxin reductase, for example, in order to regulate cell proliferation in vitro.

Active compounds may also be used as part of an in vitro assay, for example, in order to determine whether a candidate host is likely to benefit from treatment with the compound in question.

Active compounds may also be used as a standard, for example, in an assay, in order to identify other active compounds, other antiproliferative agents, anticancer agents, thioredoxin/thioredoxin reductase inhibitors, etc.

Kits

One aspect of the invention pertains to a kit comprising (a) the active ingredient, preferably provided in a suitable container and/or with suitable packaging; and (b) instructions for use, for example, written instructions about how to administer the active compound.

The written instructions may also include a list of indications for which the active ingredient is a suitable treatment.

Routes of Administration

The active compound or pharmaceutical composition comprising the active compound may be administered to a subject by any convenient route of administration, whether systemically/ peripherally or topically (i.e., at the site of desired action).

Routes of administration include, but are not limited to, oral (e.g, by ingestion); buccal; sublingual; transdermal (including, e.g., by a patch, plaster, etc.);

transmucosal (including, e.g., by a patch, plaster, etc.); intranasal (e.g., by nasal spray); ocular (e.g., by eyedrops); pulmonary (e.g., by inhalation or insufflation therapy using, e.g., via an aerosol, e.g., through the mouth or nose); rectal (e.g., by suppository or enema); vaginal (e.g., by pessary); parenteral, for example, by injection, including subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, and intrasternal; by implant of a depot or reservoir, for example, subcutaneously or intramuscularly.

The Subject

The subject may be a prokaryote (e.g., bacteria) or a eukaryote (e.g., protoctista, fungi, plants, animals).

The subject may be an animal, a mammal, a placental mammal, a marsupial (e.g., kangaroo, wombat), a monotreme (e.g., duckbilled platypus), a rodent (e.g., a guinea pig, a hamster, a rat, a mouse), murine (e.g., a mouse), a lagomorph (e.g., a rabbit), avian (e.g., a bird), canine (e.g., a dog), feline (e.g., a cat), equine (e.g., a horse), porcine (e.g., a pig), ovine (e.g., a sheep), bovine (e.g., a cow), a primate, simian (e.g., a monkey or ape), a monkey (e.g., marmoset, baboon), an ape (e.g., gorilla, chimpanzee, orangutang, gibbon), or a human.

Furthermore, the subject may be any of its forms of development, for example, a spore, a seed, an egg, a larva, a pupa, or a foetus.

Formulations

While it is possible for the active compound to be administered alone, it is preferable to present it as a pharmaceutical formulation (e.g., composition, preparation, medicament) comprising at least one active compound, as defined above, together with one or more other pharmaceutically acceptable ingredients well known to those skilled in the art, including, but not limited to, pharmaceutically

acceptable carriers, diluents, excipients, adjuvants, fillers, buffers, preservatives, anti-oxidants, lubricants, stabilisers, solubilisers, surfactants (e.g., wetting agents), masking agents, colouring agents, flavouring agents, and sweetening agents. The formulation may further comprise other active agents, for example, other
5 therapeutic or prophylactic agents.

Thus, the present invention further provides pharmaceutical compositions, as defined above, and methods of making a pharmaceutical composition comprising admixing at least one active compound, as defined above, together with one or
10 more other pharmaceutically acceptable ingredients well known to those skilled in the art, e.g., carriers, diluents, excipients, etc. If formulated as discrete units (e.g., tablets, etc.), each unit contains a predetermined amount (dosage) of the active compound.

The term "pharmaceutically acceptable" as used herein pertains to compounds, ingredients, materials, compositions, dosage forms, etc., which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of the subject in question (e.g., human) without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable
15 benefit/risk ratio. Each carrier, diluent, excipient, etc. must also be "acceptable" in the sense of being compatible with the other ingredients of the formulation.
20

Suitable carriers, diluents, excipients, etc. can be found in standard pharmaceutical texts, for example, Remington's Pharmaceutical Sciences, 18th
25 edition, Mack Publishing Company, Easton, Pa., 1990; and Handbook of Pharmaceutical Excipients, 2nd edition, 1994.

The formulations may be prepared by any methods well known in the art of pharmacy. Such methods include the step of bringing into association the active
30 compound with a carrier +which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active compound with carriers (e.g., liquid carriers, finely divided solid carrier, etc.), and then shaping the product, if necessary.

The formulation may be prepared to provide for rapid or slow release; immediate, delayed, timed, or sustained release; or a combination thereof.

5 Formulations may suitably be in the form of liquids, solutions (e.g., aqueous, non-aqueous), suspensions (e.g., aqueous, non-aqueous), emulsions (e.g., oil-in-water, water-in-oil), elixirs, syrups, electuaries, mouthwashes, drops, tablets (including, e.g., coated tablets), granules, powders, lozenges, pastilles, capsules (including, e.g., hard and soft gelatin capsules), cachets, pills, ampoules, boluses,
10 suppositories, pessaries, tinctures, gels, pastes, ointments, creams, lotions, oils, foams, sprays, mists, or aerosols.

Formulations may suitably be provided as a patch, adhesive plaster, bandage, dressing, or the like which is impregnated with one or more active compounds and
15 optionally one or more other pharmaceutically acceptable ingredients, including, for example, penetration, permeation, and absorption enhancers. Formulations may also suitably be provided in the form of a depot or reservoir.

The active compound may be dissolved in, suspended in, or admixed with one or
20 more other pharmaceutically acceptable ingredients. The active compound may be presented in a liposome or other microparticulate which is designed to target the active compound, for example, to blood components or one or more organs.

Formulations suitable for oral administration (e.g., by ingestion) include liquids,
25 solutions (e.g., aqueous, non-aqueous), suspensions (e.g., aqueous, non-aqueous), emulsions (e.g., oil-in-water, water-in-oil), elixirs, syrups, electuaries, tablets, granules, powders, capsules, cachets, pills, ampoules, boluses.

Formulations suitable for buccal administration include mouthwashes, lozenges,
30 pastilles, as well as patches, adhesive plasters, depots, and reservoirs. Lozenges typically comprise the active compound in a flavored basis, usually sucrose and acacia or tragacanth. Pastilles typically comprise the active compound in an inert

matrix, such as gelatin and glycerin, or sucrose and acacia. Mouthwashes typically comprise the active compound in a suitable liquid carrier.

Formulations suitable for sublingual administration include tablets, lozenges, pastilles, capsules, and pills.

Formulations suitable for oral transmucosal administration include liquids, solutions (e.g., aqueous, non-aqueous), suspensions (e.g., aqueous, non-aqueous), emulsions (e.g., oil-in-water, water-in-oil), mouthwashes, lozenges, pastilles, as well as patches, adhesive plasters, depots, and reservoirs.

Formulations suitable for non-oral transmucosal administration include liquids, solutions (e.g., aqueous, non-aqueous), suspensions (e.g., aqueous, non-aqueous), emulsions (e.g., oil-in-water, water-in-oil), suppositories, pessaries, gels, pastes, ointments, creams, lotions, oils, as well as patches, adhesive plasters, depots, and reservoirs.

Formulations suitable for transdermal administration include gels, pastes, ointments, creams, lotions, and oils, as well as patches, adhesive plasters, bandages, dressings, depots, and reservoirs.

Tablets may be made by conventional means, e.g., compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active compound in a free-flowing form such as a powder or granules, optionally mixed with one or more binders (e.g., povidone, gelatin, acacia, sorbitol, tragacanth, hydroxypropylmethyl cellulose); fillers or diluents (e.g., lactose, microcrystalline cellulose, calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc, silica); disintegrants (e.g., sodium starch glycolate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose); surface-active or dispersing or wetting agents (e.g., sodium lauryl sulfate); preservatives (e.g., methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, sorbic acid); flavours, flavour enhancing agents, and sweeteners. Molded tablets may be made by molding in a suitable machine a

- 92 -

mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active compound therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with a coating, for example, to affect release, for example an enteric coating, to provide release in parts of the gut other than the stomach.

Ointments are typically prepared from the active compound and a paraffinic or a water-miscible ointment base.

Creams are typically prepared from the active compound and an oil-in-water cream base. If desired, the aqueous phase of the cream base may include, for example, at least about 30% w/w of a polyhydric alcohol, i.e., an alcohol having two or more hydroxyl groups such as propylene glycol, butane-1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol and mixtures thereof. The topical formulations may desirably include a compound which enhances absorption or penetration of the active compound through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogues.

Emulsions are typically prepared from the active compound and an oily phase, which may optionally comprise merely an emulsifier (otherwise known as an emulgent), or it may comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabiliser. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabiliser(s) make up the so-called emulsifying wax, and the wax together with the oil and/or fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.

Suitable emulgents and emulsion stabilisers include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate and sodium lauryl

5 sulphate. The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations may be very low. Thus the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.

15 Formulations suitable for intranasal administration, where the carrier is a liquid, include, for example, nasal spray, nasal drops, or by aerosol administration by nebuliser, include aqueous or oily solutions of the active compound.

20 Formulations suitable for intranasal administration, where the carrier is a solid, include, for example, those presented as a coarse powder having a particle size, for example, in the range of about 20 to about 500 microns which is administered in the manner in which snuff is taken, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.

25 Formulations suitable for pulmonary administration (e.g., by inhalation or insufflation therapy) include those presented as an aerosol spray from a pressurised pack, with the use of a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane, carbon dioxide, or other suitable gases.

30 Formulations suitable for ocular administration include eye drops wherein the active compound is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active compound.

Formulations suitable for rectal administration may be presented as a suppository with a suitable base comprising, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols, for example, cocoa butter or a salicylate; or as a solution or suspension for treatment by enema.

Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active compound, such carriers as are known in the art to be appropriate.

Formulations suitable for parenteral administration (e.g., by injection), include aqueous or non-aqueous, isotonic, pyrogen-free, sterile liquids (e.g., solutions, suspensions), in which the active compound is dissolved, suspended, or otherwise provided (e.g., in a liposome or other microparticulate). Such liquids may additional contain other pharmaceutically acceptable ingredients, such as anti-oxidants, buffers, preservatives, stabilisers, bacteriostats, suspending agents, thickening agents, and solutes which render the formulation isotonic with the blood (or other relevant bodily fluid) of the intended recipient. Examples of excipients include, for example, water, alcohols, polyols, glycerol, vegetable oils, and the like. Examples of suitable isotonic carriers for use in such formulations include Sodium Chloride Injection, Ringer's Solution, or Lactated Ringer's Injection. Typically, the concentration of the active compound in the liquid is from about 1 ng/ml to about 10 µg/ml, for example from about 10 ng/ml to about 1 µg/ml. The formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets.

Dosage

It will be appreciated by one of skill in the art that appropriate dosages of the active compounds, and compositions comprising the active compounds, can vary

from patient to patient. Determining the optimal dosage will generally involve the balancing of the level of therapeutic benefit against any risk or deleterious side effects. The selected dosage level will depend on a variety of factors including, but not limited to, the activity of the particular compound, the route of administration, the time of administration, the rate of excretion of the compound, the duration of the treatment, other drugs, compounds, and/or materials used in combination, the severity of the condition, and the species, sex, age, weight, condition, general health, and prior medical history of the patient. The amount of compound and route of administration will ultimately be at the discretion of the physician, veterinarian, or clinician, although generally the dosage will be selected to achieve local concentrations at the site of action which achieve the desired effect without causing substantial harmful or deleterious side-effects.

Administration can be effected in one dose, continuously or intermittently (e.g., in divided doses at appropriate intervals) throughout the course of treatment. Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and will vary with the formulation used for therapy, the purpose of the therapy, the target cell(s) being treated, and the subject being treated. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician, veterinarian, or clinician.

In general, a suitable dose of the active compound is in the range of about 100 μg to about 100 mg per kilogram body weight of the subject per day. Where the active compound is a salt, an ester, an amide, a prodrug, or the like, the amount administered is calculated on the basis of the parent compound and so the actual weight to be used is increased proportionately.


EXAMPLES

The following examples are provided solely to illustrate the present invention and are not intended to limit the scope of the invention, as described herein.

All compounds were characterised by elemental microanalysis (C, H, and N values within 0.4% of theoretical values). Melting points were determined using a Gallenkamp melting point apparatus and are reported uncorrected. ^1H and ^{13}C NMR spectra were recorded using a Bruker ARX250 spectrometer. IR spectra (as KBr discs) were determined using a Mattson 2020 Galaxy series FT-IR spectrophotometer. Mass spectra were recorded on an AEI MS-902 or a VG Micromass 7070E spectrometer. TLC systems for routine monitoring of reaction mixtures, and for confirming the homogeneity of analytical samples used Kieselgel 60F₂₅₄ (0.25 mm) silica gel TLC aluminum sheets. Sorbsil silica gel C 60-H (40-60 μm) was used for flash chromatographic separations. All reactions were carried out under inert atmosphere using anhydrous reagents and solvents. Tetrahydrofuran (THF) was dried and purified before use by distillation from sodium-benzophenone. All other commercial materials were used as received.

Example 1

1-benzenesulfonyl-5-methoxy-1H-indole




The title compound was prepared from benzene sulfonyl chloride and 5-methoxy-1H-indole, according to Method A, described above. Yield 67%; mp 73-75 °C; ^1H NMR (CDCl_3) δ 7.55-7.82 (m, 3H), 7.41-7.48 (m, 2H), 7.31-7.37 (m, 2H), 6.83-6.90 (m, 2H), 6.51-6.52 (dd, $J = 4$ Hz, 1H); ^{13}C NMR (CDCl_3) δ 156.9, 138.6, 134.2, 132.2, 129.9, 129.6, 127.5, 127.1, 114.8, 114.2, 109.8, 104.1, 56.0; MS (ES^+) m/z 287.99 ($\text{M}^+ + 1$).

- 97 -

Example 2


1-benzenesulfonyl-5-fluoro-1H-indole



The title compound was prepared from benzene sulfonyl chloride and 5-fluoro-1H-indole, according to Method A, described above. Yield 73%; ^1H NMR (CDCl_3) δ 7.77-7.82 (dd, $J = 9$ Hz, 1H), 7.71-7.74 (m, 2H), 7.47 (d, $J = 4$ Hz, 1H), 7.30-7.45 (m, 3H), 7.03-7.07 (dd, $J = 9$ Hz, 1H), 6.87-6.95 (dt, $J = 9$ Hz, 1H), 6.51 (d, $J = 4$ Hz, 1H); MS (AP^+) m/z 276.0 ($\text{M}^+ + 1$), 214.

Example 3

1-(toluene-4-sulfonyl)-1H-indole




The title compound was prepared from toluene-4-sulfonyl chloride and 1H-indole, according to Method A, described above. Yield 91%; mp 60-62 °C; ^1H NMR (CDCl_3) δ 8.0-8.03 (dd, $J = 8$ Hz, 1H), 7.78 (d, $J = 7$ Hz, 2H), 7.57 (d, $J = 4$ Hz, 1H), 7.52-7.56 (m, 1H), 7.26-7.36 (m, 2H), 7.20-7.23 (d, $J = 8$ Hz, 2H), 6.66-6.68 (dd, $J = 4$ Hz, 1H), 2.30 (s, 3H); ^{13}C NMR (CDCl_3) δ 145.4, 135.7, 135.3, 131.2, 130.3, 127.2, 126.8, 124.9, 123.7, 121.8, 113.9, 109.5, 21.9; MS (ES^+) m/z 271.93 (M^+).

- 98 -

Example 4


1-(4-methoxy-benzenesulfonyl)-1H-indole



The title compound was prepared from 4-methoxy-benzene sulfonyl chloride and 1H-indole, according to Method A, described above. Yield 95%; mp 124-126 °C; ¹H NMR (CDCl₃) δ 7.90-7.93 (dd, *J* = 8 Hz, 1H), 7.74 (d, *J* = 9 Hz, 2H), 7.43-7.49 (m, 2H), 7.14-7.27 (m, 2H), 6.79 (d, *J* = 9 Hz, 2H), 6.56-6.58 (dd, *J* = 4 Hz, 1H), 3.41 (s, 3H); ¹³C NMR (CDCl₃) δ 164.1, 135.2, 131.2, 130.1, 129.5, 126.7, 124.9, 123.6, 121.8, 114.8, 113.9, 109.3, 56.0; MS (AP⁺) *m/z* 288.05 (M⁺ + 1).

Example 5

1-(4-fluoro-benzenesulfonyl)-1H-indole




The title compound was prepared from 4-fluoro-benzene sulfonyl chloride and 1H-indole, according to Method A, described above. Yield 81%; mp 135-137 °C; ¹H NMR (CDCl₃) δ 7.86-7.99 (m, 3H), 7.51-7.54 (m, 2H), 7.19-7.35 (m, 2H), 7.05-7.12 (m, 2H), 6.66-6.68 (dd, *J* = 4 Hz, 1H); ¹³C NMR (CDCl₃) δ 168.1, 164.0, 135.2, 134.7, 134.6, 131.2, 130.1, 129.9, 126.6, 125.2, 123.9, 121.9, 117.2, 116.9, 113.9, 110.0; MS (ES⁺) *m/z* 275.99 (M⁺ + 1).

- 99 -

Example 6


1-(naphthalene-2-sulfonyl)-1H-indole



The title compound was prepared from naphthalene-2-sulfonyl chloride and
5 1H-indole, according to Method A, described above. Yield 92%; mp 103-105 °C;
¹H NMR (CDCl₃) δ 8.33-8.34 (m, 1H), 7.85-7.89 (dd, *J* = 8 Hz, 1H), 7.69-7.76 (m,
1H), 7.52-7.64 (m, 3H), 7.29-7.46 (m, 4H), 6.97-7.24 (m, 2H), 6.46-6.48 (dd, *J* = 4
Hz, 1H); ¹³C NMR (CDCl₃) δ 135.6, 135.5, 135.3, 132.3, 131.2, 130.1, 129.8,
128.9, 128.3, 128.2, 126.8, 125.1, 123.8, 121.9, 121.8, 113.9, 109.7; MS (AP⁺)
10 *m/z* 308.04 (M⁺ + 1).

Example 7

5-fluoro-1-(toluene-4-sulfonyl)-1H-indole




The title compound was prepared from toluene-4-sulfonyl chloride and 5-fluoro-
15 1H-indole, according to Method A, described above. Yield 100%; mp 106-108 °C;
¹H NMR (CDCl₃) δ 8.13-8.19 (dd, *J* = 4, 8 Hz, 1H), 7.96 (d, *J* = 8 Hz, 2H), 7.82 (d,
J = 4 Hz, 1H), 7.40-7.48 (m, 3H), 7.25-7.38 (m, 1H), 6.83 (d, *J* = 4 Hz, 1H), 2.55
(s, 3H); ¹³C NMR (CDCl₃) δ 161.9, 158.1, 145.6, 135.4, 132.2, 132.1, 131.6,
20 130.3, 128.5, 127.2, 115.0, 114.9, 113.2, 112.8, 109.4, 109.3, 107.5, 107.1, 21.9.

- 100 -

Example 8


1-(2,4,6-Triisopropyl-benzenesulfonyl)-1H-indole



The title compound was prepared from 2,4,6-triisopropyl-benzene sulfonyl chloride and 1H-indole, according to Method A, described above. Yield 88%; mp 131-133 °C; ¹H NMR (CDCl₃) δ 7.41-7.65 (m, 3H), 7.18-7.28 (m, 4H), 6.65-6.68 (dd, J = 8 Hz, 1H), 4.15-4.31 (m, 2H), 2.81-2.97 (m, 1H), 1.28 and 1.29 (2s, 6H), 0.98-1.12 (m, 12H).

Example 9


4,4-dimethoxy-cyclohexa-2,5-dienone



The title compound was prepared from 4-methoxyphenol, according to Method B, described above, to give a pale orange oil, which solidified at 0°C. Yield 94%; ¹H NMR (CDCl₃) δ 6.8 (d, J = 12 Hz, 2H), 6.3 (d, J = 12 Hz, 2H), 3.33 (s, 6H).

Example 10

4-(1-benzenesulfonyl-1H-indol-2-yl)-4-hydroxy-cyclohexa-2,5-dienone




- 101 -

The title compound was prepared from 4,4-dimethoxy-cyclohexa-2,5-dienone and 1-benzenesulfonyl-1H-indole (available commercially), according to Method C, described above. Yield 18%; mp 170-172 °C; ^1H NMR (CDCl_3) δ 8.0 (d, J = 8 Hz, 1H), 7.87 (d, J = 8 Hz, 2H), 7.51-7.60 (m, 3H), 7.30-7.46 (m, 3H), 7.18-7.27 (m, 2H), 6.80 (s, 1H), 6.32 (d, J = 10 Hz, 2H), 5.50 (s, 1H); ^{13}C NMR (CDCl_3) δ 185.3, 147.9, 141.2, 138.6, 137.8, 134.7, 129.7, 128.7, 128.1, 127.0, 126.6, 125.0, 122.1, 115.6, 114.1, 67.9.

Example 11


4-(1-benzenesulfonyl-5-methoxy-1H-indol-2-yl)-4-hydroxy-cyclohexa-2,5-dienone



The title compound was prepared from 4,4-dimethoxy-cyclohexa-2,5-dienone and 1-benzenesulfonyl-5-methoxy-1H-indole, according to Method C, described above. Yield 32%; mp 126-128 °C; ^1H NMR (CDCl_3) δ 7.73-7.83 (m, 3H), 7.40-7.49 (m, 2H), 7.33-7.40 (m, 2H), 6.76-6.84 (m, 3H), 6.64 (s, 1H), 6.20 (d, J = 10 Hz, 2H), 5.40 (s, 1H), 3.67 (s, 3H); ^{13}C NMR (CDCl_3) δ 196.6, 185.3, 157.3, 147.9, 141.8, 137.7, 134.3, 133.2, 129.8, 129.7, 129.3, 127.9, 126.9, 116.8, 115.4, 114.4, 104.2, 81.2, 67.9, 55.9; MS (AP^+) m/z 396.09 ($\text{M}^+ + 1$), 378.08.

Example 12

4-(1-benzenesulfonyl-5-fluoro-1H-indol-2-yl)-4-hydroxy-cyclohexa-2,5-dienone




- 102 -

The title compound was prepared from 4,4-dimethoxy-cyclohexa-2,5-dienone and 1-benzenesulfonyl-5-fluoro-1H-indole, according to Method C, described above. Yield 21%; mp 166-167 °C; ¹H NMR (CDCl₃) δ 8.03-8.09 (m, 1H), 7.94 (d, *J* = 8 Hz, 2H), 7.51-7.70 (m, 5H), 7.12-7.20 (m, 2H), 6.86 (s, 1H), 6.42 (d, *J* = 10 Hz, 2H), 5.49 (s, 1H); ¹³C NMR (CDCl₃) δ 185.1, 162.4, 158.5, 147.6, 143.0, 137.7, 134.8, 129.9, 129.8, 129.7, 128.2, 126.9, 116.9, 116.8, 114.8, 114.4, 113.6, 107.8, 107.4, 67.9; MS (AP⁺) *m/z* 384.04 (M⁺ + 1).

Example 13

4-(hydroxy-4-[1-(toluene-4-sulfonyl)-1H-indol-2-yl]-cyclohexa-2,5-dienone




The title compound was prepared from 4,4-dimethoxy-cyclohexa-2,5-dienone and 1-(toluene-4-sulfonyl)-1H-indole, according to Method C, described above. Yield 12%; mp 159-161 °C; ¹H NMR (CDCl₃) δ 7.90 (d, *J* = 8 Hz, 1H), 7.65 (d, *J* = 8 Hz, 2H), 7.48 (d, *J* = 10 Hz, 2H), 7.33 (d, *J* = 7 Hz, 1H), 6.70-7.25 (m, 4H), 6.70 (s, 1H), 6.23 (d, *J* = Hz, 2H), 5.55 (s, 1H), 2.25 (s, 3H); ¹³C NMR (CDCl₃) δ 185.3, 148.0, 145.9, 141.2, 138.6, 134.9, 130.3, 128.7, 127.9, 127.0, 126.5, 124.9, 122.0, 116.6, 115.6, 113.9, 67.9, 21.9; MS (AP⁺) *m/z* 380.04 (M⁺ + 1).

- 103 -

Example 14

4-(hydroxy-4-[1-(4-methoxy-benzenesulfonyl)-1H-indol-2-yl]-cyclohexa-2,5-dienone




5 The title compound was prepared from 4,4-dimethoxy-cyclohexa-2,5-dienone and 1-(4-methoxy-benzenesulfonyl)-1H-indole, according to Method C, described above.

Yield 14%; mp 69-71 °C; ¹H NMR (CDCl₃) δ 7.84-7.94 (m, 1H), 7.73 (d, *J* = 9 Hz, 2H), 7.49 (d, *J* = 10 Hz, 2H), 7.13-7.40 (m, 3H), 6.73-6.86 (m, 2H), 6.69 (s, 1H),
10 6.23 (d, *J* = 10 Hz, 2H), 5.51 (s, 1H), 3.70 (s, 3H); ¹³C NMR (CDCl₃) δ 185.3, 164.4, 149.2, 148.0, 141.1, 140.3, 138.6, 129.6, 129.2, 128.8, 126.3, 124.6, 121.9, 115.8, 114.7, 81.9, 72.5, 67.9, 58.1, 56.0, 38.8; MS (AP⁺) *m/z* 396.03 (M⁺ + 1).

Example 15

15 4-[1-(4-fluoro-benzenesulfonyl)-1H-indol-2-yl]- 4-hydroxy-cyclohexa-2,5-dienone




The title compound was prepared from 4,4-dimethoxy-cyclohexa-2,5-dienone and 1-(4-fluoro-benzenesulfonyl)-1H-indole, according to Method C, described above.
Yield 14%; mp 165-166 °C; ¹H NMR (CDCl₃) δ 7.82-7.93 (m, 3H), 7.49 (d, *J* = 10
20 Hz, 2H), 7.35 (d, *J* = 8 Hz, 1H), 7.12-7.28 (m, 2H), 6.99-7.05 (m, 2H), 6.73 (s, 1H), 6.25 (d, *J* = 10 Hz, 2H), 5.31 (s, 1H); ¹³C NMR (CDCl₃) δ 185.2, 170.9, 170.5,

- 104 -

147.7, 141.0, 138.6, 133.6, 130.1, 129.9, 128.8, 128.1, 126.8, 125.2, 122.2, 117.3, 116.9, 115.6, 114.5, 69.5, 67.9; MS (AP⁺) *m/z* 384.04 (M⁺ + 1).

Example 16

5 4-(hydroxy-4-[1-(naphthalene-2-sulfonyl)-1H-indol-2-yl]-cyclohexa-2,5-dienone




The title compound was prepared from 4,4-dimethoxy-cyclohexa-2,5-dienone and 1-(naphthalene-2-sulfonyl)-1H-indole, according to Method C, described above.

Yield 14%; mp 66-69 °C; ¹H NMR (CDCl₃) δ 8.42 (s, 1H), 7.96 (d, *J* = 8 Hz, 1H), 7.84 (d, *J* = 7 Hz, 1H), 7.64-7.74 (m, 3H), 7.49-7.54 (m, 4H), 7.07-7.32 (m, 3H), 6.71 (s, 1H), 6.24 (d, *J* = 10 Hz, 2H), 5.50 (s, 1H); ¹³C NMR (CDCl₃) δ 185.4, 150.0, 148.1, 141.3, 138.6, 135.7, 134.7, 132.0, 130.3, 130.1, 129.9, 129.3, 128.7, 128.4, 128.3, 128.0, 126.6, 124.9, 122.1, 121.3, 116.6, 115.6, 113.9, 68.0; MS (AP⁺) *m/z* 416.07 (M⁺ + 1).

Example 17

4-[5-fluoro-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-4-hydroxy-cyclohexa-2,5-dienone



The title compound was prepared from 4,4-dimethoxy-cyclohexa-2,5-dienone and 1-benzenesulfonyl-5-fluoro-1H-indole, according to Method C, described above.

Yield 58%; ¹H NMR (CDCl₃) δ 7.85-7.90 (dd, *J* = 4, 9 Hz, 1H), 7.65 (d, *J* = 8 Hz,


- 105 -

2H), 7.47 (d, $J = 10$ Hz, 2H), 7.15 (d, $J = 8$ Hz, 2H), 6.91-7.02 (m, 2H), 6.66 (s, 1H), 6.25 (d, $J = 10$ Hz, 2H), 5.42 (s, 1H), 2.28 (s, 3H); ^{13}C NMR (CDCl_3) δ 185.2, 162.3, 158.4, 149.4, 147.8, 146.2, 142.9, 134.9, 134.6, 130.4, 129.9, 129.7, 128.6, 128.1, 127.0, 116.9, 116.8, 114.7, 114.3, 113.6, 113.5, 107.7, 107.4, 67.9, 22.0.

5

Example 18

4-[1-(2,4,6-triisopropyl-benzene-4-sulfonyl)-1H-indol-2-yl]-4-hydroxy-cyclohexa-2,5-dienone




10 The title compound was prepared from 4,4-dimethoxy-cyclohexa-2,5-dienone and 1-(2,4,6-triisopropyl-benzene-sulfonyl-1H-indole, according to Method C, described above. Yield 12%; mp 55-57 °C; ^1H NMR (CDCl_3) δ 7.37-7.47 (m, 3H), 6.92-7.09 (m, 5H), 6.70 (s, 2H), 6.25 (d, $J = 10$ Hz, 2H), 5.41 (s, 1H), 3.73-3.78 (m, 2H), 2.70-2.91 (m, 1H), 1.15 and 1.18 (2s, 6H), 0.99-1.01 (m, 12H); ^{13}C NMR (CDCl_3) δ 185.5, 155.4, 151.3, 148.4, 141.1, 137.8, 132.7, 127.8, 125.6, 124.8, 123.9, 121.9, 113.3, 111.1, 68.2, 34.6, 29.7, 24.7, 23.8; MS (AP^+) m/z 492.21 ($\text{M}^+ + 1$).

15

Example 19

4,4-dimethoxy-4H-naphthalen-1-one




20

The title compound was prepared from 4-methoxynaphthol, according to Method D, described above. Yield 98%; ^1H NMR (CDCl_3) δ 8.15 (d, $J = 8$ Hz, 1H), 7.4-7.85 (m, 3H), 6.9 (d, $J = 12$ Hz, 1H), 6.55 (d, $J = 12$ Hz, 1H), 3.15 (s, 6H).

Example 20


4-(1-benzenesulfonyl-1H-indol-2-yl)-4-hydroxy-4H-naphthalen-1-one



5 The title compound was prepared from 4,4-dimethoxy-4H-naphthalen-1-one and 1-benzenesulfonyl-1H-indole, according to Method E, described above. Yield 20%; mp 175-177 °C; ^1H NMR (CDCl_3) δ 8.19-8.23 (dd, $J = 7$ Hz, 1H), 8.02-8.05 (dd, $J = 9$ Hz, 1H), 7.80-7.92 (m, 4H), 7.68-7.73 (t, $J = 7$ Hz, 1H), 7.55-7.64 (m, 2H), 7.42-7.48 (t, $J = 7$ Hz, 2H), 7.25-7.32 (m, 3H), 7.14-7.20 (m, 1H), 6.37 (d, $J =$
10 11 Hz, 1H); ^{13}C NMR (CDCl_3) δ 189.7, 153.9, 149.7, 148.9, 143.7, 143.2, 139.0, 137.9, 135.7, 134.2, 133.7, 133.6, 132.4, 131.6, 131.3, 130.8, 129.4, 126.7, 120.5, 74.9; MS (AP^+) m/z 416.07 ($\text{M}^+ + 1$), 398.06.

Example 21

15 4-hydroxy 4-[1-(toluene-4-sulfonyl)-1H-indol-2-yl]-4H-naphthalen-1-one



The title compound was prepared from 4,4-dimethoxy-4H-naphthalen-1-one and 1-(toluene-4-sulfonyl)-1H-indole, according to Method E, described above. Yield 23%; mp 110-112 °C; ^1H NMR (CDCl_3) δ 8.35-8.39 (dd, $J = 8$ Hz, 1H), 8.04 (d, $J =$
20 8 Hz, 1H), 7.74-7.97 (m, 6H), 7.32-7.48 (m, 6H), 6.53 (d, $J = 10$ Hz, 1H), 2.52 (s, 3H); ^{13}C NMR (CDCl_3) δ 189.7, 154.0, 150.2, 149.8, 148.8, 143.6, 140.1, 137.9,

- 107 -

135.7, 134.8, 133.6, 132.3, 131.7, 131.3, 130.7, 129.3, 126.6, 120.4, 120.3, 74.8, 26.6; MS (AP⁺) *m/z* 430.09 (M⁺ + 1), 412.14.

Biological Data

5

Compounds were assessed for their activity using various in vitro and in vivo assays, described below.

NCI Screening

10

Compounds were tested for in vitro activity (48 hour drug exposure) across 60 human cancer cell lines through the National Cancer Institute (NCI) Developmental Therapies Screening Program (Boyd et al., 1995). The mean growth inhibition (GI50) and cytotoxicity lethal concentration (LC50) values are summarized in Table 1. Surprisingly and unexpectedly, many of the compounds had particular activity in colon and renal cell lines.

15

Table 1				
Activity of Compounds In NCI in Vitro 60 Cell Panel				
Cmpd	mean log ₁₀ GI ₅₀ (μ M) ^a	Mean log ₁₀ LC ₅₀ (μ M) ^a	Most Sensitive Cells Lines mean log ₁₀ LC ₅₀ (μ M) ^a	
SIQ-01	-7.41	-5.53	HCT-116: -7.48	CAKI-1: -7.28
SIQ-02	-6.87	-5.21	ACHN: -6.35	LOX IMVI: -6.33
SIQ-03	-7.18	-5.49	HCT-116: -7.30	LOX IMVI: -7.20
SIQ-04	-6.95	-5.14	HCT-116: -7.32	LOX IMVI: -6.63
SIQ-05	-6.79	-5.20	HCT-116: -6.95	LOX IMVI: -6.42
SIQ-06	-6.63	-5.11	HCT-116: -6.44	UO-31: -6.20
SIQ-07	-6.72	-5.25	HCT-116: -6.43	U251: -6.29
SIQ-08	ND	ND	ND	ND
SIQ-09	-6.37	-4.95	HCT-116: -6.26	RXF 393: -6.11
SIQ-10	-6.35	-5.11	HCT-116: -6.10	LOX IMVI: -6.11
SIQ-11	-6.41	-5.25	HCT-116: -6.31	LOX IMVI: -6.14

^aFor definitions of mean GI₅₀ and mean LC₅₀ see Boyd et al., 1995, and Weinstein et al., 1997.

ND=not done.

Colon: HCT-116.

5 Renal: CAKI-1, ACHN, RXF 393, UO-31.

Melanoma: LOX IMVI.

CNS Cancer: U251.

Growth Inhibitory Assay

10

Compounds were prepared as 10 mM top stocks, dissolved in DMSO, and stored at 4°C, protected from light, for a maximum period of 4 weeks. Human derived cell lines (HCT 116, HT29 colon carcinoma) were routinely cultivated at 37°C in an atmosphere of 5% CO₂ in RPMI 1640 medium supplemented with 2 mM

15 L-glutamine and 10% fetal calf serum and subcultured twice weekly to maintain continuous logarithmic growth. Cells were seeded into 96-well microtiter plates at

a density of 5×10^3 per well and allowed 24 hours to adhere before drugs were introduced (final concentration 0.1 nM - 100 μ M, n = 8). Serial drug dilutions were prepared in medium immediately prior to each assay. At the time of drug addition and following 72 hour exposure, MTT was added to each well (final concentration 400 g/mL). Incubation at 37°C for 4 hr allowed reduction of MTT by mitochondrial dehydrogenase to an insoluble formazan product. Well contents were aspirated and formazan solubilized by addition of DMSO:glycine buffer (pH 10.5) (4:1). Absorbance was measured using an Anthos Labtec systems plate reader at 550 nm, and used as a measure of cell viability; thus cell growth or drug toxicity was determined. The results are summarised in Table 2.

Table 2			
In Vitro Activity			
Compound		IC50 (μ M)	
		HCT 116	HT 29
SIQ-01	BW 114	0.086	0.259
SIQ-03	JMB 40.2	0.068	0.347
SIQ-04	JMB 69	0.036	0.206
SIQ-05	JMB 78	0.203	0.420
SIQ-07	JMB 79	0.193	0.274
SIQ-10	JMB 49	0.205	0.444
SIQ-11	JMB 68	0.155	0.391
DMSO	-	>100	>100

Thioredoxin Activity

Assays were performed using methods analogous to those described in Kirkpatrick et al., 1999 and Kunkel et al., 1997.

Thioredoxin (TR) (specific activity 43.6 μ mol NADPH reduced/min/mg protein at 21°C) was purified from human placenta as previously described (Oblong et al., 1993). Recombinant hTrx was expressed in *Escherichia coli* and purified as

previously described (Gasdaska et al., 1994). The Trx and TR were stored at -20°C with 5 mM dithiothreitol (DTT) which was removed before use with a desalting column (PDIO, Pharmacia, Uppsala, Sweden).

- 5 Microtitre plate colorimetric assays, based on the increase in absorbance at 405 nm which occurs as dithionitrobenzoic acid (DTNB) is reduced by the enzyme-mediated transfer of reducing equivalents from NADPH, were used to measure TR/Trx-dependent insulin-reduction and TR activity (see, e.g., Kunkel et al., 1997).
- 10 Thioredoxin reductase/thioredoxin independent insulin reducing activity was measured in an incubation with a final volume of 60 µL containing 100 mM HEPES buffer, pH 7.2, 5 mM EDTA (HE buffer), 1 mM NADPH, 1.0 µM thioredoxin reductase, 0.8 µM thioredoxin, and 2.5 mg/ml bovine insulin in flat-bottom 96-well microtitre plates. Compounds were diluted in HE buffer and added
- 15 to the wells as 20 µL aliquots. Incubations were for 30 min at 37°C. The reaction was stopped by the addition of 100 µL of 6 M guanidine HCl, 50 mM Tris, pH 8.0, and 10 mM DTNB, and the absorbance measured at 405 nm.
- 20 Assays of TR activity were run in flat-bottom 96-well microtitre plates in a final incubation volume of 60 µL containing HE buffer, 10 mM DTNB, 1.0 µM thioredoxin reductase, and 1 mM NADPH. Compounds were diluted in HE buffer and added to the wells as aliquots. To ensure uniform coverage of the bottom of the well, the plate was briefly spun at 3000 g. To start the reaction, NADPH and DTNB were added as a 20 µL aliquots in HE buffer and the plate was moved to
- 25 the plate reader preheated to 37°C. The optical density at 405 nm was measured every 10 s and initial linear reaction rates were determined. The data are summarised in Table 3.

- 111 -

Table 3				
Inhibition of Thioredoxin/Thioredoxin Reductase (Tx/TR)-catalysed reduction of Insulin				
Compound		IC ₅₀ (mM)		Mean GI ₅₀ (μ M)
		Tx/TR	TR	
SIQ-01	BW 114	0.152	ND	0.152
SIQ-03	JMB 40.2	0.527	ND	0.527
SIQ-04	JMB 69	<0.1	ND	< 0.1
SIQ-11	JMB 68	>1.0	ND	>1.0

In Vivo Studies

The in vivo activity of SIQ-01 was studied. The maximum tolerated dose of SIQ-01 in mice is 30 mg/kg on a daily (x5) schedule. Combination treatment of SIQ-01 and cisplatin was active against the HCT116 colon carcinoma tumour when administered to tumour-bearing mice (15 mg SIQ-01/kg administered by intraperitoneal injection on days 1-5 and 8-10; 4 mg cisplatin/kg administered subcutaneously on days 1 and 8), and gave a maximum T/C (Test/Control) of 49%. Treatment with cisplatin alone (same regimen) gave a maximum T/C (Test/Control) of 56%.

Without wishing to be bound to any particular theory, it is believed that thioredoxin is associated with resistance to cisplatin therapy, and that combination therapy with both a thioredoxin inhibitor (such as the compounds described herein) and cisplatin provides improved therapy, as compared to therapy with cisplatin alone. The in vivo studies describe above support this position.

* * *

The foregoing has described the principles, preferred embodiments, and modes of operation of the present invention. However, the invention should not be construed as limited to the particular embodiments discussed. Instead, the above-

- 112 -

described embodiments should be regarded as illustrative rather than restrictive, and it should be appreciated that variations may be made in those embodiments by workers skilled in the art without departing from the scope of the present invention.

REFERENCES

A number of patents and publications are cited above in order to more fully describe and disclose the invention and the state of the art to which the invention pertains. Full citations for these references are provided below. Each of these references is incorporated herein by reference in its entirety into the present disclosure, to the same extent as if each individual reference was specifically and individually indicated to be incorporated by reference.


- 5 Alcaraz, L., et al., 1998, "Manumycin A: synthesis of the (+)-enantiomer and revision of stereochemical assignment," J. Org. Chem., Vol. 63, pp. 3526-3527.
- 10 Boyd, M.R., Paull, K.D., 1995, "Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery system," Drug Dev. Res., Vol. 34, pp. 91-104.
- 15 Faaland et al., 1991, "Rapid uptake of tyrphostin into A431 human epidermoid cells is followed by delayed inhibition of epidermal growth factor (EGF) stimulated EFG receptor tyrosine kinase activity," Mol. Cell Biol., Vol. 11, pp. 2697-2703.
- 20 Gasdaska et al., 1994, "The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived cofactor (ADF): thioredoxin mRNA is elevated in some human tumors," Biochimica et Biophysica Acta, Vol. 1218, p. 292.
- 25 Kirkpatrick et al., 1999, "Parallel synthesis of disulfide inhibitors of the thioredoxin redox system as potential antitumor agents," Anti-Cancer Drug Design, Vol. 14, pp. 421-432.
- Kunkel et al., 1997, "Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs," Anti-Cancer Drug Design, Vol. 12, pp. 659-670.
- 30 Milić, D. R., et al., "X-Ray crystal structure of 10 β -hydroxy-4 β ,5 β -epoxyestr-1-en-3,17-dione and antitumor activity of its congeners," Molecules, Vol. 4, pp. 338-352.

- Oblong et al., 1993, "Purification of human thioreductase; properties and characterization by absorption and circular dichroism spectroscopy," Biochemistry, Vol. 32, p. 7271.
- 5 Powis, G., Mustacich, D, Coon, A., 2000, "The role of the redox protein thioredoxin in cell growth and cancer," Free Radical Biology & Medicine, Vol. 29, Nos. 3/4, pp. 312-322.
- Rambas et al., 1994, "The degree of inhibition of protein tyrosine kinase activity by Tyrphostin 23 and 25 is related to their instability," Cancer Research, Vol 54, pp. 867-869.
- 10 Reddy et al., 1992, "Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor," Cancer Research, Vol. 52, pp. 3631-3641.
- Stevens, M.F.G., et al., 2003, "4-Aryl Quinolins and Analogs Thereof as Therapeutic Agents," International (PCT) Patent Application number PCT/GB02/03097, publication number WO 03/_____, published ____ January 2003.
- 15 Umezawa et al., 1991, "Use of erbstatin as protein tyrosine kinase inhibitor," Methods Enzymol., Vol. 201, pp. 379-385.
- Wada, H., et al., 1987, "Chemical and chemotaxonomical studies of ferns. LXXIII. New flavonoids with modified B-ring from the genus *Pseudophegopteris* (Thelypteridaceae)," Chem. Pharm. Bull., Vol. 35, pp. 4757-4762.
- 20 Weinstein, J. N., et al., 1997, "An information-intensive approach to the molecular pharmacology of cancer," Science, Vol. 275, pp. 343-349.
- Wells et al., 06 March 2000, "Antitumour benzothiazoles. Part 10: The synthesis and antitumour activity of benzothiazole substituted quinol derivatives," Bioorganic & Medicinal Chemistry Letters, Vol. 10, No. 5, pp. 513-515.
- 25 Wipf, P., et al., "Synthesis of the antitumor antibiotic LL-C10037 α ," J. Org. Chem., Vol. 59, pp. 3518-3519.

- 115 -

CLAIMS

1. A compound having the following formula:



(1)

wherein:

5

Ar is a 1-(sulfonyl)-1H-indol-2-yl group;

the group -OR⁰ is independently:

- (a) -OH;
- (b) an ether group; or:
- (c) an acyloxy group;

10

the bond marked α is independently:

- (a) a single bond; or:
- (b) a double bond;

the bond marked β is independently:

15

- (a) a single bond; or:
- (b) a double bond;

each of R², R³, R⁵, and R⁶, is independently a ring substituent and is:

- (a) H;
- (b) a monovalent monodentate substituent; or:
- (c) a ring substituent which, together with an adjacent ring

20

substituent, and together with the ring atoms to which these ring substituents are attached, form a fused ring;

and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof.

25

* * *

- 116 -

2. A compound according to claim 1, wherein α is independently a double bond and β is independently a double bond, and the compound has the following formula:



- 5 3. A compound according to claim 1, wherein α is independently a single bond and β is independently a single bond and the compound has the following formula:



- 10 4. A compound according to claim 1, wherein α is independently a single bond and β is independently a double bond, and the compound has the following formula:



* * *

- 15 5. A compound according to any one of claims 1 to 4, wherein said monovalent monodentate substituent is selected from:

hydroxy (-OH);

halo;

cyano (-CN);

20 carboxy (-COOH);

azido;

- 117 -

ester;

amino, including:

C₁₋₇alkyl-amino;amino-C₁₋₇alkyl-amino;

5

C₁₋₇alkyl, including:halo-C₁₋₇alkyl;amino-C₁₋₇alkyl;carboxy-C₁₋₇alkyl;hydroxy-C₁₋₇alkyl;

10

C₅₋₂₀aryl-C₁₋₇alkyl;

ether, including:

C₁₋₇alkoxy;halo-C₁₋₇alkoxy;amino-C₁₋₇alkoxy;

15

carboxy-C₁₋₇alkoxy;hydroxy-C₁₋₇alkoxy;C₅₋₂₀aryl-C₁₋₇alkoxy;

acyl, including:

C₁₋₇alkyl-acyl;

20

halo-C₁₋₇alkyl-acyl;amino-C₁₋₇alkyl-acyl;carboxy-C₁₋₇alkyl-acyl;hydroxy-C₁₋₇alkyl-acyl;C₅₋₂₀aryl-C₁₋₇alkyl-acyl;

25

C₅₋₂₀aryl-acyl;C₅₋₂₀aryl;

thiol (-SH); and,

thioether.

30

6. A compound according to any one of claims 1 to 4, wherein said monovalent monodentate substituent is selected from:

-OH;

- 118 -

-F, -Cl, -Br, -I;

-CN;

-COOH;

-N₃;

5 -COOMe, -COOEt, -COOtBu, -COOPh, -COOCH₂Ph;

-NH₂, -NHMe, -NH₂Et, -NMe₂, -NEt₂;

piperidino, morpholino, piperazino, N-methyl-piperazino;

-NH(CH₂)_w-NH₂, -NH(CH₂)_w-NHMe, -NH(CH₂)_w-NMe₂, -NH(CH₂)_w-NEt₂;

10

-Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu;

-CH₂F, -CH₂Cl, -CF₃, -CCl₃, -CF₂CF₃, -CH₂CF₃, -C(CF₃)₃;

-(CH₂)_w-NH₂, -(CH₂)_w-NHMe, -(CH₂)_w-NMe₂, -(CH₂)_w-NEt₂;

-(CH₂)_w-COOH;

15

-(CH₂)_w-OH;

-CH₂Ph;

-OMe, -OEt, -OnPr, -OiPr, -OnBu, -OiBu, -OsBu, -OtBu;

-OCH₂F, -OCH₂Cl, -OCF₃, -OCCl₃, -OCF₂CF₃, -OCH₂CF₃, -OC(CF₃)₃;

20

-O(CH₂)_w-NH₂, -O(CH₂)_w-NHMe, -O(CH₂)_w-NMe₂, -O(CH₂)_w-NEt₂;

-O(CH₂)_w-COOH;

-O(CH₂)_w-OH;

-OCH₂Ph;

25

-C(=O)Me, -C(=O)Et, -C(=O)-nPr, -C(=O)-iPr, -C(=O)-nBu, -C(=O)-iBu,

-C(=O)-sBu, -C(=O)-tBu;

-C(=O)CH₂F, -C(=O)CH₂Cl, -C(=O)CF₃, -C(=O)CCl₃, -C(=O)CF₂CF₃,

-C(=O)CH₂CF₃, -C(=O)C(CF₃)₃;

-C(=O)(CH₂)_w-NH₂, -C(=O)(CH₂)_w-NHMe, -C(=O)(CH₂)_w-NMe₂,

30

-C(=O)(CH₂)_w-NEt₂;

-C(=O)(CH₂)_w-COOH;

-C(=O)(CH₂)_w-OH;

-C(=O)CH₂Ph;

- 119 -

-Ph;

-SH;

5

-SMe, -SEt, -SnPr, -S-iPr, -S-nBu, -S-iBu, -S-sBu, -S-tBu,
-S-CH₂-Ph, -S-Ph;

a thioether group derived from cysteine, homocysteine, glutathione, or a peptide comprising the sequence -Cys-(X)_y-Cys-, where X is an amino acid, and y is an integer from 1 to 6;

10

wherein w is an integer from 1 to 7.

* * *

- 15 7. A compound according to any one of claims 1 to 6, wherein each of R², R³, R⁵, and R⁶, is independently a ring substituent and is:
- (a) H; or
- (b) a monovalent monodentate substituent.

- 20 8. A compound according to any one of claims 1 to 6, wherein R⁵ and R⁶ are -H; but R² and R³ do not also form a fused ring:



9. A compound according to any one of claims 1 to 6, wherein R² and R³ are -H; but R⁵ and R⁶ do not also form a fused ring:



25

- 120 -

10. A compound according to any one of claims 1 to 6, wherein R^2 and R^6 are -H:



11. A compound according to any one of claims 1 to 6, wherein R^3 and R^5 are -H:



12. A compound according to any one of claims 1 to 6, wherein R^2 , R^3 , R^5 and R^6 are -H:



13. A compound according to any one of claims 1 to 6, wherein R^2 , R^3 , R^5 and R^6 are -H; α is a double bond; and β is a double bond:




14. A compound according to any one of claims 1 to 6, wherein R^2 , R^3 , R^5 and R^6 are -H; α is a single bond; and β is a single bond:



- 121 -

15. A compound according to any one of claims 1 to 6, wherein R^2 , R^3 , R^5 and R^6 are -H; α is a single bond; and β is a double bond:



* * *

16. A compound according to any one of claims 1 to 6, wherein

(a) R^2 and R^3 , together with the ring atoms to which they are attached, form a fused ring;

(b) R^5 and R^6 , together with the ring atoms to which they are attached, form a fused ring; or

(c) or both (a) and (b).

17. A compound according to claim 16, wherein the fused ring, or, if there are two fused rings, one of them, or each of them, is a fused aromatic ring.

18. A compound according to claim 16, wherein the fused ring, or, if there are two fused rings, one of them, or each of them, is a fused aromatic ring with 5 or 6 ring atoms.

19. A compound according to claim 16, wherein R^2 and R^3 form a fused benzene ring; and β is a double bond:



20. A compound according to claim 19, wherein R^5 and R^6 do not also form a fused ring.

21. A compound according to claim 16, wherein R^2 and R^3 form a fused benzene ring; β is a double bond; and R^5 is -H:



22. A compound according to claim 16, wherein R^2 and R^3 form a fused benzene ring; β is a double bond; and R^6 is -H:



23. A compound according to claim 16, wherein R^2 and R^3 form a fused benzene ring; β is a double bond; and R^5 and R^6 are -H:



24. A compound according to claim 16, wherein R^2 and R^3 form a fused benzene ring; β is a double bond; R^5 and R^6 are -H; and α is a double bond:



- 123 -

25. A compound according to claim 16, wherein R^5 and R^6 form a fused benzene ring; and α is a double bond:




26. A compound according to claim 25, wherein R^2 and R^3 do not also form a fused ring.

27. A compound according to claim 16, wherein R^5 and R^6 form a fused benzene ring; α is a double bond; and R^3 is -H:



28. A compound according to claim 16, wherein R^5 and R^6 form a fused benzene ring; α is a double bond; and R^2 is -H:




* * *

29. A compound according to any one of claims 1 to 28, wherein R^O is independently:
- (a) -H;
 - (b) C_{1-7} alkyl, C_{3-20} heterocyclyl, or C_{5-20} aryl; and is optionally substituted; or:
 - (c) C_{1-7} alkyl-acyl, C_{3-20} heterocyclyl-acyl, or C_{5-20} aryl-acyl; and is optionally substituted.

30. A compound according to any one of claims 1 to 28, wherein R^O is independently:
(b) C_{1-7} alkyl, C_{3-20} heterocyclyl, or C_{5-20} aryl; and is optionally substituted; or:
5 (c) C_{1-7} alkyl-acyl, C_{3-20} heterocyclyl-acyl, or C_{5-20} aryl-acyl; and is optionally substituted.
31. A compound according to claim 29 or 30, wherein R^O is optionally substituted with one more of the following groups:
10 hydroxy (-OH);
halo;
carboxy (-COOH);
amino; and,
 C_{5-20} aryl.
32. A compound according to claim 29 or 30, wherein R^O is unsubstituted.
33. A compound according to any one of claims 1 to 28, wherein R^O is -H.

* * *

34. A compound according to any one of claims 1 to 33, wherein Ar is a group of the following formula:



wherein:

R^{SO} is independently a sulfonyl substituent; and
each of R^{3N} , R^{4N} , R^{5N} , R^{6N} , and R^{7N} is independently an indolyl substituent.

- 125 -


* * *

- 5 35. A compound according to claim 34, wherein R^{SO} is C₁₋₇alkyl, C₃₋₂₀heterocyclyl, or C₅₋₂₀aryl; and is optionally substituted.
36. A compound according to claim 34, wherein R^{SO} is C₅₋₂₀aryl; and is optionally substituted.
- 10 37. A compound according to claim 34, wherein R^{SO} is C₅₋₁₀aryl; and is optionally substituted.
38. A compound according to claim 34, wherein R^{SO} is C₅₋₁₀carboaryl; and is optionally substituted.
- 15 39. A compound according to claim 34, wherein R^{SO} is phenyl or naphthyl; and is optionally substituted.
- 20 40. A compound according to claim 34, wherein R^{SO} is naphthyl; and is optionally substituted.
41. A compound according to claim 34, wherein R^{SO} is C₅₋₆carboaryl; and is optionally substituted.
- 25 42. A compound according to claim 34, wherein R^{SO} is C₅₋₆aryl; and is optionally substituted.
- 30 43. A compound according to claim 34, wherein R^{SO} is phenyl; and is optionally substituted.

* * *


- 126 -

44. A compound according to claim 34, wherein R^{SO} is:



wherein p is an integer from 0 to 5, and each R^P is a phenyl substituent.

- 5 45. A compound according to claim 34, wherein R^{SO} is selected from:



wherein q is an integer from 0 to 3; r is an integer from 0 to 4; and each R^P is a naphthyl substituent.

- 10 46. A compound according to claim 44 or 45, wherein each R^P is independently selected from:

hydroxy (-OH);

halo;

cyano (-CN);

15 carboxy (-COOH);

azido;

ester;

amino, including:

amino- C_{1-7} alkyl-amino;

20 C_{1-7} alkyl, including:

halo- C_{1-7} alkyl;

amino- C_{1-7} alkyl;

carboxy- C_{1-7} alkyl;

hydroxy- C_{1-7} alkyl;

25 C_{5-20} aryl- C_{1-7} alkyl;

ether, including:

C_{1-7} alkoxy;

halo- C_{1-7} alkoxy;

amino- C_{1-7} alkoxy;

- 127 -

carboxy-C₁₋₇alkoxy;
 hydroxy-C₁₋₇alkoxy;
 C₅₋₂₀aryl-C₁₋₇alkoxy;
 acyl, including:
 C₁₋₇alkyl-acyl;
 halo-C₁₋₇alkyl-acyl;
 amino-C₁₋₇alkyl-acyl;
 carboxy-C₁₋₇alkyl-acyl;
 hydroxy-C₁₋₇alkyl-acyl;
 C₅₋₂₀aryl-C₁₋₇alkyl-acyl;
 C₅₋₂₀aryl-acyl;
 C₅₋₂₀aryl.

47. A compound according to claim 44 or 45, wherein each R^P is independently selected from:

-OH;
 -F, -Cl, -Br, -I;
 -CN;
 -COOH;
 -N₃;
 -COOMe, -COOEt, -COOtBu, -COOPh, -COOCH₂Ph;
 -NH₂, -NHMe, -NH₂Et, -NMe₂, -NEt₂;
 piperidino, morpholino, piperazino, N-methyl-piperazino;
 -NH(CH₂)_w-NH₂, -NH(CH₂)_w-NHMe, -NH(CH₂)_w-NMe₂, -NH(CH₂)_w-NEt₂;
 -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu;
 -CH₂F, -CH₂Cl, -CF₃, -CCl₃, -CF₂CF₃, -CH₂CF₃, -C(CF₃)₃;
 -(CH₂)_w-NH₂, -(CH₂)_w-NHMe, -(CH₂)_w-NMe₂, -(CH₂)_w-NEt₂;
 -(CH₂)_w-COOH;
 -(CH₂)_w-OH;
 -CH₂Ph;

- 128 -

-OMe, -OEt, -OnPr, -OiPr, -OnBu, -OiBu, -OsBu, -OtBu;
 -OCH₂F, -OCH₂Cl, -OCF₃, -OCCl₃, -OCF₂CF₃, -OCH₂CF₃, -OC(CF₃)₃;
 -O(CH₂)_wNH₂, -O(CH₂)_wNHMe, -O(CH₂)_wNMe₂, -O(CH₂)_wNEt₂;
 -O(CH₂)_wCOOH;
 -O(CH₂)_wOH;
 -OCH₂Ph;

 -C(=O)Me, -C(=O)Et, -C(=O)-nPr, -C(=O)-iPr, -C(=O)-nBu, -C(=O)-iBu,
 -C(=O)-sBu, -C(=O)-tBu;
 -C(=O)CH₂F, -C(=O)CH₂Cl, -C(=O)CF₃, -C(=O)CCl₃, -C(=O)CF₂CF₃,
 -C(=O)CH₂CF₃, -C(=O)C(CF₃)₃;
 -C(=O)(CH₂)_wNH₂, -C(=O)(CH₂)_wNHMe, -C(=O)(CH₂)_wNMe₂,
 -C(=O)(CH₂)_wNEt₂;
 -C(=O)(CH₂)_wCOOH;
 -C(=O)(CH₂)_wOH;
 -C(=O)CH₂Ph;

 -Ph;

wherein w is an integer from 1 to 7.

48. A compound according to claim 44 or 45, wherein each R^P is independently selected from: -F, -Cl, -Br, -I, -Me, -Et, -OMe, -OEt.

49. A compound according to claim 44 or 45, wherein each R^P is independently selected from: -F, -Me, -OMe.

50. A compound according to any one of claims 34 to 49, wherein each of R^{3N}, R^{4N}, R^{5N}, R^{6N}, and R^{7N} is independently -H, or as defined for R^P.

- 129 -

51. A compound according to any one of claims 34 to 49, wherein each of R^{3N} , R^{4N} , R^{5N} , R^{6N} , and R^{7N} is independently selected from:
-H, -F, -Cl, -Br, -I, -Me, -Et, -OMe, -OEt.

5 52. A compound according to any one of claims 34 to 49, wherein each of R^{3N} , R^{4N} , R^{5N} , R^{6N} , and R^{7N} is independently selected from: -H, -F, -OMe.

* * *

10 53. A compound according to any one of claims 34 to 52, wherein R^{3N} is -H.

54. A compound according to any one of claims 34 to 52, wherein each of R^{4N} and R^{7N} is -H.

15 55. A compound according to any one of claims 34 to 52, wherein each of R^{3N} , R^{4N} and R^{7N} is -H.

56. A compound according to any one of claims 34 to 52, wherein each of R^{4N} , R^{6N} , and R^{7N} is -H.

20

57. A compound according to any one of claims 34 to 52, wherein each of R^{3N} , R^{4N} , R^{6N} , and R^{7N} is -H.

25 58. A compound according to any one of claims 34 to 52, wherein each of R^{4N} , R^{5N} , and R^{7N} is -H.

59. A compound according to any one of claims 34 to 52, wherein each of R^{3N} , R^{4N} , R^{5N} , and R^{7N} is -H.

30 60. A compound according to any one of claims 34 to 52, wherein each of R^{5N} , R^{6N} , and R^{7N} is -H.

- 130 -

61. A compound according to any one of claims 34 to 52, wherein each of R^{3N} , R^{5N} , R^{6N} , and R^{7N} is -H.
- 5 62. A compound according to any one of claims 34 to 52, wherein each of R^{4N} , R^{5N} , and R^{6N} is -H.
63. A compound according to any one of claims 34 to 52, wherein each of R^{3N} , R^{4N} , R^{5N} , and R^{6N} is -H.
- 10 64. A compound according to any one of claims 34 to 52, wherein each of R^{3N} , R^{4N} , R^{5N} , R^{6N} , and R^{7N} is -H.
- * * *
- 15 65. Compound SIQ-001 and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof.
66. Compound SIQ-002 and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof.
- 20 67. Compound SIQ-003 and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof.
68. Compound SIQ-004 and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof.
- 25 69. Compound SIQ-005 and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof.
70. Compound SIQ-006 and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof.
- 30

- 131 -

71. Compound SIQ-007 and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof.

5 72. Compound SIQ-008 and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof.

73. Compound SIQ-009 and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof.

10 74. Compound SIQ-010 and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof.

75. Compound SIQ-011 and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof.

15 76. Compound SIQ-012 and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof.

20 77. Compound SIQ-013 and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof.

* * *

25 78. A composition comprising a compound according to any one of claims 1 to 77 and a pharmaceutically acceptable carrier or diluent.

* * *

30 78. A compound according to any one of claims 1 to 77 for use in a method of treatment of the human or animal body.

* * *

- 132 -

79. Use of a compound according to any one of claims 1 to 77 for the manufacture of a medicament for use in the treatment of a proliferative condition.

5 80. Use of a compound according to any one of claims 1 to 77 for the manufacture of a medicament for use in the treatment of cancer.

10 81. Use of a compound according to any one of claims 1 to 77 for the manufacture of a medicament for use in the treatment of colon cancer or renal cancer.

15 82. Use of a compound according to any one of claims 1 to 77 for the manufacture of a medicament for use in the treatment of a condition mediated by thioredoxin/thioredoxin reductase.

* * *

20 83. A method for the treatment of a proliferative condition comprising administering to a subject suffering from said condition a therapeutically-effective amount of a compound according to any one of claims 1 to 77.

25 84. A method for the treatment of cancer comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to any one of claims 1 to 77.

85. A method for the treatment of colon cancer or renal cancer comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to any one of claims 1 to 77.

30 86. A method for the treatment of a condition mediated by thioredoxin/thioredoxin reductase comprising administering to a subject suffering from said condition a therapeutically-effective amount of a compound according to any one of claims 1 to 77.

- 133 -

* * *

- 5 87. A method of inhibiting thioredoxin/thioredoxin reductase in a cell, *in vitro* or *in vivo*, comprising contacting said cell with an effective amount of according to any one of claims 1 to 77.
- 10 88. A method of regulating cell proliferation, *in vitro* or *in vivo*, comprising contacting a cell with an effective amount of a compound according to any one of claims 1 to 77.
- 15 89. A method of (a) inhibiting cell proliferation; (b) inhibiting cell cycle progression; (c) promoting apoptosis; or (d) a combination of one or more of these, *in vitro* or *in vivo*, comprising contacting a cell with an effective amount of a compound according to any one of claims 1 to 77.

AMENDED CLAIMS

[received by the International Bureau on 17 April 2003 (17.04.03);
Claims 1 replaced by new claim 1; remaining claims unchanged]

1. A compound having the following formula:



wherein:

5 Ar is a 1-(sulfonyl)-1H-indol-2-yl group;

the group -OR^O is independently:

- (a) -OH;
- (b) an ether group; or
- (c) an acyloxy group;

10 the bond marked α is independently:

- (a) a single bond; or
- (b) a double bond;

the bond marked β is independently:

- (a) a single bond; or
- (b) a double bond;

15 each of R², R³, R⁵, and R⁶, is independently a ring substituent and is:

- (a) H;
- (b) a monovalent monodentate substituent; or
- (c) a ring substituent which, together with an adjacent ring substituent, and together with the ring atoms to which these ring substituents are attached, form a fused ring;

20 and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof.

STATEMENT UNDER ARTICLE 19(1)**International Patent Application No PCT/GB02/05842****International Filing Date: 20 December 2002****Applicant: Cancer Research Technology Limited**

Claim 1 has been amended.

Amended claim 1 differs from original claim 1 in only one respect: the chemical formula has been corrected to be identical to that shown in the description at page 6, line 7. Amended claim 1 now precisely corresponds to the description at page 6, lines 5-26.

It is clear that there is an error in original claim 1. Claim 1 includes, at lines 12-14, references to "the bond marked β ". However, the formula in original claim 1 does not have a bond marked β .

It is clear what the error is: the annular bond "across" from the bond marked α is incorrectly shown to be a double bond in original claim 1. Original claims 2 and 4 (which depend from claim 1) require an annular double bond "across" from the bond marked α . Original claim 3 (which also depends from claim 1) requires an annular single bond "across" from the bond marked α .

It is clear what the correction must be: the bond "across" from the bond marked α must be defined as a single bond or a double bond (which is precisely what is given on page 6 of the description). The correction is achieved by replacing the chemical formula in original claim 1 with the chemical formula appearing on page 6 of the description.

INTERNATIONAL SEARCH REPORT

Internatio pplication No

PCT/GB 02/05842

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/404 C07D 212

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WELLS G G ET AL: "Antitumour benzothiazoles. Part 10: The synthesis and antitumour activity of benzothiazole substituted quinol derivatives" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 10, no. 5, March 2000 (2000-03), pages 513-515, XP004202450 ISSN: 0960-894X cited in the application see Scheme 1, compound 3 ---	1-89
A	US 5 391 570 A (CATT JOHN D ET AL) 21 February 1995 (1995-02-21) see formula I and column 4 compounds i-b --- -/--	1-89

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

25 March 2003

Date of mailing of the international search report

02/04/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Scruton-Evans, I

INTERNATIONAL SEARCH REPORT

Internatio pplication No
PCT/GB 02/05842

C.(Continuation) DOCUMENTS CONSIDERED RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 03 004479 A (CANCER RESEARCH TECHNOLOGY LIMITED) 16 January 2003 (2003-01-16) cited in the application see general formula, page 19 and Q03, page 45	1-89
A	EP 0 469 984 A (SANOFI SA) 5 February 1992 (1992-02-05) the whole document	1-89

INTERNATIONAL SEARCH REPORT

International application No.
PCT/92/05842

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 83-89 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB 02/05842

Patent document cited in search report	Application date	Patent family member(s)	Publication date
US 5391570	A	21-02-1995	US 5496847 A 05-03-1996
		US 5658941 A	19-08-1997
WO 03004479	A	16-01-2003	WO 03004479 A1 16-01-2003
EP 0469984	A	05-02-1992	FR 2665441 A1 07-02-1992
		AT 129236 T	15-11-1995
		AU 5047393 A	13-01-1994
		AU 645585 B2	20-01-1994
		AU 8147891 A	06-02-1992
		CA 2048139 A1	01-02-1992
		DE 69113911 D1	23-11-1995
		DE 69113911 T2	28-03-1996
		EP 0469984 A2	05-02-1992
		ES 2080922 T3	16-02-1996
		FI 913614 A ,B,	01-02-1992
		HU 59669 A2	29-06-1992
		HU 219351 B	28-03-2001
		IE 912696 A1	12-02-1992
		IL 99012 A	23-07-1996
		IL 114934 A	04-08-1996
		JP 3195381 B2	06-08-2001
		JP 4234361 A	24-08-1992
		KR 211434 B1	02-08-1999
		NO 912970 A ,B,	03-02-1992
		NZ 239182 A	26-07-1995
		NZ 248566 A	26-07-1995
		PT 98476 A ,B	29-05-1992
		US 5397801 A	14-03-1995
		US 5481005 A	02-01-1996
		US 5578633 A	26-11-1996
		US 5338755 A	16-08-1994
		ZA 9106031 A	29-04-1992